Page last updated: 2024-08-24

valsartan and Cardiac Failure

valsartan has been researched along with Cardiac Failure in 1133 studies

Research

Studies (1,133)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's13 (1.15)18.2507
2000's148 (13.06)29.6817
2010's418 (36.89)24.3611
2020's554 (48.90)2.80

Authors

AuthorsStudies
Davis, LE; Pogge, EK2
Shen, X; Zeng, Y; Zhao, J1
Hori, M; Imamura, T; Kinugawa, K1
Bai, X; Chen, F; Li, J; Tian, G; Yuan, Z1
Abdelnabi, M; Almaghraby, A; Gerges, F; Girgis, H; Saleh, Y1
Acosta, J; Berruezo, A; Bosch, X; Jáuregui, B1
Allen, LA; Blumer, V; Carnicelli, AP; Fonarow, GC; Greene, SJ; Greiner, MA; Hardy, NC; Li, Z; Lippmann, SJ; Mentz, RJ; O'Brien, EC; Peterson, PN; Shen, X; Yancy, CW1
Bhatt, AS1
Brunetti, ND; Correale, M; Fortunato, M; Leopizzi, A; Magnesa, M; Mallardi, A; Mazzeo, P; Mennella, R; Tricarico, L; Tucci, S1
Yancy, CW1
Aggarwal, R; Bhatt, AS; Claggett, BL; Fonarow, GC; Greene, SJ; McMurray, JJV; Solomon, SD; Vaduganathan, M1
Krittayaphong, R; Permsuwan, U2
Crea, F1
Bonni, E; Coppola, G; Corrado, E; Dattilo, G; de Gregorio, C; Morabito, C; Novo, G; Zappia, L1
Axelsson, A; Bach, RG; Becker, JR; Benson, L; Braunwald, E; Bundgaard, H; Burns, KM; Canter, C; Cirino, AL; Colan, SD; Day, SM; Ho, CY; Lakdawala, NK; Lever, HM; MacRae, CA; Margossian, R; McMurray, JJV; Mestroni, L; Murphy, AM; Orav, EJ; Owens, AT; Patel, AR; Pereira, AC; Rossano, JW; Russell, MW; Seidman, CE; Solomon, SD; Soslow, JH; Taylor, MRG; Thrush, P; Vargas, JD; Wheeler, MT; Wilmot, I; Zahka, K1
Karabulut, D; Karabulut, U; Keskin, K; Yiğit, E; Yiğit, Z1
Aspromonte, N; Caldarola, P; Cipriani, M; Colivicchi, F; Di Lenarda, A; Di Tano, G; Gabrielli, D; Gulizia, MM; Iacoviello, M; Murrone, A; Oliva, F; Urbinati, S1
Gallo, G; Volpe, M; Zieroth, S1
Calò, L; Cicogna, F; De Ruvo, E; Gaudio, C; Mennuni, S; Monzo, L; Petronilli, V; Tota, C1
Alba, PR; Bress, AP; Choi, ME; Cook, J; Dodson, JA; Fang, JC; He, T; Herrick, JS; King, JB; Levitan, EB; Mohanty, AF; Obi, EN; Patterson, OV; Russo, PA; Vardeny, O1
Bedhomme, S; Bouchant, S; Boussageon, R; Bœuf-Gibot, S; Charuel, E; Menini, T; Pereira, B; Piñol-Domenech, N; Vaillant-Roussel, H1
Bhatti, P; Bromage, DI; Cannata, A; DeCourcey, J; Holm, N; Huang, M; McDonagh, TA1
Belarte-Tornero, LC; Farré, N; Mojón, D1
Chen, Z; Deng, Q; Diao, K; He, S; He, Y; Huang, B; Li, C; Ma, M; Sun, J; Tang, L; Wang, D; Wang, H; Wang, M; Wu, T; Wu, X; Yan, T; Zhang, L; Zhu, Y1
Bian, W; Cheng, H; Yang, L; Ye, N1
Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A2
Clark, J; Gandotra, C; Liu, Q; Rose, M; Senatore, FF; Stockbridge, NL; Zhang, J1
Jang, HN; Kang, MG; Kim, MJ; Lee, JS; Song, HN1
Fu, G; Lu, J; Shen, C; Xiong, C; Yang, Y1
Abdelnabi, M; Almaghraby, A; Babazade, N; Cihan, D; Dağdeviren, B; Fiore, C; Haseeb Raza Naqvi, S; Omar, B; Öz, TK1
Anstrom, KJ; Braunwald, E; Desvigne-Nickens, P; DeVore, AD; Givertz, MM; Gupta, D; Hernandez, AF; Kiernan, MS; Lala, A; Lewis, GD; Mahr, C; Mann, DL; Margulies, KB; McNulty, SE; Redfield, MM; Shah, P; Starling, RC; Vader, JM1
Gallo, G; Rubattu, S; Volpe, M1
Apaer, R; Che, H; Chen, J; Dou, X; Feng, Z; Fu, L; Fu, X; He, C; Huang, R; Ke, G; Kong, Y; Li, S; Li, X; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Mei, L; Shi, W; Su, X; Tang, B; Tao, Y; Wang, X; Wang, Y; Wen, F; Xia, Y; Xiao, J; Xiong, Y; Xu, L; Xue, Z; Ye, Z; Zhang, H; Zhang, L1
Heidenreich, PA; Kohsaka, S; Lewis, EF; Sandhu, AT; Turakhia, MP1
Berwanger, O; Braunwald, E; Cikes, M; Claggett, B; De Pasquale, CG; East, C; Fernandez, A; Gong, J; Granger, CB; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Mehran, R; Merkely, B; Petrie, MC; Petrov, I; Pfeffer, MA; Rouleau, JL; Schou, M; Senni, M; Sim, D; Solomon, SD; Steg, PG; Vaghaiwalla Mody, F; van der Meer, P; Zhou, Y1
Baldridge, A; Cowie, MR; Ibram, G; Pieske, B; Shah, SJ; Shi, V; Szeczoedy, P; Wachter, R; Zhao, Z1
Boulmpou, A; Doumas, M; Papadopoulos, C; Patoulias, D; Toumpourleka, M; Tranidou, A1
Chai, P; Cheong, AJY; Lee, CH; Lim, YC; Lin, W; Sia, CH; Syn, NL; Teo, YH; Teo, YN; Wee, CF; Wong, RCC; Yeo, TC; Yoong, CSY1
Berwanger, O; Braunwald, E; Cikes, M; Claggett, B; De Pasquale, CG; Fernandez, A; Filippatos, G; Granger, CB; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Menon, V; Merkely, B; Petrie, MC; Petrov, I; Pfeffer, MA; Rouleau, JL; Schou, M; Senni, M; Sim, D; Solomon, SD; Steg, PG; van der Meer, P; Wang, Y; Zhou, Y1
Benson, L; Daubert, JC; Donal, E; Hage, C; Linde, C; Lund, LH; Lundberg, A; Oger, E; Savarese, G; Venkateshvaran, A1
Austin, AM; Gilstrap, L; King, A; Tomlin, S1
Arnaud, H; Bouali, Y; Donal, E; Galli, E; Laurin, C; Oger, E; Paven, E1
Ammendola, E; Boriani, G; Bottino, R; D'Andrea, A; Gasperetti, A; Golino, P; Lip, GYH; Masarone, D; Nigro, G; Pacileo, G; Proietti, R; Russo, V; Schiavone, M1
Ryo, Y; Sunaga, T1
Lin, J; Liu, J; Xie, G; Zhou, J1
Castagno, D; Curtain, JP; Desai, AS; Docherty, KF; Jackson, AM; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Petrie, MC; Rohde, LE; Rouleau, JL; Shen, L; Solomon, SD; Swedberg, K; Zile, MR1
Chen, Z; Li, T; Wang, L; Xi, Q1
Ambrosio, G; Bitto, R; Brunetti, ND; Carluccio, E; Ciccarelli, M; Correale, M; D'Agostino, A; Dattilo, G; Dini, FL; Ferretti, M; Grelli, A; Guida, S; Jacoangeli, F; Lupi, L; Luschi, L; Masarone, D; Mercurio, V; Nodari, S; Pacileo, G; Palazzuoli, A; Piepoli, M; Pugliese, NR; Rispoli, A; Scelsi, L; Tocchetti, CG2
Abukhalaf, SA; Alzughayyar, TZ; Amerson-Brown, MH; Aqel, R; Brown, CA; Dunn, JJ; Misk, RA; Rahman, A; Singh, IR; Webb, CR; Zalloum, JS1
Duan, X; Feng, Y; Wang, J; Yuan, J; Zhou, J1
Bhattacharya, J; Goldhaber-Fiebert, JD; Heidenreich, PA; Lin, J; Parizo, J; Sandhu, AT1
De Ponti, F; Diemberger, I; Poluzzi, E; Potena, L; Raschi, E; Sabatino, M1
Ammirati, E; Cantone, R; Cipriani, M; D'Angelo, L; Foti, G; Frigerio, M; Garascia, A; Gentile, P; Masciocco, G; Perna, E; Varrenti, M; Verde, A1
Claggett, BL; Cunningham, JW; Lefkowitz, M; McMurray, JJV; Pabón, MA; Packer, M; Pfeffer, MA; Rizkala, A; Shi, V; Solomon, SD; Vaduganathan, M; Zile, M1
Liu, H; Liu, X; Wang, L; Xu, Q; Zhang, L1
Fröb, EJ; Reinecke, H; Sindermann, JR; Tuleta, I1
Claggett, B; Desai, AS; Fang, JC; Januzzi, JL; Mitchell, GF; Murphy, SP; Myhre, PL; Prescott, MF; Solomon, SD; Ward, JH1
Akin, I; El-Battrawy, I1
Chen, H; Chen, X; Guan, F; Han, S; Huang, S; Huang, Z; Li, H; Lin, W; Wang, Y; Ye, F1
Grimm, D; Norre, T; Simonsen, U1
Edwards, DG; Farquhar, WB; Hosmane, V; McGinty, S; Nathaniel, S; Wenner, MM; Witman, MA1
Chen, H; Chen, M; Han, J; Jiang, J; Shu, Z; Sun, Z; Wang, Q; Wu, B; Xia, Q; Zhang, B; Zhao, J; Zheng, L; Zhou, D; Zhuo, C1
Kim, BS; Kim, HJ; Lee, AH; Lim, YH; Park, IH; Shin, JH1
Biondi-Zoccai, G; Bocchi, EA; Chan, JS; de Souza Lima Bitar, Y; Duraes, AR; Liu, T; Mesquita, ET; Neto, MG; Roever, L; Tse, G1
Kozak, PM; Stacey, RB; Upadhya, B; Vasan, RS1
Andersen, UØ; Goetze, JP; Gustafsson, F; Hansen, LH; Mark, PD; Plomgaard, P; Prickett, TCR; Terzic, D; Thonsgaard, S; Wewer Albrechtsen, NJ1
Du, H; Jiang, N; Li, X; Zhao, W1
Yoshikawa, T1
Hellenkamp, K; Nolte, K; von Haehling, S1
Ohishi, M1
Ambrosio, G; Celant, S; Colatrella, A; Colivicchi, F; Di Lenarda, A; Gensini, GF; Olimpieri, PP; Onder, G; Reboldi, G; Rosano, GMC; Russo, P1
Agostoni, P; Barillà, F; Basso, C; Correale, M; Curcio, A; Filardi, PP; Indolfi, C; Mancone, M; Merlo, M; Metra, M; Muscoli, S; Nodari, S; Palazzuoli, A; Paolillo, S; Pedrinelli, R; Pontremoli, R; Senni, M; Sinagra, G; Volpe, M1
Abumayyaleh, M; Akin, I; Aweimer, A; Behnes, M; Demmer, J; El-Battrawy, I; Krack, C; Lang, S; Mügge, A; Pilsinger, C1
Chen, J; Chen, T; Shou, Y; Yan, K; Zhang, L; Zhao, H1
Colvin, BM; Guglin, M; Kido, K; Szymanski, TW1
Tsutsui, H1
Heerspink, HJL; Ter Maaten, JM; Voordes, GHD1
Woods, RH1
Pathak, P1
Pudil, R1
Agostoni, P; Barillà, F; Basile, C; Basso, C; Correale, M; Curcio, A; Indolfi, C; Mancone, M; Merlo, M; Metra, M; Muscoli, S; Nodari, S; Palazzuoli, A; Paolillo, S; Pedrinelli, R; Perrone-Filardi, P; Pontremoli, R; Senni, M; Sinagra, G; Volpe, M1
Chen, X; Feng, Y; Li, W; Liu, H1
Arps, K; Piccini, JP1
Anand, I; Chiang, LM; Cikes, M; Claggett, B; Cunningham, J; Desai, AS; Gori, M; Lam, CSP; Linssen, G; McMurray, JJV; Milicic, D; Packer, M; Pfeffer, M; Planinc, I; Redfield, M; Senni, M; Shah, SJ; Solomon, SD; Sweitzer, N; Zile, MR1
Cartailler, J; Cohen-Solal, A; Launay, JM; Lefèvre, G; Logeart, D; Michel, T; Nougué, H; Picard, F; Sadoune, M; Vodovar, N1
Kario, K; Williams, B1
Cheang, I; Dai, C; Li, X; Liao, S; Lu, Q; Lu, X; Shi, S; Su, X; Wang, J; Xu, D; Yuan, F; Yuan, J; Zhang, M; Zhao, Y; Zhou, J; Zhu, X1
Meier, ML; Pierce, KN1
Barnes, JA; Gaziano, TA; Gilstrap, L; King, A; O'Malley, AJ; Tosteson, ANA; Zipkin, RJ1
Addison, D; Breathett, K; Brewer, LC; Essien, UR; Johnson, AE; Magnani, JW; Mazimba, S; Mohammed, SF; Swabe, GM1
Claggett, BL; Desai, AS; Fang, JC; Mitchell, GF; Myhre, PL; Prescott, MF; Shah, AM; Solomon, SD; Ward, JH1
Cheng, YY; Hsu, WT; Lee, CM; Wang, SR; Weng, SE; Yang, TY1
Abdul-Jawad Altisent, O; Barceló, E; Bayes-Genis, A; Casquete, D; Cediel, G; Codina, P; de la Espriella, R; Domingo, M; Gastelurrutia, P; Lupón, J; Nuñez, J; Pascual-Figal, DA; Ruiz-Cueto, M; Santesmases, J; Santiago-Vacas, E; Spitaleri, G; Vila, J; Zamora, E1
Bao, Q; Li, G; Li, Y; Liu, T; Shao, S; Suo, Y; Wang, Y; Yang, Q; Yuan, M; Zhang, Y1
Abadir, PM; Dickinson, LE; Gilkes, DM; Godet, I; Marin, S; Nidadavolu, LS; Tian, J; Walston, JD1
Atıcı, A; Bal, E; Barman, HA; Dogan, O; Özyıldırım, S; Tanyolaç, S; Yiğit, Z1
Ding, Y; Li, J; Wei, Z; Zhu, L1
Chen, C; Fan, L; Li, J; Li, X; Lv, Q; Tian, D; Zuo, C2
Acker, N; Bailey, KR; Burnett, JC; Desai, V; Gonzalez Bonilla, HM; Iyer, S; Liu, D; Murthy, V; Nguyen, TTL; Pereira, NL; Redfield, M; Shrivastava, S; Wang, M; Weinshilboum, RM1
Bojsen-Møller, KN; Deacon, CF; Gluud, LL; Goetze, JP; Gustafsson, F; Hansen, LH; Holst, JJ; Kjeldsen, S; Madsbad, S; Martinussen, C; Møller, A; Plomgaard, P; Rashu, EB; Richter, MM; Wewer Albrechtsen, NJ1
Dai, W; Huang, X; Luo, J1
Bhatt, AS; Desai, RJ; Lauffenburger, JC; Schneeweiss, S; Solomon, SD; Vaduganathan, M1
Lozhkina, NG; Spiridonov, AN1
Campanile, A; Carrizzo, A; Ciccarelli, M; Citro, R; Correale, M; Cuomo, A; Dattilo, G; Di Pietro, P; Galasso, G; Giallauria, F; Masarone, D; Mazzeo, P; Mercurio, V; Pacileo, G; Radano, I; Ravera, A; Silverio, A; Tocchetti, CG; Vecchione, C; Visco, V1
Gupta, R; Maitz, TN; Persin, K; Sundlof, DW1
Slawson, DC1
Jia, R; Jiang, L; Li, S; Raj, A; Sun, C; Sun, D; Wu, X; Xu, Y; Zhang, X; Zheng, Z1
Claggett, B; Cunningham, JW; Jackson, A; Lefkowitz, M; McMurray, JJV; Packer, M; Pfeffer, MA; Rouleau, J; Rørth, R; Shah, SJ; Solomon, SD; Swedberg, K; Vaduganathan, M; Wijkman, MO; Zile, M1
Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE1
Samsky, MD; Sen, S1
Jatić, Z; Kulić, M; Naser, N1
Yan, C; Zhang, X; Zheng, M1
Antonio, EL; Arruda-Junior, DF; Girardi, AC; Gowdak, LHW; Martins, FL; Salles, TA; Tavares, CAM; Tucci, PJF1
Adams, J; Mosler, C1
Agrawal, R; Cristino, J; Gautam, R; Proudfoot, C; Thakur, L; Tolley, K1
Alemayehu, WG; Armstrong, PW; Butler, J; Edelmann, F; Ezekowitz, J; Hernandez, AF; Lam, CSP; McMullan, C; O'Connor, CM; Pieske, B; Ponikowski, P; Roessig, L; Senni, M; Sim, D; Voors, AA; Westerhout, CM1
Gao, M; Gong, L; Wang, X; Wang, Z; Wei, Z; Zhang, M; Zhang, Q; Zhang, Z1
Fu, Y; Peng, ML; Ren, H; Wu, CW; Zhang, Y; Zhou, SS1
Gok, M; Ozturk, C; Yalta, K; Yalta, T1
Alper, CJ; Bacon, R; Clements, KM; Coelho, A; Gabot, A; Greenwood, BC; Lavitas, P; Lenz, K; Pomfret, TC; Taylor, M1
Álvarez-García, J1
Beldhuis, IE; Chatur, S; Claggett, BL; Kober, L; Lefkowitz, M; McCausland, FR; McMurray, JJV; Peikert, A; Pfeffer, MA; Seferovic, P; Skali, H; Solomon, SD; Vaduganathan, M1
Fan, H; Ning, T; Tian, Q; Xiong, Z; Zheng, Z1
Butt, JH; McMurray, JJV1
Abdin, A; Bauersachs, J; Böhm, M; Hadëri, B; Kindermann, I; Laufs, U; Riemer, U; Schulz, M; Vukadinović, D; Wachter, R1
Chen, S; Kang, L; Liu, Y; Si, J; Xu, B; Zhong, C1
Barron, A; Mahtani, K; Patel, B; Wang, B1
Chen, D; Lai, P; Liao, YL; Ling, JY; Tian, KJ; Xie, MJ; Xue, JH; Ye, JH; Zhong, WT; Zhong, YM1
Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, HT; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY1
Lewicka, E; Sławiński, G1
Ageev, FT; Ovchinnikov, AG1
Crespo-Leiro, MG; Escobar, C; Esteban-Fernández, A; Farré, N; Garcia, A; Luis-Bonilla, J; Nuñez, J1
Alonso-Titos, J; Gaitán-Román, D; Hernández, D; Martín-Reyes, G; Martínez-Esteban, MD; Moreno-Ortiz, A; Pozo-Álvarez, R; Ruiz-Esteban, P; Vázquez-Sánchez, T1
Basu, T; Birati, E; Brady, P; Chopra, V; Hummel, SL; Kamdar, N; Nallamothu, BK; Shore, S1
Abdullah, DM; Alsemeh, AE; Khamis, T1
Bojsen-Møller, KN; Wewer Albrechtsen, NJ1
Ikari, Y; Ikeda, T; Ishii, S; Kida, K; Konishi, M; Matsumoto, S; Nakamura, N; Shibata, A1
Anker, SD; Bhatt, DL; Butler, J; Harrington, J; Hernandez, AF; Jones, WS; Petrie, MC; Udell, JA1
Anand, IS; Atar, D; Butt, JH; Desai, AS; Dewan, P; Echeverria, LE; Ge, J; Gong, J; Jhund, PS; Køber, L; Lam, CSP; Lefkowitz, MP; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Sim, D; Solomon, SD; Van Veldhuisen, DJ; Vrtovec, B; Zannad, F; Zile, MR1
Berwanger, O; Braunwald, E; Claggett, B; De Pasquale, C; Filippatos, G; Granger, CB; Jering, KS; Lewis, EF; Maggioni, AP; McMurray, JJV; Mehran, R; Merkely, B; Pfeffer, M; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y1
Huang, J; Liu, J; Lou, Y; Yu, Y1
Abushanab, D; Al-Badriyeh, D; Alyafei, SA; Arabi, AR; Kaddoura, R1
Bernard, ML; Dominic, P; Elise Hiltbold, A; Huang, E; Khatib, S; Morin, DP; Polin, GM; Rogers, PA1
Aimo, A; Anker, SD; Arfsten, H; Barison, A; Bayes-Genis, A; Butler, J; Castiglione, V; Coats, AJS; de Boer, RA; Emdin, M; Fabiani, I; Filippatos, G; González, A; Januzzi, JL; Jhund, P; Lupón, J; Metra, M; Mueller, C; Núñez, J; Ponikowski, P; Richards, M; Rosano, G; Rossignol, P; Seferovic, P; Teerlink, J; Vergaro, G; Zannad, F1
Cho, GY; Hwang, IC; Kim, HK; Kim, SH; Kim, YJ; Lee, HJ; Lee, SP; Moon, MG; Park, JB; Yoon, YE1
Abdo, VB; Ashour, RH; Elshenawy, DSA; Ramadan, NM1
Angoran, I; Anzouan-Kacou, JB; Bamba-Kamagaté, D; Coulibaly, I; Koffi, F; N'cho-Mottoh, MB; Traoré, F1
Imamura, T; Kinugawa, K1
Barrios, V; Clark, AL; Damy, T; Drozdz, J; Ferber, PC; Fonseca, C; Hussain, RI; Kalus, S; Koch, C; Lund, LH; Maggioni, AP; Zeymer, U2
Wang, S; Zhang, F; Zhu, M1
Polovina, M; Rosano, G; Seferović, J; Seferović, PM1
Ji, Y; Jia, R; Sun, D1
Afzal, O; Akhtar, MS; Altamimi, A; Hassan, MZ; Hassan, Q; Mohammad, AAS; Sharma, AK; Tabassum, F1
Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH3
Belohlavek, J; Butylin, D; Chiang, Y; Fonseca, C; Lonn, E; Noè, A; Pascual-Figal, D; Schwende, H; Senni, M; Straburzynska-Migaj, E; Wachter, R; Witte, KK1
Hellenkamp, K; Valentova, M; von Haehling, S1
Xu, Z; Yang, S; Zhang, X1
Beckendorf, J; Estler, B; Frankenstein, L; Frey, N; Fröhlich, H; Mäck, M; Schlegel, P; Täger, T1
Montepara, CA; Proco, D; Rodgers, JE; Sharma-Huynh, P; Skersick, PT1
Abuyousef, S; Ahmed, E; Alyafei, S; Hamou, F; Kasem, M; Mahfouz, A; Orabi, B; Rahhal, A; Shoukry, AE1
Ge, T; Yang, Y; Zhao, Y1
Chatur, S; Claggett, BL; Desai, AS; Jering, K; Lefkowitz, M; McMurray, JJV; Pfeffer, MA; Solomon, SD; Vaduganathan, M; Vardeny, O1
Butler, J; Contreras, J; Felker, GM; Januzzi, JL; Liu, Y; Murphy, S; Omar, AMS; Piña, IL; Solomon, S; Ward, J1
Cao, QY; Fan, ZB; Qi, GX; Shen, JF; Wu, CW; Xu, F1
Chen, W; Dai, C; Lin, G; Wu, M; Xu, K1
Adamsson Eryd, S; Bodegård, J; Bozkurt, B; Kishi, T; Lund, LH; Savarese, G; Thuresson, M; Vardeny, O1
Allam, EA; Elsharkawy, AM; Hammadi, SH; Hassan, MA; Shams, SS1
Barrios, V; Clark, AL; Damy, T; Drożdż, J; Ferber, PC; Fonseca, C; Kalus, S; Koch, C; Lund, LH; Maggioni, AP; Zeymer, U1
Walsh, MN1
Babes, EE; Behl, T; Bungau, SG; Horvath, T; Iovanovici, DC; Moisi, M; Rus, M; Tit, DM; Vesa, CM1
Chen, L; Chen, Y; He, Q; Huang, J; Li, RX; Lu, JL; Mo, DC1
Slomski, A1
Gąsior, M; Grabowski, M; Lelonek, M1
Brugaletta, S; Cristóbal, H; Dantas, AP; García de Frutos, P; García-Álvarez, A; Mendieta, G; Ortega, E; Ortega-Paz, L; Ortiz-Perez, JT; Rodriguez, JJ; Sabaté, M; Sandoval, E1
Allen, LA; Fonarow, GC; Greene, SJ; Greiner, MA; Hardy, NC; Li, Z; Lippmann, SJ; Mentz, RJ; O'Brien, EC; Peterson, PN; Pierce, JB; Shen, X; Stampehl, M1
Berwanger, O; Braunwald, E; Claggett, B; De Pasquale, CG; Ducrocq, G; Granger, C; Jering, K; Køber, L; Landmesser, U; Lefkowitz, M; Leng, DSK; Lewis, EF; Maggioni, A; Mann, DL; McMurray, JJV; Mehran, R; Petrie, M; Pfeffer, MA; Rouleau, JL; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y1
Butt, JH; Claggett, BL; de Boer, RA; Desai, AS; Docherty, KF; Hernandez, AF; Inzucchi, SE; Jering, KS; Jhund, PS; Kondo, T; Kosiborod, MN; Lam, CSP; Langkilde, AM; Martinez, FA; McMurray, JJV; Petersson, M; Shah, SJ; Solomon, SD; Vaduganathan, M; Wilderäng, U; Yang, M1
Duan, X; He, Y; Wu, Q; Yan, F; Zhu, H1
Chandra, A; Claggett, BL; Desai, AS; Lefkowitz, MP; Lewis, EF; Liu, J; McMurray, JJV; Packer, M; Pfeffer, MA; Polanczyk, CA; Rouleau, JL; Schwende, H; Shi, VC; Solomon, SD; Vaduganathan, M; Zile, MR1
Patel, RB; Sinha, A1
Benfari, G; Brunetti, ND; Cameli, M; Canepa, M; Carluccio, E; Ciccarelli, M; Cicoira, M; Citro, R; Corrado, E; Correale, M; De Carli, G; Degiovanni, A; Dini, FL; Emdin, M; Giannoni, A; Guaricci, AI; Loria, V; Malagoli, A; Mandoli, GE; Mazzeo, P; Mengoni, A; Moderato, L; Novo, G; Pasquini, A; Pastore, MC; Patti, G; Piscitelli, L; Pugliese, NR; Rosa, G; Santoro, C; Taddei, C1
Adhikari, S; Blecker, S; Chunara, R; Dodson, JA; Kozloff, S; Kronish, IM; Li, X; Mukhopadhyay, A; Ramatowski, M; Shah, B1
Butler, J; Felker, GM; Januzzi, JL; Maisel, AS; Meng, X; Murphy, SP; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH1
Fusco, F; Grimaldi, N; Iannuzzi, A; Merola, A; Palma, M; Sarubbi, B; Scognamiglio, G1
Shaikh, AS; Xu, XD; Yang, HR; Zhou, BT1
Andreozzi, F; Armentaro, G; Arturi, F; Cassano, V; Condoleo, V; Maio, R; Miceli, S; Pelaia, C; Pelle, MC; Perticone, M; Salzano, A; Sciacqua, A; Sesti, G; Succurro, E1
Abumayyaleh, M; Akin, I; Aweimer, A; Crack, C; Demmer, J; El-Battrawy, I; Mügge, A; Pilsinger, C; Zhou, X1
Wang, L; Wang, R; Wang, Y; Wei, J; Ye, H; Zhang, X; Zhao, Y1
Hawkins, NM; Yao, RJR1
Benini, A; Bingel, A; Edelmann, F; Messroghli, D; Neumann, K; Pieske, B; Schönrath, F1
Martínez-Del Río, J; Morón-Alguacil, A; Negreira-Caamaño, M; Pérez-Díaz, P; Piqueras-Flores, J1
Asile, G; Basile, C; Buonocore, D; Chirico, A; Colella, A; Gargiulo, P; Marzano, F; Nardi, E; Paolillo, S; Parlati, ALM; Perrone-Filardi, P1
Bonnet, D; Burch, M; Garito, T; Kantor, PF; Kocun, M; Shaddy, R; Solar-Yohay, S; Zhang, S1
Gao, M; Gu, L; Hou, Y; Ma, K; Wang, X; Zhang, F; Zhang, Y; Zheng, S1
Dudek, M; Kałużna-Oleksy, M; Kolasa, J; Lelonek, M; Nessler, J; Ptaszyńska-Kopczyńska, K; Rostoff, P; Straburzyńska-Migaj, E1
Chen, WW; Dang, HQ; Gao, J; Jiang, J; Li, YM; Liu, YL; Zhang, XZ1
Asai, K; Asano, M; Kanai, H; Matsushita, M; Noma, S; Nomura, A; Sawatani, T; Shirakabe, A; Takayasu, T1
Page, RL1
Chen, X; Cheng, J; Du, W; Hu, Y; Li, J; Li, X; Li, Z; Su, J; Yang, J; Yu, Q; Zhang, Z; Zheng, N1
Fukushima, H; Horio, T; Ishimitsu, T; Iwashima, Y; Rai, T1
Franceschi, F; Gabrielli, M; Romani, GR1
Cohen-Solal, A; Laribi, S; Lassus, J; Launay, JM; Logeart, D; Michel, T; Nougué, H; Picard, F; Sadoune, M; Vodovar, N1
Chen, M; Fu, P; Gan, Y; He, X; He, Y; Jin, Y; Li, K; Liao, R; Liu, R; Qin, M; Wang, Z; Xue, H; Zhang, M; Zheng, L; Zhong, H; Zhou, X; Zou, H1
Braunwald, E; Hernandez, AF; Lepage, S; Mentz, RJ; Morrow, DA; Sarwat, S; Sharma, K; Solomon, SD; Starling, RC; Velazquez, EJ; Ward, JH; Williamson, K; Zieroth, S1
Angelini, F; Coppini, L; Ferraro, I; Giordana, F; Musumeci, G; Rossini, R; Ruffino, E; Tizzani, E; Valente, E; Varbella, F1
Goetze, JP; Hansen, LH; Nersting, J; Terzic, D1
Chatur, S; Claggett, BL; Lefkowitz, M; McCausland, FR; McMurray, JJV; Packer, M; Pfeffer, MA; Rouleau, J; Solomon, SD; Vaduganathan, M; Zile, MR1
Aoki, J; Asami, M; Horiuchi, Y; Ishizawa, T; Kawakami, T; Komiyama, K; Nakajima, M; Nakase, M; Nonaka, H; Sekiguchi, M; Setoguchi, N; Tanabe, K; Tanaka, J; Watanabe, Y; Yahagi, K; Yuzawa, H1
Ahmad, J; Dominic, P; Mohammad, Z; Morin, D; Penagaluri, A; Sultan, A1
Dodd, JD; Fox, R; Gallagher, J; Ledwidge, M; McDonald, K; McVeigh, N; Murphy, DJ; Ryan, F; Shorten, E; Sweeney, C; Watson, C; Zhou, S1
Flynn, H; Hayes, W; Henter, J1
Januzzi, JL; Murphy, SP1
Ye, G1
Agostoni, P; Cimino, R; Ferrari, C; Mantegazza, V; Mapelli, M; Maragna, R; Pepi, M; Pontone, G1
Ashraf, T; Balouch, IJ; Bashir, S; Bhatti, UH; Karim, M; Khan, MN; Moazzam, A; Naseeb, K; Rauf, R; Soomro, NA1
Bonilla Palomas, JL; Escobar Cervantes, C; Esteban Fernández, A; González Costello, J; González Franco, A; Mirabet, S; Núñez Villota, J; Recio Mayoral, A; Rubio Gracia, J1
Abdelaziz, RR; Abo-Khookh, AM; Ghoneim, HA; Nader, MA; Shawky, NM1
Akrobetu, DJ; Barks, MC; Campagna, A; Davis, JK; Dickert, NW; Farley, S; Gutterman, S; Mitchell, AR; Nguyen, TV; Rao, BR; Santanam, T; Sharma, A; Speight, CD; Ubel, PA1
Chen, R; Cheng, Y; Deng, P; Gao, LC; Li, CX; Li, FJ; Li, HL; Li, L; Long, HZ; Luo, HY; Peng, XY; Xu, SG; Zhou, ZW1
Li, X; Lou, Y; Sun, M; Wang, Q; Wang, Y; Wang, Z1
Gu, J; Wang, CQ; Wang, Y; Zhang, JF1
Fu, K; Hu, Y; Ji, X; Lin, Z; Lu, H; Miao, D; Sun, Y; Wang, C; Wang, F; Xiao, J; Zhang, H; Zhang, X1
Appelbaum, JS; Huetteman, AT; Reyes, EA; Zhang, H1
Bin, J; Cao, S; Chen, L; He, M; Huang, X; Li, M; Liao, W; Liao, Y; Lin, H; Liu, C; Shen, M; Zheng, C1
Biering-Sørensen, T; Claggett, B; Lassen, MCH; Lefkowitz, M; McMurray, JJV; Packer, M; Pieske, B; Pieske-Kraigher, E; Shah, A; Shi, V; Solomon, SD; Voors, A; Zile, M1
Ayesta, A; Datino, T; Díez-Villanueva, P; Esteban-Fernández, A; Jimenez-Mendez, C; Martínez-Sellés, M; Pérez, Á1
Chen, L; He, J; Li, Q; Qiu, Z; Tang, M; Wu, Q; Xie, L; Zheng, J1
Amir, O; Braunwald, E; Butt, JH; Cadena, A; Carrillo-Calvillo, J; Cho, MC; Claggett, BL; Granger, CB; Jering, KS; Kerkar, P; Køber, L; Lewis, EF; Maggioni, AP; Mann, DL; McMurray, JJV; Merkely, B; Miao, ZM; Ntsekhe, M; Núñez, JE; Pfeffer, MA; Sim, D; Solomon, SD; Steg, PG; van der Meer, P; Zhou, Y1
Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Piña, IL; Solomon, SD; Ward, JH1
Kudryavtsev, AA; Makarovskaya, MV; Ryazanov, AS; Shikh, EV1
Abraham, WT; Butt, JH; Desai, AS; Dewan, P; Dickstein, K; Ferreira, JP; Jhund, PS; Køber, L; McMurray, JJV; Packer, M; Petrie, MC; Rouleau, JL; Solomon, SD; Stewart, S; Swedberg, K; Zile, MR1
Azushima, K; Tamura, K; Tsukamoto, S; Uehara, T; Wakui, H1
Chen, J; Li, C; Liang, W; Pei, Y; Wang, Q; Yu, J1
Akai, H; Munakata, Y; Numahata, T; Sawada, S; Tanji, Y; Watanabe, T1
Bianchi, F; Cotugno, M; Fiori, E; Forte, M; Gallo, G; Magrì, D; Marchitti, S; Raffa, S; Ranieri, D; Rubattu, S; Sciarretta, S; Stanzione, R; Testa, M; Visco, V; Volpe, M1
Alacapa, J; Alconera, CJ; Almirol, BJ; Caesar Delos Trinos, JP; Gerodias, F; Leong, RN; Lim, S; Mojica, VJ; Paredes, KP; Tamayo, RL; Tumanan-Mendoza, B1
Butler, J; Felker, GM; Januzzi, JL; Liu, Y; Mohebi, R; Myhre, PL; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH1
Hu, WS; Lin, CL2
Chen, BT; Chen, YN; Huang, XL; Wang, XJ1
Barylski, M; Drożdż, J; Filipiak, KJ; Gorczyca-Głowacka, I; Kapłon-Cieślicka, A; Kasprzak, JD; Lelonek, M; Mamcarz, A; Ochijewicz, D; Ryś-Czaporowska, A; Sobczak-Kaleta, M; Starzyk, K; Szymański, FM; Wełnicki, M; Wożakowska-Kapłon, B1
Braunwald, E; Claggett, BL; Desai, AS; Hernandez, AF; Kulac, IJ; Lefkowitz, M; McMurray, JJV; Mentz, RJ; Miao, ZM; Morrow, DA; Solomon, SD; Starling, RC; Vaduganathan, M; Velazquez, EJ; Ward, JH; Williamson, KM; Zieroth, S1
Braunwald, E; Desai, AS; Hernandez, AF; Lepage, S; Mentz, RJ; Morrow, DA; Sarwat, S; Sharma, K; Solomon, SD; Starling, RC; Velazquez, EJ; Ward, JH; Williamson, KM; Zieroth, S1
Lavie, CJ; Mehra, MR; Ventura, HO3
Bhatt, AS; Desai, RJ; Lee, SB; Vaduganathan, M1
Liu, Y; Ma, X; Sheng, Y; Sun, F; Yang, X1
Pandya, A; Spahillari, A; Yan, BW1
Fernández-Ruiz, I4
Aspromonte, N; Bonanni, A; Camilli, M; Chiorazzo, G; Crea, F; Graziani, F; Iannaccone, G; Lanza, GA; Locorotondo, G; Lombardo, A; Mango, F; Massetti, M; Meucci, MC; Montone, RA; Natali, R; Russo, M1
Chang, HY; Fong, MC; Huang, HT; Huang, JL; Ko, SL; Liao, CT; Lin, WY; Lo, HC; Wang, CY1
Adamsson Eryd, S; Bodegård, J; Bozkurt, B; Cleland, JGF; Khordoc, C; Kishi, T; Lund, LH; Savarese, G; Thuresson, M; Vardeny, O; Zhang, R1
Harada, N; Kato, T; Murakami, T; Yabe, D1
Agostoni, P; Capovilla, T; De Martino, F; Dell'Aversana, S; Esposito, I; Filardi, PP; Galotta, A; Magrì, D; Mantegazza, V; Mapelli, M; Mattavelli, I; Nepitella, AA; Paolillo, R; Paolillo, S; Salvioni, E; Tamborini, G; Vignati, C1
Ako, J; Eda, Y; Fujita, T; Iida, Y; Ikeda, Y; Ishii, S; Koitabashi, T; Nabeta, T; Oikawa, J; Takigami, Y; Yazaki, M1
Bernhardt, R; Chapa, J; Damera, N; George, B; Lee, E; Rao, RA; Reese, L; Shah, C1
Butler, J; Claggett, BL; Felker, GM; Januzzi, JL; Kulac, IJ; Liu, Y; McMurray, JJV; Myhre, PL; Piña, IL; Prescott, MF; Rouleau, JL; Solomon, SD; Ward, JH; Zile, MR1
Adamson, C; Curtain, JP; Desai, AS; Docherty, KF; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR1
Abrahamowicz, M; Behlouli, H; de Moura, CS; Pilote, L; Sohani, ZN1
Abozied, O; Anderson, JH; Andi, K; Burchill, LJ; Connolly, HM; Egbe, AC; Jain, CC; Miranda, WR1
Boonpala, P; Kalandakanond-Thongsong, S; Kijtawornrat, A; Kumphune, S; Panyasing, Y; Saengklub, N; Tantisuwat, L1
Acquaro, M; Ghio, S; Greco, A; Pasotti, B; Rordorf, R; Sanzo, A; Savastano, S; Scelsi, L; Schirinzi, S; Seganti, A; Spolverini, M; Turco, A1
Le Jemtel, TH; Samson, R1
Bachórzewska-Gajewska, H; Dobrzycki, S; Zalewska-Adamiec, M1
Cai, JL; Yu, J; Zhang, T1
Blohm, JH; Brockmöller, J; Burgdorf, C; Hundack, L; Ivanoski, S; Januszewski, M; Remppis, BA1
Chang, HY; Chen, YJ; Hou, CJ; Hsiao, CC; Hsu, CY; Hsu, NW; Huang, WH; Hung, CL; Hung, TC; Lin, YH; Su, CH; Sung, KT; Tsai, CT; Tsai, SY; Yeh, HI; Yun, CH1
Agostoni, P; Banfi, C; Biondi, ML; Bonomi, A; Capra, N; Mapelli, M; Mattavelli, I; Palermo, P; Paolillo, S; Salvioni, E1
Bellows, BK; Cohen, LP1
Alencar, AKN1
Ji, XP; Lin, ZW; Lyu, HX; Wu, AH1
Alibaşiç, H; Aydin, S; Çiçek, M; Ekici, B; Koçak, A1
Alarco, W; Figueroa, Y; Gómez-Mesa, JE; Magaña, A; Pow-Chon, F; Quesada, D; Ramos, CE; Rodríguez-García, D; Rossel, V; Saldarriaga, C; Speranza, M; Ventura-Umanzor, JR1
Cao, P; Lv, Y; Peng, H; Yang, Q; Zhai, X1
Ieda, M; Ishizu, T; Kawamatsu, N; Machino-Ohtsuka, T; Minami, K; Nakatsukasa, T; Sato, K; Terauchi, T; Yamamoto, M1
Huang, Y; Li, X; Li, Y; Liu, Z; Wu, X1
Jeong, HE; Kim, JS; Ko, H; Lim, MJ; Shin, JY; Yoo, YG1
Aili, A; Bate, B; Chen, P; Dan, S; Guo, J; Han, Z; Hou, D; Hu, G; Kuransi, A; Nay, X; Qiqike, B; Xia, B; Xie, J; Zhu, M1
Morita, H; Nakanishi, K1
Chen, H; Cid-Ruzafa, J; Delgado, JF; Duong, M; Escobar, C; Gonzalez, V; Gutiérrez, M; Hernández, I; Hunt, PR; Justo, N; Palacios, B1
Burnett, JC; Cappola, TP; Felker, GM; Hernandez, AF; Iyer, SR; Lyle, MA; Pereira, NL; Reddy, YNV; Redfield, MM; Scott, CG1
Menachem, JN; Opotowsky, AR1
Abellas-Sequeiros, M; Alonso-Salinas, GL; Del Prado Díaz, S; Del Rey, JM; Zamorano, JL1
Erviti, J; Leache, L; Saiz, LC1
López, GT; Malafarina, V; Rodil Fraile, R1
Fabris, E; Ferrari, R; Frigerio, M; Merlo, M; Metra, M; Rapezzi, C; Sinagra, G1
De Vecchis, R; Di Maio, M; Paccone, A2
Anand, IS; Boytsov, SA; Claggett, B; Cleland, J; Comin-Colet, J; Desai, AS; Düngen, HD; Ge, J; Goncalvesova, E; Gong, J; Jhund, PS; Katova, T; Kerr Saraiva, JF; Lam, CSP; Lefkowitz, MP; Lelonek, M; Maggioni, AP; Martinez, F; McMurray, JJV; Merkely, B; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Senni, M; Shah, SJ; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Zannad, F; Zhou, J; Zile, MR1
Docherty, KF; McMurray, JJV1
Chung, F; Han, J; Jackevicius, CA; Mody, FV; Nguyen, QL1
Grigg, SE1
Okunade, O1
Albert, NM; Arnold, SV; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Hellkamp, A; Khariton, Y; McCague, K; Nassif, ME; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB1
Balsam, P; Dąbrowski, R; Farkowski, MM; Gackowski, A; Grabowski, M; Jędrzejczyk-Patej, E; Kalarus, Z; Leszek, P; Nessler, J; Opolski, G; Ozierański, K; Przybylski, A; Sterliński, M1
Aguiar, C; Cardoso, J; Ferrari, R; Fonseca, MC; Fucili, A; Moreira, JI; Rapezzi, C1
Jorsal, A; McMurray, JJV; Nielsen, JC; Nielsen, RR; Pryds, K; Sommer, A; Wiggers, H1
de Jong, LA; Jansen, DEMC; Postma, MJ; van der Pol, S; Vemer, P1
Chang, HY; Chen, KC; Chong, E; Feng, AN; Fong, MC; Fu, HN; Huang, KC; Yin, WH1
Castiello, A; Gavazzoni, M; Metra, M; Sciatti, E; Vizzardi, E1
Akerman, CC; Beavers, JC1
Addetia, K; Kalantari, S; Karagodin, I; Kim, G; Lang, R; Mor-Avi, V; Sayer, G; Tayazime, S; Uriel, N; Weinert, L; Yamat, M; Yu, DB1
Meyer, P; Reny, JL; Russo-Vorms, L1
Birkeland, K; Fombu, E; Grant, D; Heywood, JT; Khandwalla, RM; McCague, K; Owens, RL; Riebman, JB; Steinhubl, S1
Heyse, A; Mahieu, E; Manhaeghe, L; Van Durme, F; Vanfraechem, C1
Akin, I; Borggrefe, M; El-Battrawy, I1
Adams, KF; Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Giblin, EM; Hernandez, AF; Hill, L; McCague, K; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB1
Dauw, J; Dupont, M; Martens, P; Mullens, W; Somers, F; Van de Broek, H; Verluyten, L1
Bover, R; De-Juan, J; Del Prado, S; Díez-Villanueva, P; Esteban-Fernández, A; Gómez-Bueno, M; López-Azor, JC; Manuel-Iniesta, Á; Martínez-Sellés, M; Pérez, Á; Valero-Masa, MJ; Vicent, L1
Książczyk, M; Lelonek, M1
Bayramoğlu, A; Dereli, S; Kaya, A1
Alba, PR; Bress, AP; Choi, ME; Dodson, JA; He, T; King, JB; LaFleur, J; Levitan, EB; Mohanty, AF; Patterson, OV; Russo, PA; Vardeny, O1
Anand, IS; Cikes, M; Claggett, B; Ge, J; Goncalvesova, E; Jackson, AM; Jhund, PS; Katova, T; Kosztin, A; Lam, CSP; Lefkowitz, MP; Lelonek, M; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Sabarwal, SV; Shah, AM; Shah, SJ; Shi, VC; Solomon, SD; Sweitzer, N; van Veldhuisen, DJ; Vardeny, O; Zannad, F; Zile, MR1
A Pfeffer, M; Anand, I; Boytsov, S; Chen, CH; Desai, A; Kober, L; L Claggett, B; Lefkowitz, M; Linssen, G; Luis Arango, J; Lund, LH; McMurray, JJV; Merkely, B; Packer, M; Rizkala, A; Rouleau, J; Senni, M; Shi, V; Sibulo, A; Solomon, SD; Swedberg, K; Sweitzer, N; Vaduganathan, M; Vinereanu, D; Zile, M1
Ajufo, E; Das, SR; Fonarow, GC; Navar, AM; Pandey, A; Sumarsono, A; Vaduganathan, M1
Angeletti, S; Anguissola, GB; Bono, MC; Ciccozzi, M; Costantino, S; Locorriere, L; Pantano, AL; Spoto, S; Terracciani, F; Valeriani, E1
Li, Y; Liu, Z; Wang, J1
Bergdahl, E; Lindmark, K; Norberg, H2
Chang, PC; Chou, CC; Chu, Y; Huang, YC; Lee, HL; Lin, SF; Wen, MS; Wo, HT1
Chen, X; Fu, M; Schaufelberger, M1
Abbate, A; Bonaventura, A; Del Buono, MG; Dixon, DL; Van Tassel, BW; Vecchié, A; Wohlford, GF1
Lund, LH; Savarese, G1
Bao, W; Belohlavek, J; Butylin, D; Chakrabarti, A; Fonseca, C; Lonn, E; Mueller, C; Noe, A; Pascual-Figal, D; Schwende, H; Senni, M; Straburzynska-Migaj, E; Wachter, R; Witte, KK1
Wilcox, JE1
Ambrosy, AP; Braunwald, E; Chakraborty, H; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ1
DeVore, AD; Hernandez, AF1
Dunlay, SM; Sangaralingham, LR; Sangaralingham, SJ; Shah, ND; Tan, NY; Yao, X1
Bhatt, AS; Butler, J; Vaduganathan, M1
Cohen-Solal, A; Logeart, D1
Gao, Y; Hao, W; Hou, A; Luan, B; Wang, L; Xing, C; Zhao, H1
Barrios, V; Escobar, C; Manzano, L1
Chang, HY; Yin, WH1
Hryniewiecki, T; Kodziszewska, K; Kruszewski, M; Leszek, P; Pączek, L; Śmigielski, W; Sochanowicz, B1
Chow, CL; Hannah, V; Nandal, S; Vaddadi, G; Van Gaal, W1
Ayesta, A; Bover-Freire, R; de Juan-Bagudá, J; de la Cuerda, F; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; Iglesias, D; Iniesta, ÁM; Martínez-Sellés, M; Perea-Egido, JÁ; Rojas-González, A; Salamanca, J; Vicent, L1
Buckley, LF; Shah, AM1
Abreu, J; Branco, L; Feliciano, J; Ferreira, RC; Galrinho, A; Moreira, RI; Pereira-da-Silva, T; Rio, P; Soares, RM; Timóteo, AT; Valentim Gonçalves, A1
Bozkurt, B; Ezekowitz, J1
Raina, A; Sokos, GG1
Castro, A; Chaparro-Muñoz, M; López-Fernández, T; Lopez-Sendon, JL; Martín-Garcia, A; Martin-Garcia, AC; Martinez-Monzonis, A; Mitroi, C; Moliner, P; Sanchez, PL1
Fu, M; Ljungman, C; Nordberg Backelin, C1
Di Tano, G; Senni, M1
Aguirre-Plans, J; Fernández-Fuentes, N; Jorba, G; Junet, V; Mas, JM; Oliva, B; Pujol, A; Ruiz, JL; Segú-Vergés, C1
Cheng, S; Hamilton, MA; Kittleson, MM; Solomon, SD; Wolfson, AM; Zern, EK; Zile, MR1
Gonçalves, FR; Polónia, J1
Briasouli, A; Briasoulis, A; Fujisaki, T; Kuno, T; Takagi, H; Ueyama, H1
Brännström, M; Hellström Ängerud, K; Holmlund, L; Lindmark, K; Sandberg, C1
Chun, KH; Ha, J; Kang, SM; Kim, H; Lee, CJ; Lee, S; Lee, SH; Oh, J; Park, S1
Carballo, D; Carballo, S; Garin, N; Marti, C; Serratrice, J; Stirnemann, J1
Ahmad, T; Desai, NR; Kahn, PA; Riello, RJ1
Abumayyaleh, M; Akin, I; Behnes, M; Borggrefe, M; El-Battrawy, I1
Anand, IS; Anker, SD; Böhm, M; Claggett, BL; Lam, CSP; Lefkowitz, MP; McMurray, JJV; Pieske, B; Selvaraj, S; Shi, VC; Solomon, SD; Vaduganathan, M; Zannad, F1
Acanfora, C; Acanfora, D; Bortone, AS; Casucci, G; Ciccone, MM; Goglia, F; Incalzi, RA; Maestri, R; Scicchitano, P; Uguccioni, M1
Chang, PC; Chou, CC; Chu, Y; Lee, HL; Lin, SF; Wen, MS; Wo, HT1
Claggett, BL; Jhund, PS; Lefkowitz, M; McMurray, JJV; Packer, M; Rizkala, A; Seferovic, P; Shi, V; Solomon, SD; Vaduganathan, M; Widimský, J1
Abete, R; Chioffi, M; Grillo, M; Margonato, D; Mazzetti, S; Mortara, A; Passafaro, G; Pisani, M; Poggio, D; Rossi, J; Scifo, C1
Anker, SD; Böhm, M; Kindermann, I; Lam, CSP; Laufs, U; Maack, C; Selejan, S; Tschöpe, C; Ukena, C; Voors, AA; Werner, C; Wintrich, J1
Januzzi, JL; Myhre, PL1
Anand, IS; Chopra, VK; Claggett, BL; Cunningham, JW; Janssens, S; Jhund, PS; Kober, L; Lam, CSP; Lefkowitz, MP; McMurray, JJV; Packer, M; Pfeffer, MA; Prescott, MF; Rouleau, J; Shah, SJ; Shi, VC; Solomon, SD; Vaduganathan, M; Zannad, F; Zile, MR1
DeVore, AD; Fonarow, GC; Fudim, M; Heidenreich, PA; Hernandez, AF; Matsouaka, RA; Sayeed, S; Velazquez, EJ; Xu, H; Yancy, CW1
Chen, X; Jin, C; Xiang, M; Xie, L1
Agra-Bermejo, R; Alvarez Rodríguez, L; González-Juanatey, JR1
Chin, KL; Liew, D; Wang, BH; Zomer, E1
Bidaut, A; Bouali, Y; Donal, E; Gallard, A; Galli, E; Hubert, A; Laurin, C; Leclercq, C1
Auria, F; Bonadies, D; Carrizzo, A; Ciccarelli, M; Citro, R; De Angelis, E; Galasso, G; Gigantino, A; Iaccarino, G; Loria, F; Polito, MV; Rispoli, A; Silverio, A; Vecchione, C; Vitulano, G1
Chui, F; Dashwood, A; Gan, J; Laher, S; Rheault, H; Vale, C; Wong, YW1
Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB1
Bewarder, Y; Böhm, M; Kindermann, I1
Ackermann, G; Ahmed, K; Dieterle, T; Hullin, R; Meyer, I; Schaefer, S1
He, LS; Huang, JQ; Lao, HY; Liu, XQ; Xia, C; Xiong, LJ1
Claggett, B; Lefkowitz, M; McMurray, JJV; Minamisawa, M; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Suzuki, K; Swedberg, K; Zile, MR; Zucker, SD1
Feng, H; Li, WJ; Liao, HH; Mou, SQ; Tang, QZ; Wu, HM; Xia, H; Zhang, N; Zhou, ZY1
Aronovitz, MJ; Blanton, RM; Jaffe, IZ; Martin, GL; Pande, S; Richards, DA; Tam, K1
Comin-Colet, J; Ecochard, L; Edelmann, F; Hussain, RI; Jaarsma, T; Piepoli, MF; Schorr, J1
Barry, M; Doran, S; Kennedy, C; Smith, A1
Butler, J; Camacho, A; Felker, GM; Januzzi, JL; Maisel, AS; Piña, IL; Prescott, MF; Rocha, R; Solomon, SD; Williamson, KM1
Dauw, J; Martens, P; Mullens, W; Tersalvi, G1
Chalikias, G; Tziakas, D1
Ambrosy, AP; Chioncel, O1
Biegus, J; Ponikowski, P; Zymliński, R1
Newby, LK; Sen, S1
Abete, R; De Ponti, R; Iacovoni, A; Marazzato, J; Mortara, A; Senni, M; Vecchi, AL1
Baković, D; Barac, A; Čapkun, V; Duplančić, D; Eterović, D; Mirić, D; Sorić, T; Vuković, I1
Estep, JD; Luthman, J; Randhawa, VK; Soltesz, EG; Starling, RC; West, L1
Chen, X; Du, F; Gao, Z; Hua, H; Jing, X; Li, S; Sun, G; Sun, J; Xiao, Y; Xu, W1
Liu, T; Roever, L; Tse, G; Wang, Y1
Node, K; Tanaka, A2
Claggett, BL; Cunningham, JW; McMurray, JJV; Solomon, SD; Vaduganathan, M2
Wu, K; Zhao, S1
Jackson, AM; Jhund, PS; McMurray, JJV; Solomon, SD1
Ambrosy, AP; Braunwald, E; Desvigne-Nickens, P; DeVore, AD; Gilotra, NA; Givertz, MM; Gorodeski, EZ; Greene, SJ; Gupta, D; Hernandez, AF; Lala, A; Lewis, GD; Mahr, C; Mann, DL; McNulty, SE; Mohammed, SF; Redfield, MM; Shah, P; Starling, RC; Vader, JM1
Ates, B; Colak, C; Ermis, N; Ozhan, O; Parlakpinar, H; Ulutas, Z; Vardi, N1
Ioannou, A; Mandal, AKJ; Metaxa, S; Missouris, CG; Simon, S2
Balsam, P; Grabowski, M; Opolski, G; Ozierański, K; Tymińska, A1
Bengtsson, O; Claggett, BL; Desai, AS; Dewan, P; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Lindholm, D; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjostrand, M; Solomon, SD1
Maksutovic, NM; Thornby, KA1
Maurer, SJ; Tutarel, O1
Chang, PC; Chou, CC; Chu, PH; Hsiao, FC; Huang, CY; Wang, CL; Wen, MS1
Ammendola, E; D'Alterio, G; Gravino, R; Limongelli, G; Masarone, D; Melillo, E; Pacileo, G; Petraio, A; Valente, F; Vastarella, R; Verrengia, M1
Chiang, LM; Claggett, BL; Cunningham, JW; Lefkowitz, MP; McMurray, JJV; O'Meara, E; Pfeffer, MA; Prescott, MF; Redfield, MM; Rizkala, AR; Rouleau, J; Shah, SJ; Shi, VC; Solomon, SD; Zannad, F; Zile, MR1
Bayes-Genis, A; Lupón, J; Núñez, J1
Gronda, E; Iacoviello, M; Napoli, C1
Almenar-Bonet, L; Batalla-Monedero, M; López-Vilella, R; Pérez-Roselló, V; Sánchez-Lázaro, I; Sierra-San Miguel, P1
Chen, G; Deng, Z; Fang, Y; Kang, H; Qin, G; Wang, K; Zhang, J; Zhang, X1
Agostoni, P; Bonomi, A; de Martino, F; Gugliandolo, P; Magini, A; Mapelli, M; Mattavelli, I; Paolillo, S; Rovai, S; Salvioni, E; Sassi, V; Vignati, C1
Chilbert, MR; Ciriello, DN; Rogers, KC; Rovelli, R; Woodruff, AE1
Branzi, G; Caravita, S; Cerea, P; Ciambellotti, F; Malfatto, G; Munforti, C; Parati, G; Ravaro, S; Villani, A1
Benson, L; Dahlström, U; Fudim, M; Hage, C; Linde, C; Lund, LH; Lundberg, A; Rosano, GMC; Savarese, G; Schrage, B; Thorvaldsen, T1
Bonow, RO; Hernandez, AF; Yancy, CW1
Braunwald, E; Fonarow, GC; Gaziano, TA; Morrow, DA; Solomon, SD; Velazquez, EJ1
Ahmad, T; Desai, NR1
Bao, W; Butylin, D; Noè, A; Pascual-Figal, D; Prescott, MF; Schwende, H; Senni, M; Wachter, R1
Berg, DD; Braunwald, E; DeVore, AD; Duffy, CI; Gurmu, Y; Lala, A; Morrow, DA; Pinney, SP; Velazquez, EJ1
Allen, LA; Dickert, N; Doermann Byrd, K; Matlock, DD; Venechuk, GE1
Arslan, U; Çoksevim, M; Dereli, S; Doğduş, M; Kaya, A; Yenerçağ, M1
Ängerud, KH; Bergdahl, E; Lindmark, K; Norberg, H1
Eworuke, E; Huang, TY; Kolonoski, J; Menzin, TJ; Welch, EC1
Anand, IS; Claggett, BL; Cleland, JGF; Desai, AS; Janssens, S; Kober, L; Lefkowitz, MP; Mc Causland, FR; McGrath, MM; McMurray, JJV; Pfeffer, MA; Pieske, B; Rouleau, JL; Selvaraj, S; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Zile, MR1
Dani, SS; Ganatra, S; Vaduganathan, M1
Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; McCague, K; Meng, X; Morrow, DA; Rocha, R; Velazquez, EJ1
Ahmed, T; Gottlieb, SS1
Hu, P; Jin, D; Ke, Z; Wu, Y; Zhang, K; Zhang, Y1
Frljak, S; Vrtovec, B; Zorz, N1
Al-Khatib, SM; Blumer, V; Felker, GM1
Costanzo, MR2
Ambrosy, AP; Berardi, C; Braunwald, E; Chakraborty, H; DeVore, AD; Duffy, CI; Morrow, DA; Mulder, HS; O'Brien, TX; Velazquez, EJ1
Chatterjee, NA; Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJV; Packer, M; Rohde, LE; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vaduganathan, M; Zile, M1
Mandal, AKJ; Missouris, CG1
Castrodeza, J; Couto-Mallón, D; Diez-López, C; Dobarro, D; Gómez-Bueno, M; Gonçalves, A; González-Costello, J; McKenzie, S; Melendo-Viu, M; Ortiz, C; Tobar, J1
Aliyev, ER; Brauer, M; Park, S; Shafrin, J; Shen, X1
Abbas, CA; Bapat, D; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Januzzi, JL; Maisel, AS; Piña, IL; Prescott, MF; Solomon, SD1
Danzi, GB; De Maria, R; Di Tano, G; Loffi, M; Verde, S1
Birkeland, K; Fombu, E; Grant, D; Heywood, JT; Khandwalla, RM; Owens, RL; Steinhubl, SR1
Abshire, M; Alexy, T; Barringhaus, KG; Blanco, R; Briasoulis, A; DeVore, AD; Dhingra, R; Duffy, CI; Dunlay, SM; Eckman, PM; Espinoza, J; Gupta, B; Hernandez, AF; Lala, A; Lowes, BD; Mentz, RJ; O'Brien, EC; Rodgers, JE; Shen, X; Simon, MA; Stehlik, J; Thomas, L; Vilaro, J; Wells, QS; Xu, H1
Docherty, KF; McMurray, JJV; Solomon, SD; Vaduganathan, M1
Elsayed, H; Ganesananthan, S; Morgan, A; Parkes, A; Phillips, J; Shah, N; Shah, P; Yousef, Z1
Lelonek, M2
Hu, J; Huo, J; Jiang, W; Shan, Q; Wang, X; Wu, Y; Zhou, X1
Chan, H; Chng, BLK; Gao, F; Hon, JS; Sim, KLD; Teo, LYL; Zheng, Y1
Celli, D; Colombo, R; Galo, J1
Bosso, G; Botta, A; Carbone, V; Carella, G; Cittadini, A; De Luca, M; Del Buono, A; Di Giovanni, G; Fimiani, B; Guardasole, V; Guarnaccia, F; Lapice, E; Martedì, E; Memoli, G; Oliva, D; Oliviero, U; Romano, G; Valvano, A; Zito, GB1
Aimo, A; Bayes-Genis, A; Emdin, M; Georgiopoulos, G; Lombardi, CM; Passino, C; Pateras, K; Stamatelopoulos, K1
Alves, S; Capilé, E; Feliciano, J; Ferreira, RC; Galrinho, A; Gonçalves, AV; Moreira, RI; Pereira-da-Silva, T; Rio, P; Silva, S; Soares, R1
Bozkurt, B; Gillette, M1
Cheng, S; Hua, W; Zhang, N1
Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY1
Balas, B; Bruce Wirta, S; Engelhard, J; Fonseca, AF; Kap, E; Klebs, S; Schlienger, R; Wachter, R1
Malfatto, G; Parati, G; Villani, A1
Haynes, R; Judge, PK1
Albert, NM; Butler, J; Duffy, CI; Fonarow, GC; Hellkamp, A; Khariton, Y; Nassif, ME; Spertus, JA; Thomas, L1
Dickert, NW; Moore, MA; Morris, AA; Rao, BR; Shore, S; Smith, GH; Speight, CD1
Kadler, KE; Lewis, GA; Miller, CA; Schelbert, EB1
Claggett, BL; Cunningham, JW; Solomon, SD; Zile, MR1
Butler, J; Camacho, A; Claggett, BL; Desai, AS; Felker, GM; Ibrahim, NE; Januzzi, JL; Maisel, AS; Piña, IL; Prescott, MF; Solomon, SD; Williamson, KM1
Abbas, C; Burnett, JC; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Iyer, SR; Januzzi, JL; Maisel, AS; Murphy, SP; Piña, IL; Prescott, MF; Solomon, SD1
Huang, J; Nie, D; Qian, J; Rong, S; Xiong, B; Yao, Y1
Emdin, M; Giannoni, A; Masotti, S; Musetti, V; Passino, C; Prontera, C; Sciarrone, P; Senni, M; Valleggi, A; Vergaro, G1
Bu, FL; Feinberg, JB; Hecht Olsen, M; Jakobsen, JC; Nielsen, EE; Raymond, I; Steensgaard-Hansen, F1
Christophy, A; Heywood, JT; Jer, D; Kuo, RS; Mohan, RC; Pandey, AC; Srivastava, AV; Yoo, DH1
Schwartzmann, P1
Elston, C; Gengler, B; Kester, J; Montepara, C; Rerick, L1
Battistoni, A; Bauersachs, J; Bayés-Genís, A; Butler, J; Cohen-Solal, A; Deichl, AS; Gallo, G; Khan, MS; Pieske, B; Saito, Y; Volpe, M; Zieroth, S1
Allen, LA; Dickert, NW; Matlock, DD; Mitchell, AR; Moore, MA; Morris, AA; Pierce, KJ; Speight, CD; Venechuk, GE1
Gallinoro, E; Golino, P; Palladino, A; Papa, AA1
Bapat, D; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Januzzi, JL; Khan, MS; Maisel, AS; Piña, IL; Prescott, MF; Solomon, SD; Ward, JH1
Hanoman, H; Mohammed, SR; Pinto Pereira, LM; Teelucksingh, S1
Comin-Colet, J; Dosantos, R; Edelmann, F; Ferber, P; Hussain, RI; Jaarsma, T; Piepoli, MF1
Maggioni, AP1
Albert, CL; Donnellan, E; Estep, JD; Faulkenberg, KD; Il'giovine, ZJ; Martyn, T; Menon, V; Nissen, SE; Randhawa, VK; Starling, RC; Wilson Tang, WH1
Cao, Y; Chen, A; Chen, M; Fan, Y; Guan, X; Li, J; Liu, Y; Yang, D1
Bianco, C; Caccamo, M; Fang, W; Kido, K; Sokos, G2
Fang, KF; Huang, YX; Jie, H; Li, BH; Lin, PH; Zhang, YH1
Ferreira, JP; McCausland, FR; Packer, M; Patel, RB; Rossignol, P; Shah, SJ; Solomon, SD; Stockbridge, N; Ter Maaten, JM; Thompson, A; Vaduganathan, M; Zannad, F1
Chang, HY; Chiou, WR; Chung, FP; Hsu, CY; Huang, JL; Lee, YH; Liang, HW; Liao, CT; Lin, PL; Lin, WY2
El Nozahi, M; Rezq, A; Saad, M1
Dormiani, K; Homayouni Moghadam, F; Nasr-Esfahani, MH; Poorgolizadeh, E; Rezaei, N1
McMurray, JJV1
Bouma, BJ; Egorova, AD; Jongbloed, MRM; Kiès, P; Nederend, M; Schalij, MJ; Tops, LF; Vliegen, HW; Zandstra, TE1
Ferrara, F; La Porta, R; Vitiello, A1
Casale, M; Correale, M; Crea, P; Dattilo, G; de Gregorio, C; Katsiki, N; Laterra, G; Luzza, F; Morabito, C; Signorelli, SS; Vaccaro, V1
Howlett, JG1
Andresen, H; Bendiksen, BA; Bergo, KK; Cataliotti, A; Christensen, G; Espe, EK; Hasic, A; Hauge-Iversen, IM; Hussain, RI; Nordén, ES; Sjaastad, I; Veras, I1
O'Connor, CM1
Ramakrishna, S; Salazar, JW; Tseng, ZH1
Rohde, LE; Solomon, SD1
Elkayam, U; Fong, MW; Grazette, LP; Havakuk, O; Hwang, J; Kwong, HY; McLeod, JM; Shavelle, D; Tran, JS; Zile, MR1
Lelonek, M; Nowakowska, I; Pawlak, A; Rubiś, P; Wiśniowska-Śmiałek, S1
Al'Aref, SJ; Almarzooq, ZI; Butler, J; Devabhaktuni, SR; Fudim, M; Greene, SJ; Khan, MS; Mentz, RJ; Salah, HM1
Ambrosy, AP; Fudim, M; Tai, A1
Agrawal, R; Corda, S; Jindal, R; Proudfoot, C; Rajput, T; Senni, M; Studer, R1
Borrelli, C; Emdin, M; Gentile, F; Giannoni, A; Passino, C; Sciarrone, P; Spiesshoefer, J; Vergaro, G1
Forteza Albertí, JF; González Colino, R; Mas-Lladó, C; Noris Mora, M; Pasamar Márquez, L; Peral Disdier, V; Pericas, P; Ramis-Barceló, MF; Rossello, X; Valadrón, I1
Anand, IS; Claggett, BL; Cleland, JGF; Desai, AS; Ferreira, JP; Kober, L; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Pfeffer, MA; Rouleau, JL; Shah, SJ; Shi, VC; Solomon, SD; van Veldhuisen, DJ; Vardeny, O; Zannad, F; Zile, MR1
Cavallari, I; Grigioni, F; Maddaloni, E1
Arroyo Rivera, B; Bravo Calero, L; de Juan Bitriá, C; Del Castillo, H; Martí Sánchez, D; Miracle Blanco, Á; Rubio Campal, JM; Sánchez Borque, P; Taibo Urquia, M; Tuñón Fernández, J1
Alphonse Mahrouse, M; Hashem, HMA; Mahmoud, ST; Moussa, BA1
Cho, GY; Choi, W; Hwang, IC; Kim, HK; Kim, YJ; Lee, SP; Moon, MG; Park, JB; Yoon, YE1
Alaarag, AF; Amin, OA1
Desai, AS; Guo, W; Iimori, T; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Saito, Y; Sakata, Y; Tsutsui, H; Yamamoto, K1
Abumayyaleh, M; Akin, I; Aweimer, A; Borggrefe, M; El-Battrawy, I; Kummer, M; Kuschyk, J; Mügge, A; Pilsinger, C; Sattler, K1
Cui, X; Han, D; He, W; Jin, Z; Liu, Z; Raphael, DM; Shangguan, J; Shen, D1
Adams, V; Augstein, A; Barthel, P; Draskowski, R; Galli, R; Goto, K; Jannasch, A; Kirchhoff, V; Linke, A; Männel, A; Mittag, J; Schauer, A; Winzer, EB1
Borghi, C; Perrone Filardi, P; Pontremoli, R1
Bitto, R; Casale, M; Correale, M; Crea, P; Dattilo, G; DE Gregorio, C; DI Bella, G; Katsiki, N; Laterra, G; Luzza, F; Migliorato, A; Morabito, C; Vaccaro, V1
Liu, X; Zhong, L1
Anand, IS; Boytsov, SA; Chen, CH; Chopra, VK; Claggett, BL; Ge, J; Inubushi-Molessa, A; Jackson, AM; Jhund, PS; Køber, L; Lam, CSP; Lefkowitz, MP; Liu, J; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Tromp, J; Van Veldhuisen, DJ; Widimský, J; Zannad, F; Zile, MR1
McMURRAY, JJV; Solomon, SD1
Chen, Y; Cui, J; Liu, X; Pan, C; Pang, Z; Ren, Y; Tian, L; Yao, Z; Zhang, L1
Beavers, JC; Orvin, NJ; Russell, SD1
Doumas, M; Papadopoulos, C; Patoulias, D1
Buonacera, A; Malatino, L; Stancanelli, B1
Ahn, KJ; Chung, WJ; Jang, AY; Kim, DH; Kwan, J; Yu, J1
Chen, C; Fang, C; Huang, Y; Ma, L; Zhang, Y; Zhou, H1
Albert, NM; Arnold, SV; Butler, J; Chan, PS; DeVore, AD; Fonarow, GC; Hernandez, AF; Hill, L; Khariton, Y; Nassif, ME; Patterson, JH; Spertus, JA; Thomas, L; Thomas, M; Williams, FB1
Felker, GM; Mann, DL1
Bayes-Genis, A; Cediel, G; Codina, P; Domingo, M; Lupón, J; Núñez, J; Revuelta-López, E; Santesmases, J; Santiago-Vacas, E; Spitaleri, G; Zamora, E1
Gronda, E; Iacoviello, M; Palazzuoli, A1
Chen, C; Li, Y; Peng, Y; Wu, X1
Aiglova, R; Cernicek, V; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M1
Butler, J; Desai, AS; Felker, GM; Januzzi, JL; McMurray, JJV; Solomon, SD1
Bhatt, AS; Claggett, BL; Desai, AS; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Vaduganathan, M; Vardeny, O; Zile, MR1
Chiang, LM; Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJV; Minamisawa, M; Packer, M; Pfeffer, MA; Solomon, SD; Suzuki, K; Zile, MR1
Brar, S; D'Albo, N; Dani, SS; Dey, A; Ganatra, S; Kim, YS; Shah, S1
Bhatt, AS; Claggett, BL; Lefkowitz, MP; McMurray, JJV; Packer, M; Solomon, SD; Vaduganathan, M; Zile, MR1
Chen, W; Dang, H; Li, Y; Liu, Y1
Lam, CSP; Solomon, SD1
Dietrich, EA; Park, H; Pepine, CJ; Riaz, M; Smith, SM1
Abdul-Aziz, AA; Adie, SK; Ketcham, SW; Konerman, MC; Thomas, MP1
Alpenglow, JK; Bunsawat, K; Ratchford, SM; Richardson, RS; Smith, AS; Stehlik, J; Wray, DW1
Briasoulis, A; Kuno, T; Ueyama, H1
Chandrsawang, A; Kaewkan, P; Nathisuwan, S; Rattanavipanon, W; Sotananusak, T; Yamaae, F; Yingchoncharoen, T1
Abbate, A; Bhardwaj, H; Damonte, JI; Del Buono, MG; Markley, R; Salloum, FN; Trankle, CR; Turlington, J; Van Tassell, BW1
da Silva, DNV; da Silva, TC; da Silva, VM; de Carvalho, WN; de Jesus, AGQ; de Melo, RMV; Figueiredo, CS; Passos, LCS; Viana, TT1
Claggett, B; Gori, M; Jhund, P; Lam, CSP; Lefkowitz, M; Liu, J; Maggioni, AP; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Prescott, MF; Rouleau, J; Senni, M; Shi, V; Solomon, SD; Van Veldhuisen, DJ; Zannad, F; Zile, M1
Abraham, WT; Adamson, P; Brett, ME; Costanzo, MR; Desai, AS; Heywood, JT; Lamba, S; Rathman, L; Raval, N; Shavelle, D; Sood, P; Stevenson, LW1
Belarte-Tornero, LC; Farré, N; Mojón, D; Ruiz-Bustillo, S; Solé-González, E; Valdivielso-More, S1
Bapat, D; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Januzzi, JL; Maisel, A; Piña, IL; Solomon, SD; Ward, JH; Williamson, KM1
Čepelová, J; Daněk, J; Malý, M1
Hori, M; Imamura, T; Kinugawa, K; Ueno, H1
Accogli, M; Ammendola, E; Antonicelli, R; Aspromonte, V; Brunetti, ND; Cannone, M; Carbone, A; Del Giorno, G; Dell'Era, G; Dello Russo, A; Floris, R; Gravellone, M; Guerra, F; Guido, A; Maglia, G; Nigro, G; Palmisano, P; Paolisso, P; Pellegrino, PL; Pimpini, L; Santoro, F; Stronati, G; Ziacchi, M1
Rakugi, H; Yamamoto, K1
Alhan, A; Altay, H; Altın, C; Ataş, AE; Baş, MM; Çakmak, HA; Demirkan, B; Dereli, S; Durakoğlugil, ME; Ekici, B; Fahri Erkan, A; Karavelioğlu, Y; Kılıçaslan, B; Kılıçaslan, F; Kıvrak, T; Küçük, M; Olgun, FE; Özkan, H; Şabanoğlu, C; Tengiz, İ; Yaman, M; Yenerçağ, M; Yiğit, Z; Zoghi, M1
Camerotto, A; Cuppini, S; Mazza, A; Minuz, P; Rigatelli, G; Rubello, D; Schiavon, L; Torin, G; Townsend, DM1
Daimon, S; Maeda, K; Yasuda, M1
Ameri, P; Benenati, S; Canepa, M; Carmisciano, L; Giovinazzo, S; Metra, M; Porto, I; Senni, M; Sormani, MP; Toma, M; Tomasoni, D1
Brunetti, ND; Correale, M; Di Biase, M; Diella, C; Ferraretti, A; Iacoviello, M; Mallardi, A; Mazzeo, P; Merolla, G; Romano, V; Tricarico, L1
Allen, LA; Carnicelli, AP; Fonarow, GC; Greene, SJ; Greiner, MA; Hammill, BG; Hardy, NC; Lippmann, SJ; Mentz, RJ; O'Brien, EC; Peterson, PN; Shen, X; Yancy, CW1
Jackevicius, CA; Krumholz, HM; Mody, FV; Ozaki, AF1
Chun, KH; Ha, J; Kang, SM; Kim, H; Lee, CJ; Lee, S; Lee, SH; Oh, J; Park, S; Yoon, M1
Anand, IS; Düngen, HD; Jackson, AM; Jhund, PS; Lam, CSP; Lefkowitz, MP; Linssen, G; Lund, LH; Maggioni, AP; McMurray, JJV; Pfeffer, MA; Rouleau, JL; Saito, Y; Saraiva, JFK; Senni, M; Solomon, SD; Vardeny, O; Wijkman, MO; Yilmaz, MB; Zile, MR1
Gallo, G; Volpe, M1
Ideishi, A; Kuwano, T; Miura, SI; Morita, H; Suematsu, Y; Tashiro, K1
Chen, W; Dang, H; Li, Z; Liu, Y; Tang, L1
Antonazzo, IC; De Ponti, F; Diemberger, I; Gatti, M; Raschi, E1
Ademi, Z; Liew, D; Perera, K; Zomer, E1
Goh, VJ; Hon, JS; Koh, N; Lim, CP; Sim, D; Teo, LLY; Teoh, CK1
Chen, Y; Wu, Y1
Birkeland, K; Dorn, J; Fombu, E; Grant, D; Heywood, JT; Khandwalla, R; Owens, RL; Steinhubl, SR1
Choi, KH; Hwang, HS; Ji, E; Kang, DH; Kang, GH; Lee, S; Song, JM; Song, N1
Gackowski, A; Gruchała, M; Gwizdała, A; Jankowska, EA; Kamiński, K; Lelonek, M; Leszek, P; Mizia-Stec, K; Nessler, J; Ponikowski, P; Rozentryt, P; Straburzyńska-Migaj, E1
Curtis, LH; Fonarow, GC; Greiner, MA; Hammill, BG; Hardy, NC; Heidenreich, PA; Hernandez, AF; Laskey, WK; Lippmann, SJ; Luo, N; Mentz, RJ; Mi, X; O'Brien, EC; Turner, SJ; Yancy, CW1
Guo, J; Wong, PC; Zhang, A1
Gervasini, G; Robles, NR1
Adams, KF; Giblin, EM; Patterson, JH; Pearce, N1
Clerico, A; Di Tano, G1
Chrysochoou, C; Georgiopoulos, G; Kalos, T; Kasiakogias, A; Katsiki, N; Konstantinidis, D; Oikonomou, D; Thomopoulos, C; Tousoulis, D; Tsioufis, C1
Ayalasomayajula, S; Boggarapu, S; Langenickel, T; Pal, P; Sunkara, G1
Chapman, RH; Heidenreich, PA; Ollendorf, DA; Pearson, SD; Sandhu, AT2
Bellows, B; Bress, A; King, J1
Butler, J; Hamo, CE; Papadimitriou, L2
Armstrong, WM; Emmett, M; Packer, M; Rothstein, JM2
Spellberg, B1
Werner, BE1
Vitting, KE1
McCartney, M1
Kitai, T; Krittanawong, C1
De Biase, L; Emdin, M; Senni, M; Trimarco, B1
Barghash, MH; Desai, AS1
Fonarow, GC; Greiner, M; Heidenreich, PA; Hernandez, AF; Lippmann, SJ; Parikh, KS; Yancy, CW1
Kittipibul, V; Perez, AL; Starling, RC; Tang, WHW1
Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR1
Elkayam, U; Havakuk, O1
Butler, J; Papadimitriou, L1
Packer, M3
Guglin, M1
Flores, D; Kozhuharov, N; Mueller, C; Sabti, Z1
Launay, JM; Logeart, D; Nougué, H; Solal, AC; Vodovar, N1
Claggett, B; Seferovic, JP; Solomon, SD1
Chrysant, SG1
Bauersachs, J; Bavendiek, U; Kempf, T1
Anand, IS; Desai, AS; Ge, J; Gong, J; Lam, CSP; Lefkowitz, MP; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Van Veldhuisen, DJ; Wang, W; Zannad, F; Zile, MR1
Agrawal, H; Albaghdadi, A; Bramblett, T; Mukherjee, D; Teleb, M1
Burrell, LM; Cherif, M; Clark, AL; Lang, CC; Singh, JSS; Squire, IB1
Claggett, BL; Desai, AS; Lefkowitz, MP; Lewis, EF; Liu, J; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR1
Aronow, WS; Shamliyan, TA1
Clem, JR; Heins, J1
Chien, FJ; Eisen, HJ; Kim, DH1
Aguiar, C; Marques da Silva, P1
Cortesi, PA; D'Angiolella, LS; Mantovani, LG; Pitotti, C; Ritrovato, D; Senni, M1
Luo, N; Mentz, RJ; O'Brien, EC1
Kherad, B; Krackhardt, F; Kresoja, KP; Schmidt, G; Spillmann, F; Tschöpe, C1
Lindblad, AJ; McDonald, T; Sehn, E1
Grimm, D; Krüger, M; Nielsen, PM; Simonsen, U; Wehland, M1
Aziz, MIA; Bin-Chia Wu, D; Leong, KTG; Liang, L; Ng, K; Sim, D; Tan, D; Wei, YQ; Wong, R2
Barbera, V; Bellasi, A; Cozzolino, M; De Pascalis, A; Di Lullo, L; Floccari, F; Mudoni, A; Rivera, R; Ronco, C; Santoro, A; Verdesca, S1
Aichner, S; Albrecht, D; Bremerich, J; Delles, C; Freyhardt, P; Heye, T; Hrabak-Paar, M; Janka, R; Keicher, C; Khder, Y; Langenickel, T; Mayr, M; Ott, C; Schmieder, RE; Wagner, F; Yates, D1
Bell, TD; Mazer, AJ; Miller, PE; Sachdev, V; Solomon, MA; Strich, JR; Wright, ME1
Andries, G; Biswas, M; Khera, S; Yandrapalli, S1
Gao, J; Goodchild, TT; Kapusta, DR; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, AL; Smart, FW; Trivedi, RK; Varner, KJ; Xia, H1
Metra, M1
Chen, L; Li, C; Li, M; Liu, XC; Qiu, CG; Wang, W; Yan, KP1
Bonnet, D; Burch, M; Bush, C; Canter, C; Chen, F; Halnon, N; Kantor, P; Kochilas, L; Rossano, J; Shaddy, R; Zhao, Z1
Karim, MA; Khan, NAJ; Siddiqui, HU; Ullah, S1
Butler, J; DeFilippis, EM; Vaduganathan, M1
Anand, IS; Charney, A; Duino, V; McIntyre, HF; McMurray, JJV; Sarkar, A; Senni, M; Shi, V; Wachter, R1
Ademi, Z; Deschaseaux, C; Hancock, E; Haroun, RH; Pfeil, AM; Schwenkglenks, M; Trueman, D1
Kałużna-Oleksy, M; Kolasa, J; Lelonek, M; Migaj, J; Nessler, J; Pawlak, A; Straburzyńska-Migaj, E1
Chen, CH; Desai, AS; Dukát, A; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Packer, M; Prescott, MF; Ramires, F; Rouleau, JL; Senni, M; Shi, VC; Solomon, SD; Swedberg, K1
Belohlavek, J; Butylin, D; Carr, D; Noè, A; Pascual-Figal, D; Senni, M; Wachter, R1
de Boer, RA; Koenders, JMA; Linssen, GCM; Meeder, JG; Ramos, IC; Rutten-van Mölken, MPMH; Versteegh, MM1
Cameli, M; Curci, V; Di Tommaso, C; Mandoli, GE; Mondillo, S; Pagliaro, A; Pastore, MC; Reccia, R1
Aspromonte, N; Valle, R1
Aldemerdash, A; Berei, TJ; Hollis, IB; Hsu, CC; Rodgers, JE; Smith, KR; Vardeny, O1
Briggs, A; Cowie, MR; Deschaseaux, C; Hancock, E; Haroun, R; Lacey, M; McMurray, JJV; Mumby-Croft, J; Taylor, M; Trueman, D; Woodcock, F1
Lang, CC; Zaid Iskandar, M1
Brink, D1
Jing, W; Kashyap, ML; Khazaeli, M; Moradi, H; Nunes, A; Suematsu, Y; Vaziri, ND1
Marketou, ME; Nakou, ES; Parthenakis, FI; Vardas, PE1
Ariano, C; De Vecchis, R; Di Biase, G; Noutsias, M3
Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA1
Cyrille, N; Elyahu, AY; Ramakrishna, H; Renew, JR1
Bayés-Genís, A; Domínguez, E; Mollar, A; Núñez, J; Palau, P; Sanchis, J1
Kario, K1
Adda, J; Akodad, M; Audurier, Y; Battistella, P; Belloc, C; Breuker, C; Castet-Nicolas, A; Chettouh, M; Cristol, JP; Curinier, C; Dupuy, AM; Fesler, P; Kalmanovich, E; Kuster, N; Lotierzo, M; Marques, S; Mercier, G; Roubille, C; Roubille, F; Solecki, K; Soltani, S; Verchere, A; Zerkowski, L1
Claggett, BL; Desai, AS; Gong, J; Jhund, PS; Køber, L; Lefkowitz, MP; McMurray, JJV; Mogensen, UM; Mueller-Velten, G; Packer, M; Rouleau, JL; Shen, L; Solomon, SD; Swedberg, K; Zile, MR1
Balas, B; Bruce Wirta, S; Calado, F; Dworak, M; Engelhard, J; Grunow, SS; Klebs, S; Proenca, CC; Schindler, M; Schlienger, R; Viriato, D; Wachter, R1
Dunlay, SM; Sangaralingham, LR; Sangaralingham, SJ; Shah, ND; Yao, X1
Colaco, NA; Kazi, DS1
Beliën, H; Dupont, M; Martens, P; Mullens, W1
Berdague, P; Bourdin, A; Dupuis, M; Galinier, M; Jaffuel, D; Mallet, JP; Molinari, N; Pathak, A; Ricci, JE; Roubille, F1
Goodchild, TT; Koiwaya, H; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, A; Trivedi, RK; Yoo, D1
Kitzman, DW; Packer, M1
Edelmann, F; Knosalla, C; Mörike, K; Muth, C; Prien, P; Störk, S1
Kabbach, G; Khalil, P; Mukherjee, D; Said, S1
Anand, IS; Chow, SL; Daniels, LB; Maisel, AS; McCullough, PA1
Atwood, A; DiDomenico, RJ; Harrington, RL; Kumar, VM; Rigoni, GC; Touchette, DR; Zueger, PM1
Chandra, A; Claggett, BL; Desai, AS; Katova, T; Lefkowitz, MP; Lewis, EF; McMurray, JJV; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR1
Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; Hernandez, AF; McCague, K; Morrow, DA; Rocha, RA; Velazquez, EJ1
Hirsh Raccah, B; Matok, I; Muszkat, M; Perlman, A1
Chiang, LM; Claggett, B; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, JL; Solomon, SD; Zile, MR1
Butler, J; Fombu, E; Januzzi, JL; Maisel, A; McCague, K; Piña, IL; Prescott, MF; Riebman, JB; Solomon, S1
Ambrosy, AP; Velazquez, EJ1
Beliën, H; Dupont, M; Martens, P; Mullens, W; Vandervoort, P1
Kaplan, A; Modgill, V; Senni, M; Shi, V; Streefkerk, H; Zhou, W1
Antol, DD; Casebeer, AW; DeClue, RW; Russo, PA; Stemkowski, S1
Aguiar, C; Freitas, P; Mendes, M; Rodrigues, G; Tralhão, A; Ventosa, A1
Liu, RC1
Ayesta, A; Bover-Freire, R; De-Juan, J; Díez-Villanueva, P; Esteban-Fernández, A; García-Aguado, M; Gómez-Bueno, M; González-Saldívar, H; Iglesias, D; Iniesta, ÁM; Martínez-Sellés, M; Perea-Egido, JA; Rojas-González, A; Vicent, L2
Stewart Coats, AJ1
Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Hernandez, AF; McCague, K; Mi, X; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB1
Dupont, M; Lambeets, S; Lau, CW; Martens, P; Mullens, W1
Gori, M; Lombardi, CM; Metra, M; Sciatti, E; Senni, M1
Störk, S1
Davis, LE; Lu, BN1
Chiu, MH; Howlett, JG; Kuriachan, VP; Sharma, NC1
Chrisant, M; Das, BB; Scholl, F; Vandale, B1
Anand, IS; Anavekar, N; Anker, SD; Arango, JL; Arenas, JL; Atar, D; Ben-Gal, T; Boytsov, SA; Chen, CH; Chopra, VK; Cleland, J; Comin-Colet, J; Duengen, HD; Echeverría Correa, LE; Filippatos, G; Flammer, AJ; Galinier, M; Ge, J; Godoy, A; Goncalvesova, E; Gong, J; Janssens, S; Katova, T; Køber, L; Lam, CSP; Lefkowitz, MP; Lelonek, M; Linssen, G; Lund, LH; Maggioni, AP; Martinez, F; McMurray, JJV; Merkely, B; Milicic, D; O'Meara, E; Oh, BH; Packer, M; Perrone, SV; Pfeffer, MA; Pieske, B; Ranjith, N; Redfield, MM; Rizkala, AR; Rouleau, JL; Saito, Y; Saraiva, JF; Seferovic, PM; Senni, M; Shah, S; Shi, VC; Sibulo, AS; Sim, D; Solomon, SD; Sweitzer, NK; Taurio, J; Van Veldhuisen, DJ; Vinereanu, D; Vrtovec, B; Widimský, J; Yilmaz, MB; Zannad, F; Zhou, J; Zile, MR; Zweiker, R1
Ghafar, MZ; Mulkerrin, EC; O'Keeffe, ST; Sharkey, AT1
Cristino, J; Lee, D; Ng, C; Tan, J; Tang, I; Trueman, D1
Malafarina, V; Rodil Fraile, R; Tiberio López, G1
Guo, W; Ito, H; Kitamura, T; Momomura, SI; Ohishi, T; Okino, N; Saito, Y; Tsutsui, H; Yamamoto, K1
Gandjour, A; Ostwald, DA1
Dargad, RR; Parekh, JD; Prajapati, MR1
Bösch, C; Dobner, S; Hunziker, L; Martinelli, M; Rhyner, D; Schnegg, B; Suter, T; Wieser, M; Wigger, O1
Rickenbacher, P1
Abdurrob, A; Balas, B; Bruce Wirta, S; Calado, F; Chang, CL; Gagne, JJ; Najafzadeh, M; Rogers, JR; Schlienger, RG; Tsacogianis, T; Turner, SJ; Wang, SV1
Zacà, V1
Carbonell, P; Gasol, M; López, P; Molina, A; Pontes, C; Vicente, M1
Bouabdallaoui, N; Claggett, B; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, JL; Solomon, SD; Swedberg, K; Zile, MR1
Ahn, R; Prasad, V1
Baliga, RR1
Aspromonte, N; De Maria, R; Di Lenarda, A; Di Tano, G; Frigerio, M; Gabrielli, D; Gulizia, MM; Iacoviello, M; Mortara, A; Murrone, A; Nardi, F; Oliva, F; Pontremoli, R; Scherillo, M; Senni, M; Urbinati, S1
Bocchi, EA; Rassi, S; Veiga Guimarães, G1
Wollert, KC1
Adda, J; Agullo, A; Akodad, M; Batistella, P; Huet, F; Kalmanovitch, E; Roubille, C; Roubille, F1
Albert, NM; Butler, J; DeVore, AD; Duffy, CI; Fonarow, GC; Hernandez, AF; Hill, CL; McCague, K; Patterson, JH; Sharma, PP; Spertus, JA; Thomas, L; Williams, FB1
Claggett, B; Gandhi, PU; Januzzi, JL; Lefkowitz, MP; Liu, J; McMurray, JJV; Packer, M; Pieske, B; Prescott, MF; Shah, AM; Shi, V; Solomon, SD; Voors, A; Zile, MR1
Bayes-Genis, A; Sarrias, A1
Bhagat, AA; Butler, J; Fonarow, GC; Greene, SJ; Vaduganathan, M1
Ambrosy, AP; Braunwald, E; DeVore, AD; Duffy, CI; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ1
D'Elia, E; Gori, M; Senni, M1
Le Bras, A1
Claggett, BL; Desai, AS; Fonarow, GC; McMurray, JJV; Packer, M; Rouleau, JL; Solomon, SD; Srivastava, PK; Swedberg, K; Zile, MR1
Danhof, M; Giraudel, J; Mochel, JP; Peyrou, M; Rigel, DF; Teng, CH1
Arrigo, M; Beauvais, F; Cohen-Solal, A; Launay, JM; Logeart, D; Nougué, H; Pezel, T; Picard, F; Sadoune, M; Vodovar, N1
Du, AX; Ezekowitz, JA; Hanninen, M; McAlister, FA; Oudit, GY; Paterson, DI; Shanks, M; Thomas, J; Westerhout, CM1
Cole, R; Jensen, BC; Pal, J; Sauer, AJ; Sharma, N; Vader, J; Yehya, A1
Hong, GR; Kang, DH; Kim, JJ; Kim, MS; Lee, S; Park, SJ; Park, SW; Shin, SH; Song, JM; Yun, SC1
Allen, LA; Dickert, NW; Markham, DW; Mitchell, AR; Moore, M; Morris, AA; Shore, S; Smith, GH; Speight, CD1
Okutucu, S; Oto, A; Sabanoglu, C1
Brito, D; Ferreira, J; Fonseca, C; Franco, F; Morais, J; Silva Cardoso, J1
Appadurai, V; Malpas, T; Nicolae, M; Thoreau, J1
Chang, CL; Curtis, LH; Fonarow, GC; Greiner, MA; Hammill, BG; Hardy, NC; Heidenreich, PA; Hernandez, AF; Laskey, WK; Lippmann, SJ; Luo, N; Mentz, RJ; O'Brien, EC; Peterson, PN1
Jarcho, J1
Ter Maaten, JM1
Claggett, B; Desai, AS; Kachadourian, J; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR1
Ahern, D; Cassagnol, M; Fuzaylova, I; Lam, C; Makaryus, AN; Talreja, O1
Claggett, B; Lefkowitz, M; McMurray, JJV; O'Meara, E; Packer, M; Prescott, MF; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR1
Ferreira, JP; Zannad, F1
Ceyssens, W; Dupont, M; Luwel, E; Martens, P; Mullens, W; Nuyens, D; Rivero-Ayerza, M; Van Herendael, H; Vercammen, J1
Coughlan, JJ; Daly, A; Liston, R; Mross, T; O'Connor, A; Wafer, M1
Fonarow, GC; Srivastava, PK1
Álvarez-García, J; Brossa, V; Fluvià-Brugues, P; López López, L; Mesado, N; Mirabet, S; Moliner-Abós, C; Pamies Besora, J; Pirla, MJ; Rivas-Lasarte, M; Roig, E; Solé-González, E1
Desai, VK; Jaffe, AS; Pereira, NL1
Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJV; Myhre, PL; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Vaduganathan, M; Zile, MR1
Dalmaso, SG; Marchitto, N; Mobilia, P; Raimondi, G; Sindona, F1
Castello, L; De Giusti, M; Dito, E; Parisi, C; Proietti, F; Tomai, F1
Bilato, C; Paolini, C; Pellizzari, CA; Perrone, C; Randon, ML1
Bentivenga, C; Berardi, E; Borghi, C; Cosentino, ER; Degli Esposti, D; Dugato, V; Fg Cicero, A; Landolfo, M; Magri, G; Miceli, R; Spinardi, L1
Pemberton, C; Richards, AM; Yandle, T1
Mboumi, K; Severini, D1
Calò, L; Fusco, A; Lanzillo, C; Lino, S; Martino, A; Minati, M; Monzo, L; Tota, C1
D'Agostino, A; Dini, FL; Fabiani, I; Galeotti, GG; Mazzola, M; Pugliese, NR; Zywicki, V1
Caivano, M; Gubelli, S1
Apple, FS; Burnett, JC; Gaggin, HK; Ibrahim, NE; Iyer, S; Januzzi, JL; McCarthy, CP; Mukai, R; Shrestha, S; Szymonifka, J1
Anand, IS1
Benson, L; Dahlström, U; Jhund, PS; Lund, LH; McMurray, JJV; Simpson, J1
Kuster, GM; Pfister, O1
Ambrosy, AP; Braunwald, E; Desai, AS; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Rocha, R; Velazquez, EJ1
deKemp, RA; Hu, X; Klein, R; Mikush, N; Pfau, D; Renaud, JM; Sinusas, AJ; Thorn, SL; Tirziu, D; Wu, X; Young, LH; Zhang, J1
Balas, B; Engelhard, J; Fonseca, AF; Kap, E; Klebs, S; Kostev, K; Schlienger, R; Wachter, R; Wirta, SB1
Chang, HC; Chang, HY; Chen, CN; Chong, E; Feng, AN; Fong, MC; Hsueh, CW; Huang, KC; Lai, WT; Yin, WH1
Cook, EA; Shipman, D; Wooster, J1
Burke, RM; Lighthouse, JK; Mickelsen, DM; Small, EM1
Albert, NM; Buysman, EK; Chang, C; Swindle, JP1
Daubert, JC; Donal, E; Hage, C; KapŁon-CieŚlicka, A; Linde, C; LÖfstrÖm, U; Lund, LH; Oger, E1
Ali, RH; Dizaye, K1
Balmforth, C; Jhund, PS; Lefkowitz, M; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shen, L; Shi, V; Simpson, J; Solomon, SD; Swedberg, K; Zile, MR1
Aboulhosn, J; Lin, J; Lluri, G; Miner, P; Reardon, L; Whalen, K1
Atallah, B; Bader, F; Cherfan, A; El Banna, M; Gabra, G; Hamour, I; Hisham, M; Kalagieh, O; Sadik, ZG; Soliman, M1
Braunwald, E; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Prescott, MF; Rocha, R; Velazquez, EJ1
Bursa, N; Okutucu, S1
Hong, SH; Kim, H; Kim, S; Lee, EK; Park, SK1
Aguiar, C; Anker, SD; Coats, A; Crespo-Leiro, MG; Filippatos, G; Kapelios, CJ; Lainscak, M; Laroche, C; Leszek, P; Lund, LH; Maggioni, AP; McDonagh, T; Murin, J; Piepoli, MF; Rosano, G; Ruschitzka, F; Savarese, G; Seferovic, P; Zanolla, L1
A L Buraiki, J; Bao, W; Belohlavek, J; Butylin, D; Bøhmer, E; Cavusoglu, Y; Chaaban, S; Fernandez, A; Fonseca, C; Gniot, J; Goncalvesova, E; Kobalava, Z; Lelonek, M; Lonn, E; Mozheiko, M; Mueller, C; Noè, A; Pascual-Figal, D; Pouleur, AC; Schwende, H; Senni, M; Straburzynska-Migaj, E; Tribouilloy, C; Wachter, R; Witte, KK1
Haslam, A; Prasad, V1
Bosotti, L; Bursi, F; Carugo, S; Massironi, L; Santangelo, G; Tombolini, E; Toriello, F; Torta, D; Valli, F1
Burnier, M; Kjeldsen, SE; Narkiewicz, K; Oparil, S1
Emdin, M; Passino, C; Vergaro, G1
Aimo, A; Emdin, M; Maisel, AS1
Ambrosy, AP; DeVore, AD; Velazquez, EJ1
Alcalde, RO; Alonso-Martín, C; Arbòs, CM; Bruña, V; Devesa, C; Fernández-Avilés, F; Juárez, M; Martínez-Sellés, M; Méndez-Zurita, F; Pamies, J; Sousa-Casasnovas, I; Vicent, L; Viñolas, X1
Chen, Q; Li, D; Lu, C; Wang, Y; Xu, T; Zhou, R1
Ewert, P; Hager, A; Maurer, SJ; Pujol Salvador, C; Schiele, S; Tutarel, O1
Alexanian, C; Cannon, CP; Doros, G; Ibrahim, NE; Januzzi, JL; Ponirakis, A; Russo, P; Song, Y1
Hryniewiecki, TT; Kodziszewska, K; Leszek, P; Sochanowicz, B; Witold, Ś1
Abbate, A; Bonaventura, A; Van Tassel, BW; Vecchié, A; Wohlford, GF1
Chen, R; DeJong, C; Dudley, RA; Kazi, DS; Tseng, CW1
Anand, IS; Chandra, A; Claggett, BL; Ge, J; Lam, CSP; Lefkowitz, MP; Lewis, EF; Maggioni, AP; Martinez, F; McMurray, JJV; Packer, M; Pfeffer, MA; Pieske, B; Redfield, MM; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Vaduganathan, M; Van Veldhuisen, DJ; Wang, W; Zannad, F; Zile, MR1
Artemieva, MM; Bloshchitsyna, MN; Feygina, EE; Katrukha, AG; Medvedeva, NA; Postnikov, AB; Semenov, AG; Tamm, NN1
Cottone, S; Geraci, G; Mulè, G; Nardi, E; Sorce, A1
Beck-da-Silva, L; Rohde, LE1
Apple, FS; Daniels, LB; Jaffe, A; Januzzi, J; Omland, T; Ordonez-Llanos, J1
Ambrosy, AP; Chioncel, O; Fudim, M1
Amurthur, B; Anand, IS; Ardell, JL; DiCarlo, LA; Gregory, DD; KenKnight, BH; Libbus, I; Mittal, S; Monteiro, R; Premchand, RK; Sharma, K1
Bobadilla, G; Bravo, C; Duarte, M; Guardamagna, C; Muñoz, P; Rossel, V; Verdugo, F1
Dorhout, B; van der Meer, P; Voors, AA1
Atar, D; Burnett, JC; Kompa, AR; Krum, H; Sangaralingham, SJ; von Lueder, TG; Wang, BH1
Cohn, JN; Gimpelewicz, C; Hua, TA; Kandra, A; Krum, H; Latini, R; Lesogor, A; Massie, B; Tognoni, G; Zalewski, A1
Solomon, SD; Tacheny, T; Vardeny, O1
Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K1
Claggett, B; Gupta, DK; Kraigher-Krainer, E; Lefkowitz, MP; McMurray, JJ; Packer, M; Pieske, B; Santos, A; Shah, AM; Solomon, SD; Voors, AA; Zile, MR1
Anand, IS; Cohn, JN; Kuskowski, M; Rector, TS; Snider, J1
Bransford, T; Claggett, B; Jhund, PS; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shi, V; Solomon, SD; Voors, AA; Zile, MR1
Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD1
Desai, AS; Gong, J; Lefkowitz, M; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR1
Gislason, GH; Kristensen, SL; Køber, L; Lamberts, M; Selmer, C; Torp-Pedersen, C; von Kappelgaard, LM1
Ambrosio, G; Anker, SD; Díez, J; Edelmann, F; Filippatos, GS; Fraser, AG; Gavazzi, A; Gheorghiade, M; Guazzi, M; Hummel, SL; Lam, CS; Levy, D; Maggioni, AP; Metra, M; Paulus, WJ; Pfeffer, MA; Pieske, BM; Senni, M; Smiseth, OA; Solomon, SD; Stewart Coats, AJ; Stough, WG; Tschöpe, C1
Baigent, C; Haynes, R; Judge, P; Landray, MJ1
Jessup, M1
Desai, AS; Gong, J; Lefkowitz, MP; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR1
Fox, KA; Jessup, M; Komajda, M; McMurray, JJ; Packer, M1
Claggett, BL; Jhund, PS; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, BM; Prescott, MF; Shah, AM; Shi, V; Solomon, SD; Voors, AA; Zile, MR1
Miller, R; Solomon, SD; Vardeny, O1
Hampton, T1
Andersen, K; Arango, JL; Arnold, JM; Bělohlávek, J; Böhm, M; Boytsov, S; Burgess, LJ; Cabrera, W; Calvo, C; Chen, CH; Desai, AS; Duarte, YC; Dukat, A; Erglis, A; Fu, M; Gomez, E; Gong, J; Gonzàlez-Medina, A; Hagège, AA; Huang, J; Katova, T; Kiatchoosakun, S; Kim, KS; Kozan, Ö; Lefkowitz, MP; Llamas, EB; Martinez, F; McMurray, JJ; Mendoza, I; Merkely, B; Mosterd, A; Negrusz-Kawecka, M; Packer, M; Peuhkurinen, K; Ramires, FJ; Refsgaard, J; Rizkala, AR; Rosenthal, A; Rouleau, JL; Senni, M; Shi, VC; Sibulo, AS; Silva-Cardoso, J; Solomon, SD; Squire, IB; Starling, RC; Swedberg, K; Teerlink, JR; Vanhaecke, J; Vinereanu, D; Wong, RC; Zile, M1
Krum, H1
Andersen, K; Arango, JL; Arnold, M; Bayram, E; Bĕlohlávek, J; Böhm, M; Boytsov, S; Burgess, L; Cabrera, W; Chen, CH; Desai, A; Erglis, A; Fu, M; Gomez, E; Gong, J; Gonzalez, A; Greenlaw, N; Hagege, AA; Katova, T; Kiatchoosakun, S; Kim, KS; Lefkowitz, M; Martinez, F; McMurray, J; Mendoza, I; Merkely, B; Mosterd, A; Negrusz-Kawecka, M; Packer, M; Peuhkurinen, K; Ramires, F; Refsgaard, J; Rizkala, A; Rouleau, J; Senni, M; Shi, V; Sibulo, AS; Silva-Cardoso, J; Solomon, S; Squire, I; Starling, RC; Swedberg, K; Teerlink, JR; Vinereanu, D; Wong, R; Zile, MR1
Bodey, F; Hopper, I; Krum, H1
Pitt, B; Rossignol, P; Zannad, F1
Athyros, VG; Karagiannis, A; Katsiki, N1
Ferrari, L; Sada, S1
Swedberg, K1
Bramlage, P; Ferrero, C; Gomez, T; Minguet, J; Sutton, G1
İkitimur, B; Karadağ, B; Kılıçkıran Avcı, B; Öngen, Z1
Califf, R; Claggett, B; Køber, L; Lam, CS; Lewis, E; Liu, J; McEntegart, M; McMurray, JJ; Pfeffer, M; Rouleau, J; Skali, H; Solomon, S; Velazquez, E1
Claggett, B; Gori, M; Lefkowitz, MP; Liu, LC; McMurray, JJ; Packer, M; Pieske, B; Shi, V; Solomon, SD; Voors, AA; Zile, MR1
Pieske, B; Tschöpe, C1
McMurray, JJ3
Braunwald, E2
Alves, C; Carballo, S; Darbellay, P; Lebowitz, D; Moret, M; Sabeh, N1
Gradman, AH1
Gallagher, B; Patel, Y; Pham, AQ1
Brahimi, A; Chen, F; Claggett, B; Desai, AS; Finn, PV; Gong, J; Hartley, LH; Lefkowitz, M; Liu, J; McMurray, JJ; Packer, M; Rizkala, AR; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Zile, MR1
Lang, CC; Singh, JS1
Battistoni, A; Rubattu, S; Tocci, G; Volpe, M1
Fabbri, LM; Roversi, S; Tonelli, R1
Buggey, J; DeVore, AD; Mentz, RJ; Velazquez, EJ1
Bayram, E; Chen, CH; Desai, AS; Fu, M; Jhund, PS; Lefkowitz, MP; McMurray, JJ; Negrusz-Kawecka, M; Packer, M; Rizkala, AR; Rosenthal, A; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR1
Traynor, K1
Li, GP; Li, LF; Liang, YZ; Liu, T; Qi, WW; Xu, G; Ye, L1
Andersen, MB; Grimm, D; Pietsch, J; Simonsen, U; Wehland, M1
Fath, R2
Macdonald, PS1
Morrow, T1
Bress, AP; King, JB; Munger, MA; Reese, AD1
Krum, H; von Lueder, TG1
Mills, J; Vardeny, O1
Desai, AS; Gong, J; Jhund, PS; Lefkowitz, MP; Martinez, F; McMurray, JJV; Mosterd, A; Packer, M; Ramires, F; Rizkala, AR; Rouleau, JL; Senni, M; Shi, VC; Silva Cardoso, J; Simpson, J; Solomon, SD; Squire, I; Swedberg, K; Zile, MR1
Nguyen, E; Weeda, ER; White, CM1
Claggett, B; Jhund, P; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR1
DeKosky, ST; Feldman, AM; Haller, JA1
Gori, M; Senni, M1
Ayalasomayajula, S; Gevorkyan, H; Hinder, M; Jhee, S; Langenickel, TH; Pal, P; Rajman, I; Tsubouchi, C; Valentin, MA1
Amirbegishvili, IM; Averkov, OA; Babaeva, LA; Kobalava, ZhD; Kotovskaya, YV; Merai, I; Moisfev, VS; Pavlikova, EP1
Hayes, WJ; Wachholtz, CD1
Ollendorf, DA; Pearson, SD; Sandhu, AT1
Køber, L1
Arimura, T; Goto, M; Imaizumi, S; Iwata, A; Kuwano, T; Matsuo, Y; Miura, S; Saku, K; Suematsu, Y; Yahiro, E1
Baicu, CF; Claggett, BL; Jhund, PS; Lefkowitz, M; McMurray, JJ; Pieske, B; Prescott, MF; Shi, V; Solomon, SD; Voors, AA; Zile, MR1
Cardoso, JS; Desai, AS; Jhund, PS; Kristensen, SL; Lefkowitz, MP; Martinez, F; McMurray, JJ; Merkely, B; Packer, M; Preiss, D; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Squire, I; Starling, RC; Swedberg, K; Zile, MR1
Giannitsis, E; Huber, K; Jaffe, AS; Lindahl, B; Mair, J; Möckel, M; Müller, C; Plebani, M; Thygesen, K1
Aksnes, TA; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M1
Correia, LC; Rassi, A1
Katrukha, AG; Semenov, AG1
McCormack, PL1
Gu, Y; Liu, XY; Wang, H; Wu, J; Zhang, MJ; Zhu, PF1
Claggett, B; Desai, AS; Dukat, A; Kozan, Ö; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shi, VC; Solomon, SD; Starling, RC; Swedberg, K; Zile, M1
Latini, R; Masson, S; Staszewsky, L1
Korabathina, R; Wojnowich, K1
Bruhn, C1
Brown, NJ; Hubers, SA1
Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I1
Ansara, AJ; Koehler, JM; Kolanczyk, DM1
Fonarow, GC; Gordin, JS1
Coats, AJ; Lainscak, M1
Bellows, BK; Bress, AP; King, JB; Nelson, RE; Shah, RU1
Einecke, D1
Wise, J1
Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJ; Okumura, N; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR2
Anand, I; Andreka, P; Charney, A; Chen, F; Cosmi, F; Fischer, S; Galve, E; Gelev, V; Gogia, H; Gómez-Doblas, JJ; Majercak, I; Martinez-Selles, M; McIntyre, HF; McMurray, JJ; Nociar, J; Radomska, M; Reimund, B; Reyes, A; Sarkar, A; Senni, M; Shehova-Yankova, N; Sokolova, B; Volterrani, M; Wachter, R; Yilmaz, MB; Zilahi, Z1
Patel, S; Veltri, K1
Jhund, PS; McMurray, JJ1
Oliveira, GH; Robinson, MR1
Greenberg, B; Hsiao, R1
Vilela-Martin, JF1
Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Teerlink, JR; Vardeny, O; Zile, MR1
Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, J; Shi, V; Solomon, S; Swedberg, K; Zile, M1
Lippi, G; Sanchis-Gomar, F1
Claggett, B; Fonarow, GC; Hernandez, AF; McMurray, JJ; Solomon, SD1
Gori, M; Piepoli, M; Senni, M; Volterrani, M1
Claggett, B; Desai, A; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, J; Shi, V; Solomon, SD; Swedberg, K; Zile, MR1
Anand, IS; Cohn, JN; Florea, VG; Rector, TS1
Claggett, BL; Desai, AS; Lefkowitz, M; McMurray, JJV; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Starling, R; Swedberg, K; Teerlink, J; Zile, MR1
Mentz, RJ; O'Brien, EC1
Fu, M; Lund, LH; Swedberg, K1
Chan, WW; Claggett, B; Deschaseaux-Voinet, C; Fonarow, GC; Gaziano, TA; McMurray, JJ; Rouleau, JL; Solomon, SD; Turner, SJ; Zile, MR1
Ahmed, A; Banach, M; Bielecka-Dabrowa, A; Misztal, M; Pietrucha, T; Rysz, J; Sakowicz, A; von Haehling, S1
Parker, JD; Ross, HJ1
Hein, L; Lother, A1
Rosenberg, K1
Bistola, V; Farmakis, D; Karavidas, A; Parissis, J1
Cameron, SJ; Howell, EH1
Chaggar, PS; Orsborne, C; Shaw, SM; Williams, SG1
Brozena, S; Jessup, M; Owens, AT1
Adhyaru, B; Raj, L1
Blumenthal, RS; Gilotra, NA; Hsu, S; Lewsey, S; Mathews, L; Nwabueze, C; Okwuosa, IS; Princewill, O; Russell, SD1
Desai, AS; Vaduganathan, M1
Díez, J1
Cook, JC; Patterson, JH; Rodgers, JE; Tran, RH1
Brandenburg, VM; Marx, N; Rocca, HB1
Ezekowitz, JA1
Claggett, B; Desai, AS; Lefkowitz, M; McMurray, JJ; Packer, M; Rouleau, JL; Shi, V; Solomon, SD; Swedberg, K; Vardeny, O; Zile, MR1
Lin, JX; Lin, LM; Wu, MF; Wu, Y1
Cannon, JA; Chen, F; Gong, J; Jhund, PS; Kristensen, SL; Køber, L; Lefkowitz, MP; McMurray, JJ; Packer, M; Rouleau, JL; Shen, L; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR1
Hua, Y; Kelly, DJ; Liew, D; Liu, B; Reid, C; Wang, BH; Wang, I; Zhou, Y1
Alfonso Manterola, F; Almenar Bonet, L; Ariza Solé, A; Arribas Ynsaurriaga, F; Bover Freire, R; Bueno, H; Coca Payeras, A; Díaz Molina, B; Evangelista Masip, A; Ferreira González, I; González Juanatey, JR; Jiménez Navarro, M; Lambert Rodríguez, JL; López de Sá, E; López Fernández, S; Manito Lorite, N; Marin Ortuño, F; Martín Asenjo, R; Mirabet Pérez, S; Pascual Figal, D; Pérez de Isla, L; Rodríguez Padial, L; Ruilope Urioste, LM; San Román Calvar, JA; Sánchez Fernández, PL; Segovia Cubero, J; Sionis Green, A; Sionis, A; Varela Román, A; Vázquez García, R; Zamorano Gómez, JL1
Huynh, K1
Claggett, BL; Desai, AS; Gong, J; McMurray, JJ; Packer, M; Prescott, MF; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Zile, MR1
Cheng, J1
Callan, PD; Clark, AL1
Campbell, DJ2
Sabbah, HN1
Khder, Y; Lefkowitz, MP; McMurray, JJV; Shi, V1
Guo, W; Ito, H; Momomura, S; Ohishi, T; Okino, N; Saito, Y; Tsutsui, H; Yamamoto, K1
Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z1
Teerlink, JR; Tyler, JM1
Bruno, RM; Taddei, S1
Böhm, M; Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Young, R; Zile, MR1
Boutari, C; Doumas, M; Faselis, C; Imprialos, K; Kokkinos, P; Stavropoulos, K1
Banerjee, D; Kang, G1
Clark, AL; Cleland, JGF; Dierckx, R; Kazmi, S; MacNamara, A; Pellicori, P; Shah, P; Urbinati, A; Zhang, J1
Riddell, E; Vader, JM1
Rodgers, JE1
Kobalava, ZD; Lukina, OI; Villevalde, SV1
Degener, F; Postma, MJ; van der Pol, S; Vemer, P1
Baumhäkel, M; Böhm, M; Müller, U1
Fu, L; Gao, Y; Han, Y; Li, Y; Ma, D; Shen, J; Wang, F; Wang, Y; Xie, R; Zhou, P1
Jiang, B; Liu, ZH; Qu, FZ1
Baumhäkel, M; Müller, U1
Feldman, D; Wexler, R1
Califf, RM; Maggioni, AP; McMurray, JJ; Moukarbel, GV; Pfeffer, MA; Scheiman, JM; Signorovitch, JE; Solomon, SD; Velazquez, EJ; White, HD1
Andrews, CD; Brunel, P; MacDonald, TM; Parthasarathy, HK; Pieske, B; Struthers, AD; Weisskopf, M1
Anand, IS; Bishu, K; Cohn, JN; Ishani, A; Kuskowski, MA; Rector, TS1
Anand, IS; Cohn, JN; Holwerda, NJ; Kuskowski, M; Rector, TS; Thomas, S1
Bailey, J; Black, HR; Samuel, R; Zappe, D1
Han, LH; Jiang, B; Jiang, WP; Li, HX; Liu, ZH; Qu, FZ; Zou, C1
Iannazzo, S; Pradelli, L; Zaniolo, O1
Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B1
Bellocci, F; Crea, F; Giubilato, G; Ierardi, C; Pieroni, M; Santangeli, P; Vitulano, N1
McMurray, JJ; Swedberg, K2
Bourgoun, M; Califf, RM; Ghali, JK; Hassanein, AH; Hung, CL; Køber, L; Pfeffer, MA; Shin, SH; Solomon, SD; Uno, H; Velazquez, EJ; Verma, A1
Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Vahtola, E1
Bernheim, A; Brunner-La Rocca, HP; Kiowski, W; Kuster, GM; Morgenthaler, NG; Mueller, B; Nietlispach, F; Rickli, H; Riesen, W; Rüter, F; Schindler, R; Schuetz, P1
Belenkov, Y; Califf, RM; Finn, PV; Kenchaiah, S; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Shamshad, F; Soler-Soler, J; Solomon, SD; Swedberg, K; Varshavsky, S; Velazquez, EJ1
Anand, IS; Deswal, A; Kereiakes, DJ; Purkayastha, D; Zappe, DH1
Allhoff, T; Anand, IS; Cohn, JN; Drexler, H; Jantzen, F; Kempf, T; Kuskowski, M; Rector, TS; Tapken, H; Wollert, KC1
Califf, R; Kober, L; Maggioni, A; McMurray, JJ; Pfeffer, MA; Rouleau, J; Signorovitch, JE; Solomon, SD; Swedberg, K; Thune, JJ; Velazquez, E1
Ruilope, LM; Segura, J1
Anand, IS; Angelici, L; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Prescott, M; Solomon, S; Tognoni, G1
Akhtari, S; Andalib, A; Curnew, G; Leclerc, JM; Rigal, R; Tardif, JC; Vaillancourt, M1
Adams, F; Birkenfeld, AL; Engeli, S; Jordan, J; Schroeder, C1
Aparasu, RR; Ashton, CM; Chen, H; Desai, RJ; Deswal, A; Johnson, ML; Mehta, HB; Morgan, RO1
Biala, A; Finckenberg, P; Korpi, A; Levijoki, J; Loytainen, M; Martonen, E; Mervaala, E1
Maksimov, ML; Mochkin, IA; Starodubtsev, AK1
Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H1
Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H1
Joffe, MM; Yang, W1
Clark, AL; Cleland, JG1
Bransford, T; Gong, J; Kraigher-Krainer, E; Lefkowitz, M; McMurray, JJ; Packer, M; Pieske, B; Shah, A; Shi, V; Solomon, SD; Takeuchi, M; Voors, A; Zile, M1
Crunkhorn, S1
Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T1
Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM1
Adourian, A; Anand, IS; Cohn, JN; Kuskowski, M; Muntendam, P; Rector, TS1
Califf, RM; Giles, T; Haffner, SM; Hernandez, AF; Krum, H; Leiter, LA; Martinez, FA; Mazzone, T; McMurray, JJ; Rutten, GE; Standl, E; Sun, JL; Thomas, L; Tognoni, G; Wong, YW1
Lee, TH1
Cherubini, A; Di Lenarda, A; Perkan, A; Salvatore, L; Sinagra, G1
Gordon, A; Helmers, C; Löfdahl, P; Pantev, E; Rydberg, E; Willenheimer, R1
Barlera, S; Benza, RL; Chiang, YT; Cohn, JN; Gottlieb, SO; Kleemann, TD; Latini, R; Rosconi, F; Staszewsky, L; Vandervoort, PM; Volpi, A; Wong, M1
Anand, I; Cohn, JN; Gottlieb, SO; Latini, R; Maggioni, AP; Tognoni, G1
Greenberg, BH1
Inagaki, K; Iwanaga, Y; Kihara, Y; Mochly-Rosen, D; Onozawa, Y; Sarai, N; Takenaka, H1
Cohn, JN3
Anand, I; Bevilacqua, M; Cardano, P; Chiang, YT; Cohn, JN; Dunselman, PH; Holwerda, NJ; Judd, D; Latini, R; Maggioni, AP; Masson, S; Salio, M; Tognoni, G1
Hollenberg, NK1
Anand, IS; Chiang, YT; Cohn, JN; Fisher, LD; Glazer, RD; Latini, R; Maggioni, AP; Masson, S; Tognoni, G1
Komajda, M2
Kohno, M1
Kubota, T; Takeshita, A1
Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Suzuki, T; Takayama, Y; Toyama, T1
Carson, P; Cohn, JN; Tognoni, G1
Terra, SG1
Califf, RM; Edwards, S; Gallo, P; Henis, M; Kober, L; Leimberger, JD; Maggioni, AP; McMurray, JV; Pfeffer, MA; Rouleau, JL; Sellers, MA; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, HD1
Hashimoto, R; Kawahara, S; Matsuzaki, M; Umemoto, S1
Ghali, JK1
Jermendy, G; Matos, L; Winkler, G1
Bertocchi, F; Ceconi, C; De Tommasi, E; Ferrari, R; Francolini, G; Guida, P; Iacoviello, M; Massari, F; Pitzalis, MV; Rizzon, P; Romito, R1
Vachiéry, JL1
Deswal, A; Mann, DL1
Califf, RM; Edwards, S; Henis, M; Køber, L; Leimberger, JD; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Sellers, MA; Solomon, SD; Swedberg, K; Van de Werf, F; Velazquez, EJ; White, H; Zelenkofske, S1
Latini, R; Maggioni, AP; Masson, S; Staszewsky, L1
Goa, KL; Wellington, K1
Doi, M; Kobayashi, S; Kohno, M; Matsuzaki, M; Oda, T; Ohkusa, T; Okuda, S; Tokuhisa, T; Yamamoto, T; Yano, M1
Hukai, D; Ishii, C; Kanamori, T; Ohbayashi, Y; Ohnishi, M; Ohno, K; Okabayashi, T; Ozawa, T; Sakaguchi, T; Sichiri, G; Tanaka, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yokohama, H1
Pfeffer, M1
McAnulty, JH1
Lai, KN; Lam, KY; Leung, JC; Li, PS; Wing-Hon Lai, K; Yu, CM1
Liebson, PR1
Schlosshan, D; Tan, LB; Williams, SG1
Anzai, T; Hashimoto, K; Himeno, H; Imai, K; Kawana, M; Kitakaze, M; Koretsune, Y; Maruyama, S; Masaoka, Y; Matsubara, H; Matsuoka, T; Miyao, Y; Miyatake, K; Miyauchi, T; Nakamura, Y; Nomura, F; Okamoto, H; Ozono, K; Sekiya, M; Shinohara, H; Shintani, U; Shiraki, T; Takaoka, H; Tsutamoto, T; Yasumura, Y; Yokoya, K; Yokoyama, H1
Crijns, HJ; Folkeringa, RJ; Pinto, YM1
Aknay, N; Anand, I; Barlera, S; Cohn, JN; Glazer, R; Hester, A; Latini, R; Staszewsky, L; Wong, M1
Angeli, F; Verdecchia, P1
Califf, RM; Friedman, JY; Gnanasakthy, A; Reed, SD; Schulman, KA; Velazquez, EJ1
Birkenhäger, WH; Staessen, JA1
Käser, L; Kolyvanos Naumann, U; Vetter, W1
Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ1
Dahlöf, B; Kanae, K; Mochizuki, S; Shimizu, M; Tajima, N; Taniguchi, I; Yoshida, S1
Nguyen, A; Sharma, S1
Croom, KF; Keating, GM1
Aknay, N; Carson, P; Chiang, YT; Cohn, JN; Farsang, C; Glazer, RD; Krum, H; Maggioni, AP1
Aknay, N; Anand, I; Baruch, L; Cohn, JN; Glazer, RD; Hester, A; Heywood, JT; Krum, H; Vanhaecke, J1
Ripley, TL1
Aknay, N; Baruch, L; Feliciano, N; Goedel-Meinen, L; Hester, A; Hofmann, M; Majahalme, SK; Prescott, MF1
Anand, I; Barlera, S; Carbonieri, E; Cohn, J; Gonzini, L; Latini, R; Maggioni, AP; Opasich, C; Tavazzi, L1
Komuro, I; Kuwabara, Y1
Erhardt, LR1
Barlera, S; Carson, PE; Cerè, E; Cohn, JN; Glazer, R; Latini, R; Maggioni, AP; Masson, S; Singh, SN; Tognoni, G1
Cohn, JN; Giardini, A; Glazer, R; Hester, A; Majani, G; Opasich, C; Tavazzi, L; Tognoni, G1
Allsbrook, JS; Califf, RM; Masselink, LE; McMurray, JJ; Pfeffer, MA; Radeva, JI; Reed, SD; Schulman, KA; Sellers, MA; Velazquez, EJ; Weinfurt, KP1
Cohen-Solal, A; Dietz, R; Eichhorn, E; Erhardt, L; Hobbs, FD; Krum, H; Maggioni, A; McKelvie, RS; McMurray, J; Piña, IL; Soler-Soler, J; Swedberg, K1
Aknay, N; Anand, IS; Chiang, YT; Cohn, JN; Florea, VG; Glazer, RD; Hester, A; Kuskowski, MA; Latini, R; Maggioni, AP; Opasich, C; Rector, TS1
Cerulli, A; Frech, FH; Smith, DG1
Anand, IS; Cohn, JN; Florea, VG; Glazer, R; Hester, A; Kuskowski, MA; Latini, R; Masson, S; Mocarelli, P; Rector, T; Signorini, S1
Hatori, T; Ichikawa, S; Kasama, S; Kumakura, H; Kurabayashi, M; Sumino, H; Suzuki, T; Takayama, Y; Toyama, T1
Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV1
Barrios Alonso, V; Calderón Montero, A; Escobar Cervantes, C1
Temple, R1
Aylward, PE; Barvik, S; Califf, RM; Dalby, AJ; Huang, Z; Marin-Neto, JA; McMurray, JJ; Murin, J; Nordlander, RO; Pfeffer, MA; van Gilst, WH; Weaver, WD; White, HD; Zannad, F1
Liu, DS; Ye, JF1
Drexler, H; Landmesser, U1
Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tan, LB; Tognoni, G; Vago, T; Wong, M1
Kjeldsen, SE; Mistry, NB; Westheim, AS1
Anand, I; Carretta, E; Cohn, J; Glazer, R; Ingrillì, F; Krum, H; Latini, R; Maggioni, AP; Masson, S; Pettinati, G; Tognoni, G1
Battegay, E; Calvo-Vargas, C; Cieśliński, A; Degaute, JP; Holwerda, NJ; Hua, T; Julius, S; Kjeldsen, S; Kobalava, J; Laragh, JH; McInnes, GT; Pedersen, OL; Plat, F; Rudyatmoko, FP; Siamopoulos, KC; Störset, O; Weber, M; Zanchetti, A1
Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Skvortsov, AA; Sychev, AV2
Anavekar, NS; Arnold, JM; Bourgoun, M; Ghali, JK; Køber, L; Pfeffer, MA; Skali, H; Solomon, SD; Thune, JJ; Velazquez, EJ1
Aylward, PG; Califf, RM; Kober, L; McMurray, JJ; Pfeffer, MA; Pieper, KS; Skali, H; Solomon, SD; Stephenson, K; Van de Werf, F; Velazquez, EJ; White, HD1
Ott, P1
Behlouli, H; Hudson, M; Humphries, K; Pilote, L; Sheppard, R; Tu, JV1
Esaki, M; Fujiwara, H; Fujiwara, T; Kanamori, H; Kondo, T; Li, L; Li, Y; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Ohno, T; Okada, H; Takemura, G1
Dahlöf, B; Ikewaki, K; Kanae, K; Kawai, M; Mochizuki, S; Ogawa, K; Ohta, M; Okazaki, F; Seki, S; Shimizu, M; Tajima, N; Taniguchi, I; Taniguchi, M; Yamada, T; Yoshida, S; Yoshikawa, M1
Mitsuyama, S2
Akazawa, H; Komuro, I; Kudo, Y1
Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Omvik, P; Rostrup, M1
Bissessor, N; White, H1
Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S1
Deswal, A; Mann, DL; Ramasubbu, K1
Anand, IS; Barlera, S; Carretta, E; Cohn, JN; Latini, R; Maggioni, AP; Masson, S; Staszewsky, L; Tognoni, G; Wong, M1
Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ1
Gaballa, MA; Goldman, S; Guarraia, D; Johnson, N; Thai, H1
Havranek, EP1
Califf, RM; Francis, GS; Huang, Z; Lewis, EF; McMurray, JJ; Pfeffer, MA; Prisant, LM; Thomas, KL; Velazquez, EJ; Weaver, WD1
Burrell, LM; Johnston, CI1
Clair, MJ; de Gasparo, M; Hebbar, L; Iannini, JP; Krombach, RS; Melton, DM; Mukherjee, R; O, SJ; Spinale, FG; Whitebread, S1
Clair, MJ; Cox, MH; de Gasparo, M; Hebbar, L; Iannini, JP; Melton, DM; Mukherjee, R; Spinale, FG; Thomas, PB; Whitebread, S1
Bolshakova, TD; Fomina, IG; Kazakov, EN; Lyusov, VA; Mazayev, VP; Olbinskaya, LI; Orlov, VA; Spormann, DO; Sulimov, VA; Sullivan, J; Zvereva, TV1
Clair, MJ; de Gasparo, M; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Spinale, FG; Whitebread, S; Zellner, JL1
Clair, MJ; de Gasparo, M; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Rios, G; Spinale, FG; Whitebread, S1
Leary, AC; Lim, PO; MacDonald, TM; McMahon, AD; Shiels, P1
Anand, I; Baruch, L; Cohen, IS; Cohn, JN; Judd, D; Ziesche, S1
Kirk, JK1
Cohn, JN; Glazer, RD; Hester, A; Spormann, D; Tognoni, G1
Bohlender, J; Dietz, R; Haass, M; Höhnel, K; Luft, FC; Scheuermann, M; Thibault, G; Willenbrock, R1
van Veldhuisen, DJ; Voors, AA1
Coca, A; Giner, V1
Califf, RM; Cohn, JN1
Pfeffer, MA1
Petkun, W1
Cukon, S; Ennezat, PV; Hammer, A; Infeld, J; Jorde, UP; Le Jemtel, TH; Lisker, J; Sonnenblick, EH; Suryadevara, V1
Bonarjee, VV; Dickstein, K1
Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG1
Cohn, JN; Glazer, R; Spormann, D; Tognoni, G1
Iwao, H; Izumi, Y; Kawano, H; Kim, S; Kimoto, M; Yoshiyama, M; Zhan, Y1
Kulbertus, H1
Thürmann, PA1
Miller, AB; Srivastava, P1
Hayashida, W; Yasaka, A1
Fruhwald, FM; Kickenweiz, E; Klein, W; Zweiker, R1
De Gasparo, M; Domergue, V; Fornes, P; Giudicelli, JF; Richer, C1
Auer, JW; Berent, R; Eber, B1
Ogihara, T; Rakugi, H1
Armstrong, PW; Borer, J; Fleming, T; Lipicky, R1
Cohn, JN; Tognoni, G1
Piérard, L1
Baicu, SC; deGasparo, M; Goldberg, AT; Hendrick, JW; Joffs, C; King, MK; Krombach, RS; Multani, MM; Sample, JA; Spinale, FG1
Barlera, S; Höglund, C; Latini, R; Staszewsky, L; Volpi, A; Wong, M1
Haddy, FJ1
Cayley, WE1
Forfar, JC; Munir, S1

Reviews

229 review(s) available for valsartan and Cardiac Failure

ArticleYear
Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis.
    Clinical cardiology, 2021, Volume: 44, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2021
Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review.
    Current cardiology reviews, 2022, Volume: 18, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
    Pharmacology research & perspectives, 2021, Volume: 9, Issue:5

    Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hospitalization; Humans; Hyperkalemia; Hypotension; Mortality; Renal Insufficiency; Risk Assessment; Stroke Volume; Valsartan

2021
Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis.
    International urology and nephrology, 2022, Volume: 54, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Stroke Volume; Valsartan

2022
Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders.
    The American journal of cardiology, 2021, 12-15, Volume: 161

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Valsartan

2021
Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis.
    Clinical drug investigation, 2022, Volume: 42, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Glucose; Heart Failure; Humans; Network Meta-Analysis; Sodium; Stroke Volume; Tetrazoles; Valsartan

2022
Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article.
    Medicine, 2021, Dec-30, Volume: 100, Issue:52

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.
    PloS one, 2022, Volume: 17, Issue:1

    Topics: Aminobutyrates; Atrial Fibrillation; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Randomized Controlled Trials as Topic; Valsartan

2022
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.
    JACC. Heart failure, 2022, Volume: 10, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diuretics; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents

2022
Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.
    Basic & clinical pharmacology & toxicology, 2022, Volume: 130, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glucose; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Pyrimidines; Sodium; Tetrazoles; Treatment Outcome; Valsartan

2022
Effectiveness of sacubitril-valsartan in patients with cancer therapy-related cardiac dysfunction: a systematic review of clinical and preclinical studies.
    Minerva medica, 2022, Volume: 113, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Neoplasms; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
    Current hypertension reports, 2022, Volume: 24, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
New paradigm shift in the pharmacotherapy for heart failure-where are we now and where are we heading?
    Journal of cardiology, 2023, Volume: 81, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan

2023
Therapeutic effects and safety of early use of sacubitril/valsartan after acute myocardial infarction: a systematic review and meta-analysis.
    Annals of palliative medicine, 2022, Volume: 11, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Function, Left

2022
Sacubitril/Valsartan Off-Label Uses for Heart Failure.
    Journal of cardiac failure, 2022, Volume: 28, Issue:7

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Neprilysin; Off-Label Use; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.
    Pharmacology & therapeutics, 2022, Volume: 238

    Topics: Aminobutyrates; Biphenyl Compounds; Cardiac Myosins; Chronic Disease; Glucose; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Sodium; Sodium-Glucose Transporter 2; Soluble Guanylyl Cyclase; Stroke Volume; Valsartan; Ventricular Function, Left

2022
Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.
    European journal of internal medicine, 2022, Volume: 102

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan

2022
Angiotensin receptor-neprilysin inhibitors for hypertension-hemodynamic effects and relevance to hypertensive heart disease.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2022, Volume: 45, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Hypertension; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan

2022
New therapies for the treatment of heart failure with preserved ejection fraction.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022, 08-19, Volume: 79, Issue:17

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review.
    Expert review of cardiovascular therapy, 2022, Volume: 20, Issue:7

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Model parameters influencing the cost-effectiveness of sacubitril/valsartan in heart failure: evidence from a systematic literature review.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2023, Volume: 24, Issue:3

    Topics: Cost-Benefit Analysis; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2023
A narrative review on sacubitril/valsartan and ventricular arrhythmias.
    Medicine, 2022, Jul-08, Volume: 101, Issue:27

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
The Efficacy and Safety of Sacubitril-Valsartan for the Treatment of Heart Failure in Adults: A Meta-Analysis.
    The Annals of pharmacotherapy, 2023, Volume: 57, Issue:4

    Topics: Adult; Aminobutyrates; Heart Failure; Humans; Tetrazoles; Valsartan

2023
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials.
    ESC heart failure, 2022, Volume: 9, Issue:6

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Female; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Valsartan

2022
Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control.
    International journal of cardiology, 2022, 11-15, Volume: 367

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycemic Control; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan

2022
Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction: A Review.
    JAMA cardiology, 2022, 10-01, Volume: 7, Issue:10

    Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials.
    Frontiers in public health, 2022, Volume: 10

    Topics: Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Heart Failure; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Valsartan

2022
Sacubitril/valsartan: An antiarrhythmic drug?
    Journal of cardiovascular electrophysiology, 2022, Volume: 33, Issue:11

    Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology.
    European journal of heart failure, 2022, Volume: 24, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2022
Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 155

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Calcium Channel Blockers; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan

2022
Evaluating the evidence for sacubitril/valsartan across the continuum of heart failure.
    Pharmacotherapy, 2022, Volume: 42, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan

2022
Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis.
    Current problems in cardiology, 2023, Volume: 48, Issue:1

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2023
Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.
    International journal of molecular sciences, 2022, Sep-26, Volume: 23, Issue:19

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Prospective Studies; Quality of Life; Renin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials.
    Medicine, 2022, Oct-14, Volume: 101, Issue:41

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Valsartan

2022
Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis.
    The Annals of pharmacotherapy, 2023, Volume: 57, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Heart Failure; Humans; Hypotension; Quality of Life; Stroke Volume; Tetrazoles; Valsartan

2023
Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
    BMC medicine, 2022, 12-17, Volume: 20, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Hypoglycemia; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan

2022
Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2023, 01-01, Volume: 24, Issue:1

    Topics: Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2023
Efficacy and safety of low-dose sacubitril/valsartan in heart failure patients: A systematic review and meta-analysis.
    Clinical cardiology, 2023, Volume: 46, Issue:3

    Topics: Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2023
Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis.
    Journal of cardiovascular electrophysiology, 2023, Volume: 34, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Heart Failure; Humans; Incidence; Valsartan

2023
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization.
    Expert opinion on pharmacotherapy, 2023, Volume: 24, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Treatment Outcome; Valsartan

2023
Effects of Sacubitril-Valsartan in Patients With Various Types of Heart Failure: A Meta-analysis.
    Journal of cardiovascular pharmacology, 2023, 06-01, Volume: 81, Issue:6

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2023
Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?
    Cardiology, 2023, Volume: 148, Issue:3

    Topics: Aged; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Humans; Prognosis; Stroke Volume; Tetrazoles; Valsartan

2023
Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.
    Journal of the American Heart Association, 2023, 04-18, Volume: 12, Issue:8

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Enzyme Inhibitors; Heart Failure; Humans; Kidney; Neprilysin; Receptors, Angiotensin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan

2023
Sacubitril/valsartan-induced liver injury: A case report and literature review.
    Medicine, 2023, Aug-11, Volume: 102, Issue:32

    Topics: Adult; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chemical and Drug Induced Liver Injury, Chronic; Drug Combinations; Female; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Sacubitril/Valsartan: Updates and Clinical Evidence for a Disease-Modifying Approach.
    Drugs, 2019, Volume: 79, Issue:14

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan

2019
[« ARNI » (Angiotensin Receptor-Neprilysin Inhibitor): when, for whom and how?]
    Revue medicale suisse, 2019, Oct-16, Volume: 15, Issue:667

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Cognition; Drug Combinations; Enalapril; Heart Failure; Humans; Kidney; Neprilysin; Tetrazoles; Treatment Outcome; Valsartan

2019
Angiotensin receptor/neprilysin inhibitor-a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings.
    Heart failure reviews, 2020, Volume: 25, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2020
Recent advances in the treatment of chronic heart failure.
    F1000Research, 2019, Volume: 8

    Topics: Aminobutyrates; Amyloid Neuropathies, Familial; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hemodynamics; Humans; Iron Deficiencies; Mitral Valve Insufficiency; Monitoring, Physiologic; Sodium-Glucose Transporter 2; Tetrazoles; Treatment Outcome; Valsartan

2019
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
    Vascular health and risk management, 2020, Volume: 16

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2020
The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure.
    Revista portuguesa de cardiologia, 2019, Volume: 38, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neurosecretory Systems; Renin-Angiotensin System; Sympathetic Nervous System; Tetrazoles; Valsartan; Vasopressins

2019
Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    The American journal of cardiology, 2020, 04-15, Volume: 125, Issue:8

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Hospitalization; Humans; Irbesartan; Mineralocorticoid Receptor Antagonists; Mortality; Network Meta-Analysis; Perindopril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Spironolactone; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2020
Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2020, Volume: 109, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Valsartan

2020
LCZ696 and preservation of renal function in heart failure: A meta-analysis of 6 randomized trials.
    Reviews in cardiovascular medicine, 2020, Mar-30, Volume: 21, Issue:1

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Evidence-Based Medicine; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan

2020
Cost-effectiveness analyses of sacubitril-valsartan for heart failure.
    Heart failure reviews, 2021, Volume: 26, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Impact of Sacubitril-Valsartan on Markers of Glomerular Function.
    Current heart failure reports, 2020, Volume: 17, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glomerular Filtration Rate; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2020
Angiotensin Receptor Neprilysin Inhibitors-2019 Update.
    Cardiovascular drugs and therapy, 2020, Volume: 34, Issue:5

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Patient Safety; Protease Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Recovery of Function; Risk Assessment; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan

2020
Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?
    Heart failure reviews, 2022, Volume: 27, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Heart Failure; Humans; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan

2022
A Systematic Review on the Use of Sacubitril/Valsartan Initiated Prior to Discharge in Hospitalized Patients With Heart Failure.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Patient Discharge; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2021
Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    European journal of pharmacology, 2020, Oct-05, Volume: 884

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Stroke Volume; Treatment Outcome; Valsartan

2020
Inpatient Initiation of Sacubitril/Valsartan.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Heart Failure; Hospitalization; Humans; Inpatients; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan

2021
Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
    International journal of cardiology, 2021, 01-15, Volume: 323

    Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Valsartan

2020
Heart failure with preserved ejection fraction after the PARAGON-HF trial results: current knowledge and future directions.
    Kardiologia polska, 2020, 12-23, Volume: 78, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Female; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Valsartan

2020
Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Clinical Trials as Topic; Cognition Disorders; Drug Combinations; Heart Failure; Humans; Neprilysin; United States; United States Food and Drug Administration; Valsartan

2021
Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Network Meta-Analysis; Pyrimidines; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan

2021
Sacubitril/Valsartan in the Management of Heart Failure Patients with Cardiac Implantable Electronic Devices.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Defibrillators, Implantable; Dose-Response Relationship, Drug; Drug Combinations; Electrocardiography; Heart Failure; Humans; Stroke Volume; Valsartan

2021
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
    Current opinion in nephrology and hypertension, 2021, Volume: 30, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan

2021
The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis.
    Heart, lung & circulation, 2021, Volume: 30, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left

2021
Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
    Open heart, 2020, Volume: 7, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Global Health; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Survival Rate; Valsartan

2020
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
    Circulation, 2021, 03-02, Volume: 143, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Valsartan

2021
Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening!
    European journal of pharmacology, 2021, Mar-05, Volume: 894

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Brain Diseases; Chemotherapy-Related Cognitive Impairment; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Valsartan

2021
Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
    The American journal of cardiology, 2021, 04-15, Volume: 145

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cause of Death; Drug Combinations; Heart Failure; Hospitalization; Humans; Mortality; Natriuretic Peptide, Brain; Peptide Fragments; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review.
    International journal of cardiology, 2021, 05-15, Volume: 331

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Asia; Biphenyl Compounds; Drug Combinations; Europe; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2021
Renal protection in chronic heart failure: focus on sacubitril/valsartan.
    European heart journal. Cardiovascular pharmacotherapy, 2021, 09-21, Volume: 7, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled Trials.
    Journal of cardiovascular pharmacology, 2021, 08-01, Volume: 78, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Valsartan; Young Adult

2021
Mechanisms and Models in Heart Failure: A Translational Approach.
    Circulation research, 2021, 05-14, Volume: 128, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Development; Enzyme Activators; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Models, Biological; Natriuretic Peptides; Neprilysin; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Soluble Guanylyl Cyclase; Stroke Volume; Urea; Valsartan; Ventricular Remodeling

2021
Recent advances in pharmacological treatment of heart failure.
    European journal of clinical investigation, 2021, Volume: 51, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Drug Combinations; Ferric Compounds; Heart Failure; Heterocyclic Compounds, 2-Ring; Hospitalization; Humans; Iron Deficiencies; Maltose; Pyrimidines; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea; Valsartan; Vasodilator Agents; Ventricular Remodeling

2021
Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
    Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:5

    Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Pharmacovigilance; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week.
    Journal of the American College of Cardiology, 2021, 06-29, Volume: 77, Issue:25

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan

2021
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.
    The American journal of cardiology, 2021, 08-15, Volume: 153

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Enalapril; Enzyme Inhibitors; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Neprilysin; Ramipril; Severity of Illness Index; Stroke Volume; Valsartan; Ventricular Dysfunction, Left

2021
Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2021, Volume: 44, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan

2021
Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis.
    ESC heart failure, 2021, Volume: 8, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan

2021
Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug.
    Expert opinion on investigational drugs, 2017, Volume: 26, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Diseases; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Diseases; Renin-Angiotensin System; Tetrazoles; Valsartan

2017
Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge.
    Pharmacotherapy, 2017, Volume: 37, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Tetrazoles; Treatment Outcome; Valsartan

2017
Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots.
    Current vascular pharmacology, 2017, Volume: 16, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Combinations; Heart Failure; Humans; Hypertension; Life Style; Prognosis; Risk Factors; Stroke Volume; Sympathectomy; Tetrazoles; Valsartan

2017
Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.
    Clinical pharmacokinetics, 2017, Volume: 56, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biphenyl Compounds; Drug Combinations; Drug Interactions; Heart Failure; Humans; Liver Diseases; Renal Insufficiency; Tetrazoles; Valsartan

2017
Heart Failure Guidelines on Pharmacotherapy.
    Handbook of experimental pharmacology, 2017, Volume: 243

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Hydralazine; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Nitrates; Practice Guidelines as Topic; Severity of Illness Index; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents

2017
Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects.
    Cardiovascular therapeutics, 2017, Volume: 35, Issue:4

    Topics: Alzheimer Disease; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Pharmacogenetics; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2017
First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Clinical pharmacology and therapeutics, 2017, Volume: 102, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2017
Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap.
    JACC. Heart failure, 2017, Volume: 5, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Heart Failure; Humans; Tetrazoles; United States; United States Food and Drug Administration; Valsartan

2017
Angiotensin Receptor-Neprilysin Inhibition.
    Journal of cardiovascular pharmacology and therapeutics, 2017, Volume: 22, Issue:4

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan

2017
"Fast Track" Development and Approval Process for Heart Failure Therapeutics.
    Clinical pharmacology and therapeutics, 2017, Volume: 102, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Approval; Drug Combinations; Drug Discovery; Heart Failure; Humans; Ivabradine; Tetrazoles; United States; United States Food and Drug Administration; Valsartan

2017
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Journal of the American Society of Hypertension : JASH, 2017, Volume: 11, Issue:7

    Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Clinical Trials as Topic; Cough; Cyclic GMP; Diuresis; Drug Combinations; Heart Failure; Heart Ventricles; Humans; Hypertension; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan; Vasodilation

2017
[New pharmacologic therapies for chronic heart failure].
    Der Internist, 2017, Volume: 58, Issue:9

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Digitalis Glycosides; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2017
Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    JACC. Heart failure, 2017, Volume: 5, Issue:7

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan

2017
Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option.
    Cardiovascular & hematological disorders drug targets, 2017, Volume: 17, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart; Heart Failure; Humans; Irbesartan; Perindopril; Tetrazoles; Valsartan

2017
Sacubitril/valsartan: beyond natriuretic peptides.
    Heart (British Cardiac Society), 2017, Volume: 103, Issue:20

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Tetrazoles; Valsartan

2017
Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction.
    The American journal of cardiology, 2017, Oct-01, Volume: 120, Issue:7

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2017
Pharmacologic Management for Heart Failure and Emerging Therapies.
    Current cardiology reports, 2017, 08-24, Volume: 19, Issue:10

    Topics: Aminobutyrates; Benzazepines; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Glucosides; Heart Failure; Humans; Ivabradine; Neuregulin-1; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Urea; Valsartan

2017
Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2017, Volume: 36, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2017
[Acute and chronic heart failure].
    Herz, 2017, Volume: 42, Issue:7

    Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy; Chronic Disease; Defibrillators, Implantable; Diuretics; Drug Combinations; Extracorporeal Membrane Oxygenation; Guideline Adherence; Heart Failure; Heart-Assist Devices; Infusions, Intravenous; Iron; Tetrazoles; Valsartan

2017
The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
    Basic & clinical pharmacology & toxicology, 2018, Volume: 122, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hypertension; Imidazoles; Natriuretic Peptides; Neprilysin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan

2018
[Neprilysin inhibition and chronic kidney disease].
    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2017, Sep-28, Volume: 34, Issue:5

    Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Diuresis; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Models, Biological; Molecular Targeted Therapy; Natriuresis; Natriuretic Peptides; Neprilysin; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valsartan

2017
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
    Vascular health and risk management, 2017, Volume: 13

    Topics: Aminobutyrates; Angiotensin II Type 2 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Patient Selection; Practice Guidelines as Topic; Protease Inhibitors; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan

2017
What will be the impact of sacubitril/valsartan in clinical practice?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2018, Volume: 19 Suppl 1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Decision-Making; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Heart Failure; Humans; Patient Selection; Recovery of Function; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2018
PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions.
    Pharmacotherapy, 2018, Volume: 38, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Prospective Studies; Tetrazoles; Valsartan

2018
Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients.
    Drugs of today (Barcelona, Spain : 1998), 2017, Volume: 53, Issue:10

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Tetrazoles; Valsartan

2017
Heart failure treatment: Keeping up with best practices.
    The Journal of family practice, 2018, Volume: 67, Issue:1

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cardiac Rehabilitation; Cardiac Resynchronization Therapy; Cardiovascular Agents; Defibrillators, Implantable; Diuretics; Drug Combinations; Echocardiography; Heart Failure; Heart-Assist Devices; Humans; Ivabradine; Obesity; Physician's Role; Physicians, Family; Sleep Apnea, Obstructive; Stroke Volume; Tetrazoles; Valsartan

2018
B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction.
    Journal of cardiothoracic and vascular anesthesia, 2018, Volume: 32, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Disease Management; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Signal Transduction; Stroke Volume; Tetrazoles; Valsartan

2018
The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Current cardiology reports, 2018, 01-27, Volume: 20, Issue:1

    Topics: Aged; Aging; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Systole; Tetrazoles; Treatment Outcome; Valsartan

2018
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Obesity; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan

2018
Entresto, a New Panacea for Heart Failure?
    Cardiovascular & hematological agents in medicinal chemistry, 2018, Volume: 16, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Molecular Structure; Tetrazoles; Valsartan

2018
Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/neprilysin inhibitor therapy.
    Postgraduate medicine, 2018, Volume: 130, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2018
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018, Volume: 18, Issue:6

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Heart Rate; Humans; Natriuretic Peptides; Neprilysin; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Valsartan

2018
Sacubitril/valsartan: from a large clinical trial to clinical practice.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2018, Volume: 19, Issue:9

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Clinical Trials as Topic; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Patient Selection; Practice Guidelines as Topic; Protease Inhibitors; Research Design; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan

2018
Sacubitril/Valsartan: potential treatment for paediatric heart failure.
    Cardiology in the young, 2018, Volume: 28, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Child; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2018
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
    Indian heart journal, 2018, Volume: 70 Suppl 1

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2018
[Pharmacological therapy of heart failure with reduced ejection fraction].
    Therapeutische Umschau. Revue therapeutique, 2018, Volume: 75, Issue:3

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Output, Low; Combined Modality Therapy; Diuretics; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Ivabradine; Life Style; Mineralocorticoid Receptor Antagonists; Stroke Volume; Tetrazoles; Valsartan

2018
[Heart failure with "mid-range" ejection fraction: a new clinical entity?]
    Therapeutische Umschau. Revue therapeutique, 2018, Volume: 75, Issue:3

    Topics: Aged; Aminobutyrates; Benzimidazoles; Biomarkers; Biphenyl Compounds; Comorbidity; Coronary Disease; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Natriuretic Peptides; Perindopril; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Spironolactone; Stroke Volume; Survival Rate; Syndrome; Tetrazoles; Valsartan

2018
Sacubitril/Valsartan: The Newest Neurohormonal Blocker for Guideline-Directed Medical Therapy for Heart Failure.
    Heart failure clinics, 2018, Volume: 14, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Guideline Adherence; Heart Failure; Humans; Tetrazoles; Valsartan

2018
Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2019, Volume: 19, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2019
Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
    JACC. Heart failure, 2019, Volume: 7, Issue:1

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Decision-Making; Deprescriptions; Drug Combinations; Drug Substitution; Heart Failure; Hospitalization; Humans; Medication Adherence; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Valsartan

2019
Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives.
    International journal of cardiology, 2019, 04-15, Volume: 281

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan

2019
Practical guidance on the use of sacubitril/valsartan for heart failure.
    Heart failure reviews, 2019, Volume: 24, Issue:2

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Cost of Illness; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2019
Sacubitril/valsartan: A practical guide.
    Revista portuguesa de cardiologia, 2019, Volume: 38, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Valsartan

2019
Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
    Cardiovascular drugs and therapy, 2019, Volume: 33, Issue:3

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2019
Chronic heart failure: advances in pharmacological treatment and future perspectives.
    Swiss medical weekly, 2019, Mar-11, Volume: 149

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2019
Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
    Clinical therapeutics, 2019, Volume: 41, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Health Care Costs; Heart Failure; Humans; Models, Statistical; Republic of Korea; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2019
Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis.
    Journal of the American Heart Association, 2019, 07-02, Volume: 8, Issue:13

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Remodeling; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Remodeling; Walk Test

2019
The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure.
    Expert opinion on investigational drugs, 2013, Volume: 22, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.
    Circulation. Heart failure, 2013, Volume: 6, Issue:3

    Topics: Alternative Splicing; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Designer Drugs; Drug Combinations; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Natriuretic Peptides; Neprilysin; Peptidyl-Dipeptidase A; Protease Inhibitors; Receptors, Angiotensin; Renin-Angiotensin System; Snake Venoms; Tetrazoles; Valsartan

2013
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
    European heart journal, 2014, Oct-21, Volume: 35, Issue:40

    Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Diabetic Angiopathies; Diuretics; Drug Combinations; Exercise Therapy; Heart Failure; Homeostasis; Humans; Hypertension, Pulmonary; Iron Deficiencies; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; Obesity; Observational Studies as Topic; Patient Selection; Phenotype; Phosphodiesterase 5 Inhibitors; Sodium Channel Blockers; Stroke Volume; Tetrazoles; Valsartan; Vascular Stiffness

2014
Neprilysin inhibition in chronic kidney disease.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, Volume: 30, Issue:5

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Disease Progression; Drug Combinations; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Natriuresis; Nephrology; Neprilysin; Proteinuria; Pyridines; Renin-Angiotensin System; Tetrazoles; Thiazepines; Treatment Outcome; Valsartan

2015
Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
    JACC. Heart failure, 2014, Volume: 2, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Tetrazoles; Valsartan

2014
Neprilysin inhibitors preserve renal function in heart failure.
    International journal of cardiology, 2015, Jan-20, Volume: 179

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Kidney; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2015
Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
    International journal of cardiology, 2014, Dec-20, Volume: 177, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Registries; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Time Factors; Valsartan

2014
Heart failure therapies in 2014: Mixed results for heart failure therapies.
    Nature reviews. Cardiology, 2015, Volume: 12, Issue:2

    Topics: Aminobutyrates; Anemia, Iron-Deficiency; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotonic Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Spironolactone; Tetrazoles; Valsartan

2015
LCZ696 : a new paradigm for the treatment of heart failure?
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Clinical Trials, Phase II as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Prospective Studies; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2015
Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2014, Volume: 14 Suppl 2

    Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2014
Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    European journal of heart failure, 2015, Volume: 17, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2015
The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
    Journal of the American College of Cardiology, 2015, Mar-17, Volume: 65, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Design; Heart Failure; History, 20th Century; Humans; Neprilysin; Physiology; Renin-Angiotensin System; Research Design; Tetrazoles; Valsartan

2015
LCZ696: the next step in improving RAS inhibition?
    Current hypertension reports, 2015, Volume: 17, Issue:5

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; ras Proteins; Renin-Angiotensin System; Tetrazoles; Valsartan

2015
LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
    Journal of pharmacy practice, 2015, Volume: 28, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Rats; Tetrazoles; Valsartan

2015
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
    Vascular health and risk management, 2015, Volume: 11

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hypertension; Indans; Natriuretic Peptide, Brain; Neprilysin; Propionates; Pyridines; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Stroke Volume; Tetrazoles; Thiazepines; Valsartan

2015
Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy.
    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2015, Volume: 22, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Discovery; Heart Failure; Humans; Hypertension; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2015
Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
    Journal of cardiac failure, 2015, Volume: 21, Issue:9

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2015
Sacubitril/valsartan (Entresto) for heart failure.
    The Medical letter on drugs and therapeutics, 2015, Aug-03, Volume: 57, Issue:1474

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiotonic Agents; Disease Progression; Drug Combinations; Drug Interactions; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2015
LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
    Basic & clinical pharmacology & toxicology, 2016, Volume: 118, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Molecular Structure; Natriuretic Peptides; Neprilysin; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan

2016
Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Clinical therapeutics, 2015, Oct-01, Volume: 37, Issue:10

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Neprilysin; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valsartan

2015
Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
    Pharmacotherapy, 2015, Volume: 35, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Design; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2015
New medical therapies for heart failure.
    Nature reviews. Cardiology, 2015, Volume: 12, Issue:12

    Topics: Amides; Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Digoxin; Drug Combinations; Fumarates; Heart Failure; Humans; Natriuretic Peptides; Peptide Fragments; Snake Venoms; Tetrazoles; Valsartan

2015
A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Journal of clinical pharmacology, 2016, Volume: 56, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2016
Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
    Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan

2016
Sacubitril-Valsartan for the Treatment of Heart Failure: Effectiveness and Value.
    JAMA internal medicine, 2016, Volume: 176, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2016
Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Drugs, 2016, Volume: 76, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Heart Failure; Heart Function Tests; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan

2016
Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.
    Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:6

    Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Medication Therapy Management; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Valsartan

2016
Heart Failure Update: Outpatient Management.
    FP essentials, 2016, Volume: 442

    Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiotonic Agents; Cardiovascular Agents; Diet, Sodium-Restricted; Digoxin; Diuretics; Drug Combinations; Exercise Therapy; Fatty Acids, Omega-3; Female; Heart Failure; Heart Transplantation; Hospice Care; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan; Vasodilator Agents

2016
[Angiotensin-receptor- and neprilysin-inhibition: a new option against heart failure].
    Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:1

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Drug Combinations; Enzyme Inhibitors; Heart Failure; Hospitalization; Humans; Neprilysin; Tetrazoles; Valsartan

2016
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Circulation, 2016, Mar-15, Volume: 133, Issue:11

    Topics: Abnormalities, Drug-Induced; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bradykinin; Contraindications; Drug Combinations; Drug Costs; Drug Synergism; Enalapril; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Failure; Humans; Hyperkalemia; Hypertension; Kidney; Multicenter Studies as Topic; Natriuretic Peptides; Neprilysin; Pregnancy; Prodrugs; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Thiazepines; Valsartan

2016
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2016
New medications for heart failure.
    Trends in cardiovascular medicine, 2016, Volume: 26, Issue:6

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Benzazepines; Biphenyl Compounds; Cyclic Nucleotide-Gated Cation Channels; Drug Combinations; Heart Failure; Heart Rate; Humans; Ivabradine; Neprilysin; Practice Guidelines as Topic; Protease Inhibitors; Recovery of Function; Signal Transduction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2016
New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
    Journal of pharmacy practice, 2017, Volume: 30, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Ivabradine; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2017
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Heart (British Cardiac Society), 2016, 09-01, Volume: 102, Issue:17

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular System; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Patient Selection; Protease Inhibitors; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan

2016
Contemporary clinical trial updates in heart failure.
    Current opinion in cardiology, 2016, Volume: 31, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Rate; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction

2016
Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
    Current heart failure reports, 2016, Volume: 13, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Quality of Life; Tetrazoles; Valsartan

2016
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2016
Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge?
    International journal of cardiology, 2016, Sep-15, Volume: 219

    Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Valsartan

2016
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.
    European journal of heart failure, 2016, Volume: 18, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan

2016
Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    International journal of cardiology, 2017, Jan-01, Volume: 226

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan

2017
Pharmacology of heart failure: From basic science to novel therapies.
    Pharmacology & therapeutics, 2016, Volume: 166

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Guanylate Cyclase; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Myosins; Neprilysin; Practice Guidelines as Topic; Renin-Angiotensin System; Tetrazoles; Valsartan

2016
Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA.
    European journal of heart failure, 2016, Volume: 18, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2016
Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.
    Cardiology journal, 2016, Volume: 23, Issue:6

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan

2016
The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.
    Postgraduate medical journal, 2017, Volume: 93, Issue:1095

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2017
Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
    Annual review of medicine, 2017, 01-14, Volume: 68

    Topics: Alzheimer Disease; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Patient Selection; Pyridines; Stroke Volume; Tetrazoles; Thiazepines; Valsartan

2017
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
    Postgraduate medical journal, 2016, Volume: 92, Issue:1094

    Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Natriuretic Factor; Benzazepines; Biphenyl Compounds; Calcium Channel Blockers; Cardiology; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Drug Combinations; Erythropoietin; Evidence-Based Medicine; Fumarates; Heart Failure; Hematinics; Humans; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Societies, Medical; Stroke Volume; Tetrazoles; United States; Valsartan; Vasodilator Agents

2016
The ABCs of managing systolic heart failure: Past, present, and future.
    Cleveland Clinic journal of medicine, 2016, Volume: 83, Issue:10

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy Devices; Defibrillators, Implantable; Digoxin; Diuretics; Drug Combinations; Evidence-Based Medicine; Exercise; Heart Failure; Heart-Assist Devices; Humans; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Peptide Fragments; Practice Guidelines as Topic; Systole; Tetrazoles; Valsartan

2016
Angiotensin-Neprilysin Inhibition as a Paradigm for All?
    Current cardiology reports, 2016, Volume: 18, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2016
Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
    European journal of heart failure, 2017, Volume: 19, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Chronic Disease; Drug Combinations; Endothelin-1; Heart Failure; Humans; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Receptors, Atrial Natriuretic Factor; Renin-Angiotensin System; Sympathetic Nervous System; Tetrazoles; Valsartan

2017
Evolving therapies for the management of chronic and acute decompensated heart failure.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Nov-01, Volume: 73, Issue:21

    Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Disease Management; Drug Combinations; Ferric Compounds; Heart Failure; Humans; Ivabradine; Maltose; Tetrazoles; Valsartan

2016
[Sacubitril / Valsartan in patients with diabetes and heart failure].
    Deutsche medizinische Wochenschrift (1946), 2016, Volume: 141, Issue:22

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Complications; Dose-Response Relationship, Drug; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Tetrazoles; Treatment Outcome; Valsartan

2016
Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.
    Cardiovascular drugs and therapy, 2016, Volume: 30, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Contraindications; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, Chronic; Tetrazoles; Valsartan

2016
Heart failure - what's new and what's changed?
    Clinical medicine (London, England), 2016, Volume: 16, Issue:Suppl 6

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Complications; Drug Combinations; Heart Failure; Humans; Positive-Pressure Respiration; Practice Guidelines as Topic; Sleep Apnea, Central; Tetrazoles; Valsartan

2016
Long-term neprilysin inhibition - implications for ARNIs.
    Nature reviews. Cardiology, 2017, Volume: 14, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biological Availability; Biphenyl Compounds; Blood Pressure; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2017
Silent disease progression in clinically stable heart failure.
    European journal of heart failure, 2017, Volume: 19, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Apoptosis; Atrial Natriuretic Factor; Biphenyl Compounds; Calcium; Disease Progression; Diuretics; Drug Combinations; Fibrosis; Heart Failure; Humans; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stress, Mechanical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2017
Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Handbook of experimental pharmacology, 2017, Volume: 243

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan

2017
The safety of sacubitril-valsartan for the treatment of chronic heart failure.
    Expert opinion on drug safety, 2017, Volume: 16, Issue:2

    Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Chronic Disease; Drug Combinations; Enalapril; Heart Failure; Humans; Risk Factors; Tetrazoles; Valsartan

2017
Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun.
    Current pharmaceutical design, 2017, Volume: 23, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Naphthyridines; Neprilysin; Tetrazoles; Valsartan

2017
Neprilysin Inhibitors in Cardiovascular Disease.
    Current cardiology reports, 2017, Volume: 19, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2017
Heart failure guidelines: What's new?
    Trends in cardiovascular medicine, 2017, Volume: 27, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Drug Combinations; Guideline Adherence; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tetrazoles; Treatment Outcome; Valsartan

2017
Potential Expanded Indications for Neprilysin Inhibitors.
    Current heart failure reports, 2017, Volume: 14, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2017
Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    The American journal of medicine, 2017, Volume: 130, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Costs; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan

2017
[A Breakthrough in the Treatment of Patients With Heart Failure With Reduced Ejection Fraction: the Clinical Significance of the PARADIGM HF-Trial].
    Kardiologiia, 2017, Volume: 57, Issue:2

    Topics: Angiotensin Receptor Antagonists; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2017
Valsartan: more than a decade of experience.
    Drugs, 2009, Volume: 69, Issue:17

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Hypotension; Meta-Analysis as Topic; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan

2009
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Minerva cardioangiologica, 2009, Volume: 57, Issue:6

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2009
Dual-acting angiotensin receptor-neprilysin inhibition.
    Current hypertension reports, 2011, Volume: 13, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Volume; Endopeptidases; Heart Failure; Humans; Hypertension; Neprilysin; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan; Vasoconstriction

2011
[Application of AT1-angiotensin II receptor blocker valsartan in clinical practice].
    Kardiologiia, 2011, Volume: 51, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Drug Monitoring; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renal Insufficiency; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Water-Electrolyte Balance

2011
[Treatment of heart failure: an update].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2002, Volume: 3, Issue:7

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Benzazepines; Bosentan; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Heart Failure; Heart-Assist Devices; Humans; Metoprolol; Multicenter Studies as Topic; Placebos; Propanolamines; Prospective Studies; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tetrazoles; Valine; Valsartan; Vasodilator Agents

2002
[Pharmacological treatment of heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 4

    Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Infusions, Intravenous; Pyridazines; Tetrazoles; Valine; Valsartan; Vasodilator Agents

2003
[Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:5

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2003
[Angiotensin receptor blockers in chronic heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9

    Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Failure; Humans; Hypertension; Japan; Losartan; Myocardial Infarction; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling

2003
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
    Orvosi hetilap, 2003, Sep-21, Volume: 144, Issue:38

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Complications; Heart Failure; Humans; Hypertension; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2003
Valsartan for the treatment of heart failure.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:1

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2004
Valsartan: in chronic heart failure.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2002, Volume: 2, Issue:4

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Agents; Drug Administration Schedule; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2002
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
    Clinical therapeutics, 2004, Volume: 26, Issue:4

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2004
VALUE: to the heart of the matter.
    Journal of hypertension, 2004, Volume: 22, Issue:8

    Topics: Antihypertensive Agents; Heart Failure; Humans; Hypertension; Risk Factors; Tetrazoles; Valine; Valsartan

2004
Valsartan: a review of its use in patients with heart failure and/or left ventricular systolic dysfunction after myocardial infarction.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2004
Valsartan in chronic heart failure.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:3

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Drug Therapy, Combination; Female; Formularies, Hospital as Topic; Heart Failure; Humans; Liver Diseases; Male; Patient Education as Topic; Pregnancy; Randomized Controlled Trials as Topic; Renal Insufficiency; Tetrazoles; Valine; Valsartan

2005
[Ace inhibitors and angiotensin II receptor antagonists for therapy of chronic heart failure].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2005, Feb-10, Volume: 94, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Enalapril; Heart Failure; Humans; Indoles; Lisinopril; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2005
A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    International journal of clinical practice, 2005, Volume: 59, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Drug Tolerance; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2005
[ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
    Revista clinica espanola, 2005, Volume: 205, Issue:10

    Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Losartan; Systole; Tetrazoles; Valine; Valsartan

2005
Chronic heart failure: an overview of conventional treatment versus novel approaches.
    Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cardiac Glycosides; Erythropoietin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Pacemaker, Artificial; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2005
The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2006
Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2000, Volume: 1, Issue:2 Suppl

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Heart Failure; Humans; Long-Term Care; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2000
[Val-HeFT trial--evidence for valsartan in heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Apr-28, Volume: 65 Suppl 4

    Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Tetrazoles; Valine; Valsartan

2007
[ARB: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Contraindications; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Telmisartan; Tetrazoles; Valine; Valsartan

2007
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Myocardial Infarction; Severity of Illness Index; Survival Rate; Tetrazoles; Valine; Valsartan

2007
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
    Vascular health and risk management, 2007, Volume: 3, Issue:4

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left

2007
Anti-angiotensin therapy: new perspectives.
    Cardiology clinics, 2007, Volume: 25, Issue:4

    Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Fumarates; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan

2007
Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
    Drugs & aging, 1997, Volume: 10, Issue:6

    Topics: Aged; Aged, 80 and over; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Imidazoles; Kidney Diseases; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

1997
Angiotensin-II receptor antagonists: their place in therapy.
    American family physician, 1999, Volume: 59, Issue:11

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan

1999
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Revista espanola de cardiologia, 1999, Volume: 52 Suppl 3

    Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

1999
Cardiac protection: evolving role of angiotensin receptor blockers.
    American heart journal, 2000, Volume: 139, Issue:1 Pt 2

    Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Middle Aged; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan

2000
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    American heart journal, 2000, Volume: 139, Issue:1 Pt 2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Prognosis; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

2000
[Use of angiotensin II receptor blockaders in heart failure].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2000, Mar-10, Volume: 120, Issue:7

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Heart Failure; Humans; Irbesartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2000
Valsartan: a novel angiotensin type 1 receptor antagonist.
    Expert opinion on pharmacotherapy, 2000, Volume: 1, Issue:2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan

2000
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Cardiology clinics, 2001, Volume: 19, Issue:2

    Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan

2001
[Angiotensin I receptor blockers for heart failure].
    Wiener medizinische Wochenschrift (1946), 2001, Volume: 151, Issue:7-8

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Austria; Benzimidazoles; Biphenyl Compounds; Contraindications; Cough; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan

2001
[Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:10

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2001
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2001, Volume: 2, Issue:2

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2001

Trials

196 trial(s) available for valsartan and Cardiac Failure

ArticleYear
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.
    JAMA cardiology, 2021, 12-01, Volume: 6, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Disease Progression; Drug Combinations; Drug Labeling; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Time Factors; United States; United States Food and Drug Administration; Valsartan; Ventricular Function, Left

2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial.
    Nature medicine, 2021, Volume: 27, Issue:10

    Topics: Adolescent; Adult; Cardiomyopathy, Hypertrophic; Double-Blind Method; Female; Heart; Heart Failure; Humans; Male; Middle Aged; Valsartan; Young Adult

2021
Rationale and design of a multi-center, prospective randomized controlled trial on the effects of sacubitril-valsartan versus enalapril on left ventricular remodeling in ST-elevation myocardial infarction: The PERI-STEMI study.
    Clinical cardiology, 2021, Volume: 44, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Prospective Studies; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Remodeling

2021
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    JAMA cardiology, 2022, 01-01, Volume: 7, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan

2022
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
    The New England journal of medicine, 2021, 11-11, Volume: 385, Issue:20

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Stroke Volume; Valsartan; Ventricular Dysfunction, Left

2021
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    JAMA, 2021, 11-16, Volume: 326, Issue:19

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Stroke Volume; Valsartan; Walk Test

2021
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.
    European journal of heart failure, 2022, Volume: 24, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2022
Sacubitril/Valsartan Can Reduce Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation.
    Cardiovascular drugs and therapy, 2023, Volume: 37, Issue:3

    Topics: Atrial Fibrillation; Catheter Ablation; Heart Failure; Humans; Recurrence; Treatment Outcome; Valsartan

2023
Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men.
    Clinical chemistry, 2022, 05-18, Volume: 68, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Neprilysin; Peptide Fragments; Sitagliptin Phosphate; Tetrazoles; Valsartan

2022
The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
    Journal of healthcare engineering, 2022, Volume: 2022

    Topics: Adiponectin; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Carotid Intima-Media Thickness; Drug Combinations; Endothelium; Heart Failure; Humans; Hypertension; Matrix Metalloproteinase 9; Natriuretic Peptide, Brain; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left

2022
Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.
    The Journal of the Association of Physicians of India, 2022, Volume: 70, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Ramipril; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial.
    European journal of heart failure, 2022, Volume: 24, Issue:7

    Topics: Aged; Aminobutyrates; Biomarkers; Biphenyl Compounds; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Troponin T; Valsartan

2022
Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure.
    Computational and mathematical methods in medicine, 2022, Volume: 2022

    Topics: Aminobutyrates; Biphenyl Compounds; Blood Coagulation; Calcitonin Gene-Related Peptide; Delayed-Action Preparations; Drug Combinations; Heart Failure; Humans; Metoprolol; Superoxide Dismutase; Valsartan

2022
Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.
    Diabetes, obesity & metabolism, 2022, Volume: 24, Issue:10

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide 1; Glucose Tolerance Test; Heart Failure; Humans; Hypoglycemic Agents; Male; Middle Aged; Neprilysin; Sitagliptin Phosphate; Tetrazoles; Valsartan

2022
No Improved Patient-Oriented Outcomes With Sacubitril/Valsartan in Adults With Heart Failure and Preserved Ejection Fraction.
    American family physician, 2022, 06-01, Volume: 105, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
    European journal of heart failure, 2022, Volume: 24, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hyperkalemia; Hypotension; Pyrimidines; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction.
    Journal of the American College of Cardiology, 2022, 09-20, Volume: 80, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Frailty; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.
    European journal of heart failure, 2022, Volume: 24, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Ramipril; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.
    ESC heart failure, 2023, Volume: 10, Issue:1

    Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Heart Failure; Humans; Patient Discharge; Stroke Volume; Tetrazoles; Valsartan

2023
The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure.
    Computational and mathematical methods in medicine, 2022, Volume: 2022

    Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Echocardiography; Enalapril; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan

2022
A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease.
    Perfusion, 2023, Volume: 38, Issue:8

    Topics: Heart Diseases; Heart Failure; Humans; Pulmonary Arterial Hypertension; Stroke Volume; Valsartan; Ventricular Function, Left

2023
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.
    European journal of heart failure, 2023, Volume: 25, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan

2023
The Value of Sacubitril/Valsartan in Acute Anterior Wall ST-Segment Elevation Myocardial Infarction before Emergency Percutaneous Coronary Intervention.
    Cardiology, 2022, Volume: 147, Issue:5-6

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Percutaneous Coronary Intervention; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
    Circulation, 2022, 12-06, Volume: 146, Issue:23

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Prospective Studies; Ramipril; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
Health-related quality of life outcomes in PARAGON-HF.
    European journal of heart failure, 2022, Volume: 24, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Valsartan

2022
Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial.
    Circulation. Heart failure, 2023, Volume: 16, Issue:3

    Topics: Adolescent; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Child; Drug Combinations; Heart Failure; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2023
Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event.
    Journal of cardiac failure, 2023, Volume: 29, Issue:6

    Topics: Adolescent; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2023
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
    JAMA cardiology, 2023, 04-01, Volume: 8, Issue:4

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Female; Heart Atria; Heart Failure; Humans; Hypertension; Male; Natriuretic Peptide, Brain; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2023
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction.
    BMC cardiovascular disorders, 2023, 03-13, Volume: 23, Issue:1

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Kidney Diseases; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2023
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).
    Journal of cardiac failure, 2023, Volume: 29, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2023
Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension.
    Journal of hypertension, 2023, 07-01, Volume: 41, Issue:7

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Perimenopause; Prospective Studies; Valsartan; Ventricular Remodeling

2023
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
    European heart journal, 2023, 08-14, Volume: 44, Issue:31

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2023
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
    Journal of the American College of Cardiology, 2023, 07-04, Volume: 82, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2023
Study on the Efficacy of Sacubitril/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Peritoneal Dialysis.
    Cardiology, 2023, Volume: 148, Issue:5

    Topics: Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left

2023
Changes in mid-regional pro-adrenomedullin during treatment with sacubitril/valsartan.
    European journal of heart failure, 2023, Volume: 25, Issue:8

    Topics: Adrenomedullin; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Microcirculation; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2023
Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
    JACC. Heart failure, 2023, Volume: 11, Issue:7

    Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Clinical benefits of angiotensin receptor-Neprilysin inhibitor in adults with congenital heart disease.
    International journal of cardiology, 2023, 09-15, Volume: 387

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan

2023
Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.
    JACC. Heart failure, 2020, Volume: 8, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Case-Control Studies; Drug Combinations; Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2020
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    The New England journal of medicine, 2019, 10-24, Volume: 381, Issue:17

    Topics: Aged; Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Neprilysin; Quality of Life; Sex Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Valsartan

2019
Optimizing heart failure treatment following cardiac resynchronization therapy.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2020, Volume: 109, Issue:5

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2020
Activity Sensors to Evaluate the Effect of Sacubitril/Valsartan on Quality-of-Life in Heart Failure: rational and design of the AWAKE-HF study.
    ESC heart failure, 2019, Volume: 6, Issue:6

    Topics: Accelerometry; Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Monitoring, Physiologic; Quality of Life; Tetrazoles; Valsartan; Young Adult

2019
Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study.
    European journal of heart failure, 2020, Volume: 22, Issue:2

    Topics: Aftercare; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Discharge; Valsartan

2020
Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    JAMA cardiology, 2020, 02-01, Volume: 5, Issue:2

    Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Discharge; Peptide Fragments; Tetrazoles; Valsartan

2020
The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure.
    International heart journal, 2020, Jan-31, Volume: 61, Issue:1

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Treatment Outcome; Troponin T; Valsartan; Ventricular Function, Left

2020
Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan.
    Journal of the American College of Cardiology, 2020, 04-14, Volume: 75, Issue:14

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Outcome Assessment, Health Care; Peptide Fragments; Sex Factors; Stroke Volume; Tetrazoles; Valsartan

2020
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
    JACC. Heart failure, 2020, Volume: 8, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Protein Precursors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2020
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
    Hypertension (Dallas, Tex. : 1979), 2020, Volume: 75, Issue:6

    Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Assessment; Stroke; Time; Valsartan

2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction.
    European journal of heart failure, 2020, Volume: 22, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Liver; Prognosis; Stroke Volume; Valsartan

2020
Rationale and study design of OUTSTEP-HF: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction.
    European journal of heart failure, 2020, Volume: 22, Issue:9

    Topics: Accelerometry; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Europe; Exercise; Heart Failure; Humans; Quality of Life; Stroke Volume; Valsartan

2020
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Betacoronavirus; Biphenyl Compounds; Cardiotonic Agents; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Early Termination of Clinical Trials; Glomerular Filtration Rate; Heart Failure; Heart Transplantation; Heart-Assist Devices; Hospitalization; Humans; Hypotension; Natriuretic Peptide, Brain; Pandemics; Peptide Fragments; Pneumonia, Viral; SARS-CoV-2; Stroke Volume; Tetrazoles; Valsartan

2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Europe; Glucosides; Heart Failure; Humans; North America; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan

2020
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.
    Journal of the American College of Cardiology, 2020, 08-04, Volume: 76, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Female; Heart Failure; Humans; Male; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2020
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.
    Journal of internal medicine, 2021, Volume: 289, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Registries; Stroke Volume; Sweden; Valsartan

2021
Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left

2020
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Journal of the American College of Cardiology, 2020, 09-01, Volume: 76, Issue:9

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valsartan

2020
Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention.
    Coronary artery disease, 2021, Aug-01, Volume: 32, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anterior Wall Myocardial Infarction; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Early Medical Intervention; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Percutaneous Coronary Intervention; Postoperative Complications; Stroke Volume; Treatment Outcome; Valsartan

2021
Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Black or African American; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Valsartan

2020
The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:2

    Topics: Actigraphy; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Comorbidity; Double-Blind Method; Drug Combinations; Enalapril; Exercise; Female; Heart Failure; Humans; Male; Middle Aged; Severity of Illness Index; Sleep; Stroke Volume; Valsartan

2021
OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction.
    European journal of heart failure, 2021, Volume: 23, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Exercise; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
    The American journal of cardiology, 2021, 03-15, Volume: 143

    Topics: Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Diseases; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Ramipril; ST Elevation Myocardial Infarction; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
    European journal of heart failure, 2021, Volume: 23, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Female; Heart Failure; Humans; Potassium; Stroke Volume; Valsartan

2021
Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
    Circulation journal : official journal of the Japanese Circulation Society, 2021, 04-23, Volume: 85, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Japan; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2021
Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    Circulation. Heart failure, 2021, Volume: 14, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Global Health; Heart Failure; Hospitalization; Humans; Male; Neprilysin; Quality of Life; Risk Factors; Stroke Volume; Valsartan

2021
A study of the sequential treatment of acute heart failure with sacubitril/valsartan by recombinant human brain natriuretic peptide: A randomized controlled trial.
    Medicine, 2021, Apr-23, Volume: 100, Issue:16

    Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arterial Pressure; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Hormone Antagonists; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; Pulmonary Artery; Stroke Volume; Tetrazoles; Treatment Outcome; Troponin T; Valsartan

2021
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial.
    European journal of heart failure, 2021, Volume: 23, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial.
    European journal of heart failure, 2021, Volume: 23, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.
    ESC heart failure, 2021, Volume: 8, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; China; Drug Combinations; Female; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left

2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    European heart journal, 2021, 09-21, Volume: 42, Issue:36

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Sleep Outcomes From AWAKE-HF: A Randomized Clinical Trial of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Journal of cardiac failure, 2021, Volume: 27, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Sleep; Stroke Volume; Tetrazoles; Valsartan; Wakefulness

2021
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    American heart journal, 2017, Volume: 188

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Global Health; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Myocardial Revascularization; Prospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Valsartan

2017
Health-Related Quality of Life Outcomes in PARADIGM-HF.
    Circulation. Heart failure, 2017, Volume: 10, Issue:8

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Follow-Up Studies; Health Status; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2017
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    European heart journal, 2017, Nov-21, Volume: 38, Issue:44

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Aorta; Aorta, Thoracic; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Essential Hypertension; Female; Heart Failure; Humans; Hypertrophy, Left Ventricular; Imidazoles; Magnetic Resonance Angiography; Male; Medication Adherence; Middle Aged; Neprilysin; Tetrazoles; Valsartan; Vascular Stiffness; Ventricular Remodeling

2017
Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study).
    American heart journal, 2017, Volume: 193

    Topics: Adolescent; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Infant, Newborn; Male; Myocardial Ischemia; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2017
Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.
    European journal of heart failure, 2018, Volume: 20, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Cause of Death; Double-Blind Method; Drug Combinations; Drug Tolerance; Europe; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Survival Rate; Systole; Tetrazoles; Treatment Outcome; United States; Valsartan

2018
Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
    Swiss medical weekly, 2017, Volume: 147

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Stroke Volume; Switzerland; Tetrazoles; Valsartan

2017
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF.
    European journal of heart failure, 2018, Volume: 20, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Uric Acid; Valsartan

2018
Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.
    ESC heart failure, 2018, Volume: 5, Issue:2

    Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Discharge; Patient Readmission; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2018
Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial.
    Contemporary clinical trials, 2018, Volume: 66

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Ivabradine; Male; Mineralocorticoid Receptor Antagonists; Patient Care Planning; Patient Readmission; Sodium Potassium Chloride Symporter Inhibitors; Tetrazoles; Valsartan

2018
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
    European journal of heart failure, 2018, Volume: 20, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Europe; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Prospective Studies; Recurrence; Stroke Volume; Survival Rate; Tetrazoles; United States; Valsartan

2018
Insights into implementation of sacubitril/valsartan into clinical practice.
    ESC heart failure, 2018, Volume: 5, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Neprilysin; Renin-Angiotensin System; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2018
Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design.
    ESC heart failure, 2018, Volume: 5, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Neprilysin; Polysomnography; Prospective Studies; Sleep Apnea Syndromes; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2018
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
    JAMA cardiology, 2018, 06-01, Volume: 3, Issue:6

    Topics: Activities of Daily Living; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Exercise; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Social Behavior; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2018
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    American heart journal, 2018, Volume: 198

    Topics: Administration, Oral; Aged; Aminobutyrates; Biphenyl Compounds; Cardiac Output, Low; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Safety; Peptide Fragments; Prognosis; Prospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan

2018
Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).
    American heart journal, 2018, Volume: 199

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protein Precursors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2018
Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
    International journal of cardiology, 2018, 08-01, Volume: 264

    Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Allergic Agents; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Risk Assessment; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2018
Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Circulation. Heart failure, 2018, Volume: 11, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Stroke Volume; Valsartan; Ventricular Function, Left

2018
Angiotensin Receptor Neprilysin Inhibitor in Japanese Patients With Heart Failure and Reduced Ejection Fraction - Baseline Characteristics and Treatment of PARALLEL-HF Trial.
    Circulation journal : official journal of the Japanese Circulation Society, 2018, 09-25, Volume: 82, Issue:10

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Japan; Male; Neprilysin; Randomized Controlled Trials as Topic; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2018
Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.
    European journal of heart failure, 2018, Volume: 20, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Disease Progression; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Growth Differentiation Factor 15; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2018
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    The New England journal of medicine, 2019, 02-07, Volume: 380, Issue:6

    Topics: Acute Disease; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Output, Low; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan

2019
Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Dat
    JAMA cardiology, 2018, 12-01, Volume: 3, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Follow-Up Studies; Heart Arrest; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prognosis; Prospective Studies; Quebec; Stroke Volume; Survival Rate; Sweden; Tetrazoles; Time Factors; United Kingdom; United States; Valsartan

2018
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
    Circulation, 2019, 03-12, Volume: 139, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Republic of Korea; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
    European journal of heart failure, 2019, Volume: 21, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biological Availability; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Enalapril; Female; Furosemide; Heart Failure; Humans; Male; Medication Therapy Management; Middle Aged; Outcome Assessment, Health Care; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan

2019
Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF.
    Journal of the American College of Cardiology, 2019, 02-26, Volume: 73, Issue:7

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cohort Studies; Drug Combinations; Enalapril; Extracellular Matrix; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2019
In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
    JAMA cardiology, 2019, Mar-01, Volume: 4, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Hospital Mortality; Hospitalization; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan

2019
B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.
    Journal of the American College of Cardiology, 2019, 03-26, Volume: 73, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Tetrazoles; Valsartan

2019
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.
    Circulation, 2019, 05-07, Volume: 139, Issue:19

    Topics: Aminobutyrates; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Risk; Survival Analysis; Tetrazoles; Treatment Outcome; Valsartan

2019
Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria.
    Journal of cardiac failure, 2020, Volume: 26, Issue:8

    Topics: Aftercare; Aged; Heart Failure; Humans; Patient Discharge; Prognosis; Stroke Volume; Valsartan

2020
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
    JACC. Heart failure, 2019, Volume: 7, Issue:6

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiomyopathy, Alcoholic; Cardiomyopathy, Dilated; Cardiotoxicity; Cardiovascular Diseases; Cause of Death; Dangerous Behavior; Diabetic Cardiomyopathies; Drug Combinations; Enalapril; Female; Heart Failure; Heart Valve Diseases; Hospitalization; Humans; Hypertension; Infections; Male; Middle Aged; Mortality; Myocardial Ischemia; Peripartum Period; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Virus Diseases

2019
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
    European heart journal, 2019, 10-21, Volume: 40, Issue:40

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cyclic GMP; Drug Combinations; Enalapril; Female; Heart Failure; Hemodynamics; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Tetrazoles; Treatment Outcome; Troponin; Valsartan

2019
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.
    European journal of heart failure, 2019, Volume: 21, Issue:8

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Male; Neprilysin; Patient Discharge; Tetrazoles; Treatment Outcome; Valsartan

2019
Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
    ESC heart failure, 2019, Volume: 6, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Vagus Nerve Stimulation; Valsartan; Ventricular Function, Left; Walk Test

2019
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
    European journal of heart failure, 2013, Volume: 15, Issue:11

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    The American journal of cardiology, 2013, Dec-01, Volume: 112, Issue:11

    Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
    Journal of the American College of Cardiology, 2014, Feb-11, Volume: 63, Issue:5

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Echocardiography, Doppler, Color; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Neprilysin; Prognosis; Prospective Studies; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

2014
Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial.
    Circulation. Heart failure, 2014, Volume: 7, Issue:3

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Receptors, Cell Surface; Regression Analysis; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan

2014
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    European journal of heart failure, 2014, Volume: 16, Issue:6

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Glomerular Filtration Rate; Heart Atria; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valine; Valsartan

2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
    JACC. Heart failure, 2014, Volume: 2, Issue:2

    Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan

2014
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2014
Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
    Circulation. Heart failure, 2014, Volume: 7, Issue:6

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Troponin T; Valine; Valsartan

2014
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
    Circulation, 2015, Jan-06, Volume: 131, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Valsartan

2015
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
    European heart journal, 2015, Feb-14, Volume: 36, Issue:7

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Placebo Effect; Tetrazoles; Treatment Outcome; Valsartan

2015
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    European journal of heart failure, 2015, Volume: 17, Issue:3

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Risk; Risk Factors; Sex Factors; Valsartan; Ventricular Dysfunction, Left

2015
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
    European journal of heart failure, 2015, Volume: 17, Issue:5

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Creatinine; Double-Blind Method; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2015
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
    European heart journal, 2015, Aug-07, Volume: 36, Issue:30

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Tetrazoles; Treatment Outcome; Valsartan

2015
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.
    European heart journal, 2015, Oct-07, Volume: 36, Issue:38

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cause of Death; Drug Combinations; Heart Failure; Humans; Middle Aged; Tetrazoles; Treatment Outcome; Valsartan; Young Adult

2015
Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
    Trials, 2015, Aug-07, Volume: 16

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Clinical Protocols; Electrocardiography, Ambulatory; Fatty Acids, Monounsaturated; Fluvastatin; Heart Failure; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Myocardial Infarction; Prospective Studies; Recurrence; Research Design; Risk Assessment; Risk Factors; Shock, Cardiogenic; Time Factors; Treatment Outcome; Valsartan

2015
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
    Journal of the American College of Cardiology, 2015, Nov-10, Volume: 66, Issue:19

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Global Health; Heart Failure; Humans; Male; Middle Aged; Morbidity; Neprilysin; Prognosis; Prospective Studies; Risk Assessment; Survival Rate; Tetrazoles; Valsartan; Young Adult

2015
The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects.
    British journal of clinical pharmacology, 2016, Volume: 81, Issue:5

    Topics: Adolescent; Adult; Aminobutyrates; Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood-Brain Barrier; Double-Blind Method; Drug Combinations; Female; Healthy Volunteers; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Young Adult

2016
[First Experience of Clinical Application of LCZ696--an AT1-angiotensin Receptors and Neprilysin Inhibitor--in Patients With Chronic Heart Failure and Reduced Ejection Fraction].
    Kardiologiia, 2015, Volume: 55, Issue:7

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2015
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
    Circulation. Heart failure, 2016, Volume: 9, Issue:1

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Proteins; Double-Blind Method; Drug Combinations; Female; Fibrosis; Galectin 3; Galectins; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Matrix Metalloproteinase 2; Middle Aged; Myocardium; Peptide Fragments; Procollagen; Prospective Studies; Receptors, Cell Surface; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2016
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial.
    Circulation. Heart failure, 2016, Volume: 9, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Enalapril; Female; Glycated Hemoglobin; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prediabetic State; Prevalence; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Single-Blind Method; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2016
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
    Blood pressure, 2016, Volume: 25, Issue:4

    Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Risk Factors; Valsartan

2016
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (
    Circulation. Heart failure, 2016, Volume: 9, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cause of Death; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Proportional Hazards Models; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2016
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:4

    Topics: Aged; Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Administration Schedule; Drug Combinations; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Russia; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2016
Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).
    Circulation, 2016, Jun-07, Volume: 133, Issue:23

    Topics: Aged; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Endpoint Determination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Research Design; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2016
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens.
    European journal of heart failure, 2016, Volume: 18, Issue:9

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Hyperkalemia; Hypotension; Male; Middle Aged; Neprilysin; Renal Insufficiency; Tetrazoles; Treatment Outcome; Valsartan

2016
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.
    European journal of heart failure, 2016, Volume: 18, Issue:10

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2016
Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
    Circulation. Heart failure, 2016, Volume: 9, Issue:6

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chi-Square Distribution; Disease Progression; Double-Blind Method; Drug Combinations; Enalapril; Female; Glomerular Filtration Rate; Heart Failure; Hospitalization; Humans; Kidney; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Dropouts; Proportional Hazards Models; Prospective Studies; Risk Factors; Severity of Illness Index; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2016
Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.
    JACC. Heart failure, 2016, Volume: 4, Issue:10

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Case-Control Studies; Disease Progression; Double-Blind Method; Drug Combinations; Drug Substitution; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Tetrazoles; Treatment Outcome; Valsartan

2016
Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Circulation. Heart failure, 2016, Volume: 9, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2016
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization.
    Journal of the American College of Cardiology, 2016, 07-19, Volume: 68, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Patient Discharge; Patient Readmission; Prognosis; Prospective Studies; Stroke Volume; Tetrazoles; Time Factors; Valsartan

2016
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
    Circulation. Heart failure, 2016, Volume: 9, Issue:9

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiotonic Agents; Defibrillators, Implantable; Diuretics; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Electric Countershock; Enalapril; Heart Failure; Humans; Myocardial Revascularization; Proportional Hazards Models; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    JAMA cardiology, 2017, 01-01, Volume: 2, Issue:1

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Hyperkalemia; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2017
Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.
    European journal of heart failure, 2017, Volume: 19, Issue:1

    Topics: Aged; Aminobutyrates; Amnesia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Confusion; Delirium; Dementia; Disorders of Excessive Somnolence; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Proportional Hazards Models; Stroke Volume; Tetrazoles; Valsartan

2017
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Journal of the American College of Cardiology, 2016, Dec-06, Volume: 68, Issue:22

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Prospective Studies; Single-Blind Method; Stroke Volume; Treatment Outcome; Valsartan

2016
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Journal of cardiology, 2017, Volume: 70, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Asian People; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Research Design; Single-Blind Method; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2017
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    European heart journal, 2017, 04-14, Volume: 38, Issue:15

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chronic Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2017
What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
    European journal of heart failure, 2017, Volume: 19, Issue:6

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Selection; Peptide Fragments; Retrospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2017
[Valsartan improves symptoms and quality of life in patients with chronic heart failure].
    MMW Fortschritte der Medizin, 2008, Apr-10, Volume: 150 Suppl 1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Data Interpretation, Statistical; Diastole; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Outpatients; Practice Guidelines as Topic; Prospective Studies; Systole; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2008
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial.
    European heart journal, 2009, Volume: 30, Issue:18

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Female; Gastrointestinal Hemorrhage; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2009
A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.
    European journal of heart failure, 2009, Volume: 11, Issue:10

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Exercise Tolerance; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan

2009
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Circulation, 2009, Oct-20, Volume: 120, Issue:16

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan

2009
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Circulation. Heart failure, 2008, Volume: 1, Issue:1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Risk Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan

2008
Role of RAS inhibition in the regulation of Cu/Zn-SOD in the cardiac and peripheral arterial beds in humans.
    Clinical pharmacology and therapeutics, 2010, Volume: 87, Issue:6

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Renin-Angiotensin System; Superoxide Dismutase; Tetrazoles; Valine; Valsartan

2010
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
    American heart journal, 2010, Volume: 160, Issue:1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Female; Follow-Up Studies; Heart Failure; Heart Rupture, Post-Infarction; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left

2010
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure.
    Vascular health and risk management, 2010, Aug-09, Volume: 6

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Creatinine; Cystatin C; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Potassium; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan

2010
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
    Circulation, 2010, Oct-05, Volume: 122, Issue:14

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biomarkers; Diabetic Angiopathies; Female; Growth Differentiation Factor 15; Heart Failure; Humans; Hypertension; Male; Middle Aged; Placebos; Prognosis; Regression Analysis; Risk Assessment; Risk Factors; Severity of Illness Index; Tetrazoles; Valine; Valsartan

2010
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.
    European journal of heart failure, 2011, Volume: 13, Issue:2

    Topics: Age Factors; Aged; Captopril; Cause of Death; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Recurrence; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left

2011
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).
    Journal of cardiac failure, 2010, Volume: 16, Issue:12

    Topics: Aged; Biomarkers; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Predictive Value of Tests; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan

2010
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
    Journal of human hypertension, 2012, Volume: 26, Issue:11

    Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2012
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2012, Volume: 34, Issue:2

    Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan

2012
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
    Lancet (London, England), 2012, Oct-20, Volume: 380, Issue:9851

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Stroke Volume; Tetrazoles; Valine; Valsartan

2012
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    European journal of heart failure, 2013, Volume: 15, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Galectin 3; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2013
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
    Circulation. Heart failure, 2013, Volume: 6, Issue:2

    Topics: Adiposity; Aged; Albuminuria; Biomarkers; Blood Glucose; Creatinine; Cyclohexanes; Double-Blind Method; Female; Glucose Metabolism Disorders; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Incidence; Linear Models; Male; Middle Aged; Multivariate Analysis; Nateglinide; Nonlinear Dynamics; Obesity, Abdominal; Phenylalanine; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Waist Circumference

2013
Safety and efficacy of valsartan versus enalapril in heart failure patients.
    International journal of cardiology, 2002, Volume: 85, Issue:2-3

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
    Journal of the American College of Cardiology, 2002, Sep-04, Volume: 40, Issue:5

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2002
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Circulation, 2002, Nov-05, Volume: 106, Issue:19

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Survival Rate; Tetrazoles; Time; Valine; Valsartan

2002
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
    Circulation, 2003, Mar-11, Volume: 107, Issue:9

    Topics: Biomarkers; Double-Blind Method; Follow-Up Studies; Heart Failure; Humans; Kinetics; Natriuretic Peptide, Brain; Norepinephrine; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan

2003
Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003, Volume: 44, Issue:6

    Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Treatment Outcome; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left

2003
Effect of Valsartan on hospitalization: results from Val-HeFT.
    Journal of cardiac failure, 2003, Volume: 9, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2003
Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure.
    American heart journal, 2003, Volume: 146, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Disease Progression; Double-Blind Method; Female; Heart Failure; Heart Rate; Humans; Lisinopril; Male; Middle Aged; Norepinephrine; Tetrazoles; Valine; Valsartan

2003
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
    The New England journal of medicine, 2003, Nov-13, Volume: 349, Issue:20

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2003
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
    Journal of cardiovascular pharmacology, 2003, Volume: 42 Suppl 1

    Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Coronary Disease; Delayed-Action Preparations; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Valine; Valsartan

2003
The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    International journal of clinical practice, 2004, Volume: 58, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Double-Blind Method; Heart Failure; Hospitalization; Humans; Risk Factors; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling

2004
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
    Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Synergism; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Failure; Heart Function Tests; Humans; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan

2004
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
    Journal of the American College of Cardiology, 2004, Jun-02, Volume: 43, Issue:11

    Topics: Antihypertensive Agents; Echocardiography; Heart Failure; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Survival Analysis; Tetrazoles; United States; Valine; Valsartan; Ventricular Remodeling

2004
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    American heart journal, 2004, Volume: 148, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Health Care Costs; Health Resources; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2004
JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:4

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Ischemia; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2004
Heart attack patients with complications. Treat with valsartan, captopril, or both?
    Canadian family physician Medecin de famille canadien, 2004, Volume: 50

    Topics: Aged; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2004
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
    European journal of heart failure, 2004, Volume: 6, Issue:7

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Quality of Life; Risk Factors; Single-Blind Method; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan

2004
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    American heart journal, 2004, Volume: 148, Issue:6

    Topics: Adult; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Neurotransmitter Agents; Quality of Life; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Function, Left

2004
Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial).
    The American journal of cardiology, 2005, Feb-15, Volume: 95, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Severity of Illness Index; Sex Distribution; Tetrazoles; United States; Valine; Valsartan

2005
Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice.
    Journal of cardiac failure, 2005, Volume: 11, Issue:2

    Topics: Aged; Anemia; Antihypertensive Agents; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemoglobins; Humans; Male; Middle Aged; Multivariate Analysis; Prevalence; Prognosis; Prospective Studies; Registries; Risk; Sex Factors; Survival Analysis; Tetrazoles; Time Factors; Valine; Valsartan

2005
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
    Journal of cardiac failure, 2005, Volume: 11, Issue:4

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Placebos; Quality of Life; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People

2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    American heart journal, 2005, Volume: 150, Issue:2

    Topics: Ambulatory Care; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Costs; Global Health; Health Care Costs; Health Resources; Heart Failure; Hospital Costs; Hospitalization; Humans; Myocardial Infarction; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2005
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
    Circulation, 2005, Aug-23, Volume: 112, Issue:8

    Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Morbidity; Multivariate Analysis; Prevalence; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan

2005
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
    Circulation, 2005, Sep-06, Volume: 112, Issue:10

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; C-Reactive Protein; Female; Heart Failure; Humans; Male; Middle Aged; Morbidity; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Tetrazoles; Valine; Valsartan

2005
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
    Heart (British Cardiac Society), 2006, Volume: 92, Issue:5

    Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Heart; Heart Failure; Humans; Male; Mediastinum; Middle Aged; Natriuretic Peptide, Brain; Observer Variation; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System; Tetrazoles; Valine; Valsartan

2006
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
    Terapevticheskii arkhiv, 2005, Volume: 77, Issue:8

    Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan

2005
Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    Nature clinical practice. Cardiovascular medicine, 2005, Volume: 2, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan

2005
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
    Circulation, 2005, Nov-29, Volume: 112, Issue:22

    Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Captopril; Cardiovascular Diseases; Cause of Death; Heart Failure; Humans; Middle Aged; Morbidity; Mortality; Myocardial Infarction; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left

2005
[Effects of benazepril combined with valsartan on congestive heart failure].
    Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2005, Volume: 25, Issue:11

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

2005
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
    Journal of hypertension, 2006, Volume: 24, Issue:11

    Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Female; Heart Arrest; Heart Failure; Humans; Hypertension; Male; Middle Aged; Proportional Hazards Models; Sex Factors; Tetrazoles; Treatment Outcome; Valine; Valsartan

2006
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Terapevticheskii arkhiv, 2006, Volume: 78, Issue:9

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Follow-Up Studies; Heart Failure; Humans; Quinapril; Severity of Illness Index; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan

2006
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Terapevticheskii arkhiv, 2006, Volume: 78, Issue:8

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bisoprolol; Drug Therapy, Combination; Electrocardiography, Ambulatory; Exercise Test; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Quinapril; Stroke Volume; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan

2006
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience.
    Heart rhythm, 2007, Volume: 4, Issue:3

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Electrocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Research Design; Risk Factors; Stroke Volume; Survival Analysis; Survivors; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left

2007
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
    Lancet (London, England), 2007, Apr-28, Volume: 369, Issue:9571

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Coronary Disease; Endpoint Determination; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Tetrazoles; Valine; Valsartan

2007
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:3

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Tetrazoles; Valine; Valsartan

2007
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
    Journal of cardiac failure, 2007, Volume: 13, Issue:10

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cause of Death; Confidence Intervals; Creatinine; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Inflammation; Male; Middle Aged; Norepinephrine; Pulmonary Disease, Chronic Obstructive; Survival Rate; Tetrazoles; Treatment Outcome; Troponin T; Valine; Valsartan

2007
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
    American heart journal, 2008, Volume: 155, Issue:1

    Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction

2008
Valsartan in heart failure patients previously untreated with an ACE inhibitor.
    International journal of cardiology, 1998, Volume: 65, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Humans; Least-Squares Analysis; Lisinopril; Male; Matched-Pair Analysis; Middle Aged; Renin-Angiotensin System; Tetrazoles; Time Factors; Valine; Valsartan

1998
Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man.
    British journal of clinical pharmacology, 1999, Volume: 47, Issue:3

    Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Cardiovascular Agents; Cross-Over Studies; Diastole; Double-Blind Method; Echocardiography; Heart Failure; Hemodynamics; Humans; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan

1999
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Circulation, 1999, May-25, Volume: 99, Issue:20

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Hemodynamics; Hormones; Humans; Lisinopril; Middle Aged; Single-Blind Method; Tetrazoles; Time Factors; Valine; Valsartan

1999
Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
    European journal of heart failure, 2000, Volume: 2, Issue:4

    Topics: Adrenergic beta-Antagonists; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Sex Factors; Tetrazoles; Valine; Valsartan

2000
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    The New England journal of medicine, 2001, Dec-06, Volume: 345, Issue:23

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Probability; Quality of Life; Stroke Volume; Survival Analysis; Tetrazoles; Valine; Valsartan

2001
Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT).
    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2002, Volume: 15, Issue:4

    Topics: Angiotensin Receptor Antagonists; Double-Blind Method; Echocardiography; Heart Failure; Humans; Quality Assurance, Health Care; Quality Control; Reproducibility of Results; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

2002

Other Studies

708 other study(ies) available for valsartan and Cardiac Failure

ArticleYear
Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice.
    The Annals of pharmacotherapy, 2022, Volume: 56, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Pharmacists; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2022
Optimal Therapeutic Strategy Using Sacubitril/Valsartan in a Patient with Systolic Heart Failure and Chronic Kidney Disease - An Initial Case Report in Japan.
    Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:17

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Japan; Male; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Annals of palliative medicine, 2021, Volume: 10, Issue:8

    Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Discharge; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2021
"Echocardiographic response" to sacubitril-valsartan: does it decrease defibrillation implantation, as well as the incidence of malignant arrhythmias?
    Revista espanola de cardiologia (English ed.), 2022, Volume: 75, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Incidence; Stroke Volume; Tetrazoles; Valsartan

2022
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    JACC. Heart failure, 2021, Volume: 9, Issue:12

    Topics: Aftercare; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Medicare; Patient Discharge; Stroke Volume; Tetrazoles; United States; Valsartan

2021
Adherence to Evidence-Based Therapies in Heart Failure: Deepening the Implementation Divide.
    JACC. Heart failure, 2021, Volume: 9, Issue:12

    Topics: Aftercare; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Discharge; Stroke Volume; Valsartan

2021
Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure.
    Clinical physiology and functional imaging, 2021, Volume: 41, Issue:6

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Stroke Volume; Valsartan; Ventricular Function, Left; Ventricular Function, Right

2021
An Expanded Heart Failure Indication for Sacubitril/Valsartan: Evolving the Evidence Bar.
    JAMA cardiology, 2021, 12-01, Volume: 6, Issue:12

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Valsartan

2021
Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.
    Clinical drug investigation, 2021, Volume: 41, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Thailand; Valsartan

2021
The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    European heart journal, 2021, 09-21, Volume: 42, Issue:36

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Hypertrophy; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2021
Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left; Walk Test

2022
Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction.
    Angiology, 2022, Volume: 73, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Male; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2022
[ANMCO Position paper: Use of sacubitril/valsartan in hospitalized patients with acute heart failure].
    Giornale italiano di cardiologia (2006), 2021, Volume: 22, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; COVID-19; Drug Combinations; Heart Failure; Humans; Pandemics; Prospective Studies; SARS-CoV-2; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Are Post Hoc Analyses on Subgroups Sufficient to Support New Treatment Algorithms of Heart Failure? The Case of SGLT2 Inhibitors Associated with Sacubitril/Valsartan.
    Cardiology, 2022, Volume: 147, Issue:1

    Topics: Algorithms; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan

2022
Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:18

    Topics: Aged; Aminobutyrates; Biosimilar Pharmaceuticals; Biphenyl Compounds; Chronic Disease; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2021
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Journal of the American Heart Association, 2021, 10-19, Volume: 10, Issue:20

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Renin-Angiotensin System; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left; Veterans

2021
Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2022, 01-01, Volume: 23, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Black People; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Retrospective Studies; Stroke Volume; Valsartan; White People

2022
"Echocardiographic response" to sacubitril-valsartan: does it decrease defibrillation implantation, as well as the incidence of malignant arrhythmias? Response.
    Revista espanola de cardiologia (English ed.), 2022, Volume: 75, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Incidence; Stroke Volume; Tetrazoles; Valsartan

2022
Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
    Therapeutic innovation & regulatory science, 2022, Volume: 56, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Spironolactone; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan; Ventricular Function, Left

2022
Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor.
    Internal medicine (Tokyo, Japan), 2022, May-15, Volume: 61, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Necrosis; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Sacubitril/Valsartan in the Treatment of Right Ventricular Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction: A Real-world Study.
    Journal of cardiovascular pharmacology, 2022, 02-01, Volume: 79, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right; Ventricular Function, Left

2022
Assessment of sacubitril/valsartan effects on left ventricular dynamics using 3D echocardiography and 3D strain in heart failure with reduced ejection fraction patients.
    Minerva cardiology and angiology, 2022, Volume: 70, Issue:4

    Topics: Aminobutyrates; Biphenyl Compounds; Echocardiography, Three-Dimensional; Heart Failure; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2022
Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?
    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2021, Volume: 28, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hypertension; Neprilysin; Pyrimidines; Stroke Volume; Tetrazoles; Valsartan

2021
Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure.
    Blood purification, 2022, Volume: 51, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Renal Dialysis; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
    JAMA cardiology, 2022, 02-01, Volume: 7, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Mortality; Nitrates; Practice Guidelines as Topic; Quality of Health Care; Stroke Volume; United States; United States Department of Veterans Affairs; Valsartan; Veterans

2022
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
    Circulation, 2022, 01-04, Volume: 145, Issue:1

    Topics: Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ramipril; Valsartan

2022
Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial.
    ESC heart failure, 2022, Volume: 9, Issue:1

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Stroke Volume; Valsartan; Ventricular Function, Left

2022
Variation in early diffusion of sacubitril/valsartan and implications for understanding novel drug diffusion.
    The American journal of managed care, 2021, Volume: 27, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Medicare; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan

2021
Impact of sacubitril/valsartan on systolic heart failure: Right heart location and clustering analysis.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2022, Volume: 31, Issue:2

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cluster Analysis; Drug Combinations; Female; Heart Failure; Heart Failure, Systolic; Humans; Male; Middle Aged; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left

2022
Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients.
    Journal of cardiovascular pharmacology, 2022, 04-01, Volume: 79, Issue:4

    Topics: Aminobutyrates; Atrial Fibrillation; Biphenyl Compounds; Cardiac Resynchronization Therapy; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left

2022
Potential Safety Signals for Rhabdomyolysis Associated With High-Potency Statin Use With or Without Sacubitril/Valsartan.
    The American journal of cardiology, 2022, 03-01, Volume: 166

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rhabdomyolysis; Rosuvastatin Calcium; Stroke Volume; Tetrazoles; United States; Valsartan

2022
Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction.
    The Journal of international medical research, 2022, Volume: 50, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study.
    International journal of cardiology, 2022, Mar-01, Volume: 350

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Hemodynamics; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
    Future virology, 2021

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arabs; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Infant; Morbidity; Pilot Projects; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Valsartan Regulates PI3K/AKT Pathways through lncRNA GASL1 to Improve Isoproterenol-Induced Heart Failure.
    Disease markers, 2022, Volume: 2022

    Topics: Animals; Apoptosis; Carrier Proteins; Heart Failure; Humans; Isoproterenol; Male; Myocardium; Myocytes, Cardiac; Rats; RNA, Long Noncoding; Signal Transduction; Valsartan

2022
Perks and Pitfalls of Performance-Linked Reimbursement for Novel Drugs: The Case of Sacubitril-Valsartan.
    Circulation. Cardiovascular quality and outcomes, 2022, Volume: 15, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan

2022
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2022
Haemodynamic effects of sacubitril/valsartan in advanced heart failure.
    ESC heart failure, 2022, Volume: 9, Issue:2

    Topics: Adult; Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2022
Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from PARAGON-HF.
    European journal of heart failure, 2022, Volume: 24, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Natriuretic Peptides; Stroke Volume; Valsartan; Vasodilator Agents

2022
Efficacy and safety of sacubitril/valsartan in an outpatient setting: A single-center real-world retrospective study in HFrEF patients with focus on possible predictors of clinical outcome.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2022, Volume: 31, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Outpatients; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left

2022
Impact of sacubitril/valsartan on cardiac arrest event rate. Letter regarding the article 'Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline ch
    European journal of heart failure, 2022, Volume: 24, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Arrest; Heart Failure; Humans; Myocardial Infarction; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan

2022
Efficacy and safety of sacubitril valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients.
    Medicine, 2022, Feb-04, Volume: 101, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left

2022
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan.
    ESC heart failure, 2022, Volume: 9, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Hemodynamics; Humans; Prognosis; Stroke Volume; Valsartan

2022
A new lead: Sacubitril-valsartan's unique benefit in HFrEF could lie with sympathoinhibition.
    Autonomic neuroscience : basic & clinical, 2022, Volume: 238

    Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Pilot Projects; Stroke Volume; Valsartan

2022
Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity.
    Archives of toxicology, 2022, Volume: 96, Issue:4

    Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiotoxicity; Doxorubicin; Drug Combinations; Endoplasmic Reticulum Stress; Heart Failure; Male; Rats; Rats, Sprague-Dawley; Valsartan; Water

2022
Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Valsartan

2022
Sacubitril/valsartan-A new weapon for fighting the hypertension paradox.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2022, Volume: 45, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Tetrazoles; Valsartan

2022
Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
    European journal of heart failure, 2022, Volume: 24, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Communicable Disease Control; COVID-19; Drug Combinations; Heart Failure; Humans; Pandemics; Prescriptions; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
[Position paper of the Italian Society of Cardiology: The renin-angiotensin-aldosterone system blockade in heart failure patients - Part II: Mechanistic effects of sacubitril/valsartan, placement in current guidelines and use in clinical practice].
    Giornale italiano di cardiologia (2006), 2022, Volume: 23, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiology; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valsartan

2022
Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2022
The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function.
    European journal of heart failure, 2022, Volume: 24, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Kidney; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Sacubitril/Valsartan and Rhabdomyolysis: Reanalysis of a Potential Safety Signal.
    The American journal of cardiology, 2022, 06-15, Volume: 173

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Rhabdomyolysis; Stroke Volume; Tetrazoles; Valsartan

2022
Optimal potassium levels in patients with heart failure.
    Vnitrni lekarstvi, 2021,Winter, Volume: 67, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Potassium; Stroke Volume; Tetrazoles; Valsartan

2021
Low dose sacubitril/valsartan is effective and safe in hemodialysis patient with decompensated heart failure and hypotension: A case report.
    Medicine, 2022, Apr-15, Volume: 101, Issue:15

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Hypotension; Neprilysin; Renal Dialysis; Tetrazoles; Valsartan

2022
Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full?
    JACC. Heart failure, 2022, Volume: 10, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Valsartan

2022
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    JACC. Heart failure, 2022, Volume: 10, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2022
proANP Metabolism Provides New Insights Into Sacubitril/Valsartan Mode of Action.
    Circulation research, 2022, 05-27, Volume: 130, Issue:11

    Topics: Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; MicroRNAs; Neprilysin; Stroke Volume; Valsartan

2022
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients.
    Journal of cardiovascular translational research, 2022, Volume: 15, Issue:5

    Topics: Angiotensin Receptor Antagonists; China; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
Sacubitril/valsartan vs ACEi/ARB at hospital discharge and 5-year survival in older patients with heart failure with reduced ejection fraction: A decision analysis approach.
    American heart journal, 2022, Volume: 250

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Decision Support Techniques; Drug Combinations; Heart Failure; Humans; Medicare; Patient Discharge; Stroke Volume; Survival Analysis; United States; Valsartan

2022
Relation of Household Income to Access and Adherence to Combination Sacubitril/Valsartan in Heart Failure: A Retrospective Analysis of Commercially Insured Patients.
    Circulation. Cardiovascular quality and outcomes, 2022, Volume: 15, Issue:7

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Dysfunction, Left

2022
Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril-valsartan.
    Scientific reports, 2022, 05-17, Volume: 12, Issue:1

    Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
    ESC heart failure, 2022, Volume: 9, Issue:4

    Topics: Aminobutyrates; Arterial Pressure; Biphenyl Compounds; Heart Failure; Humans; Hypertension, Pulmonary; Neprilysin; Quality of Life; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan

2022
Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
    Clinical and experimental pharmacology & physiology, 2022, Volume: 49, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Diastole; Disease Models, Animal; Drug Combinations; Heart Failure; Mice; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction

2022
Valsartan and sacubitril combination treatment enhances collagen production in older adult human skin cells.
    Experimental gerontology, 2022, Volume: 165

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Collagen; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction.
    Clinical drug investigation, 2022, Volume: 42, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cholesterol; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, HDL; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Triglycerides; Valsartan

2022
Effectiveness and safety of sacubitril/valsartan for patients with hypertension and heart failure in the real-world setting: A retrospective study in China.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:10

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Creatinine; Drug Combinations; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Retrospective Studies; Tetrazoles; Uric Acid; Valsartan

2022
Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences.
    Circulation. Heart failure, 2022, Volume: 15, Issue:9

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Proteomics; Sex Characteristics; Valsartan

2022
Sacubitril/Valsartan for heart failure: A protocol for systematic review and meta-analysis.
    Medicine, 2022, Jun-10, Volume: 101, Issue:23

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Meta-Analysis as Topic; Neprilysin; Stroke Volume; Systematic Reviews as Topic; Tetrazoles; Treatment Outcome; Valsartan

2022
Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries.
    European journal of heart failure, 2022, Volume: 24, Issue:9

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cohort Studies; Drug Combinations; Heart Failure; Humans; Medicare; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan

2022
[Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension].
    Kardiologiia, 2022, May-31, Volume: 62, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Drug Combinations; Heart Failure; Humans; Hypertension; Metabolic Syndrome; Stroke Volume; Tetrazoles; Valsartan

2022
Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    ESC heart failure, 2022, Volume: 9, Issue:5

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
Utilization of sacubitril-valsartan for right ventricular failure in a patient with arrhythmogenic right ventricular cardiomyopathy.
    Future cardiology, 2022, Volume: 18, Issue:7

    Topics: Adult; Aminobutyrates; Arrhythmogenic Right Ventricular Dysplasia; Biphenyl Compounds; Cardiomyopathies; Contrast Media; Diuretics; Drug Combinations; Female; Gadolinium; Heart Failure; Humans; Valsartan

2022
Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
    European journal of pharmacology, 2022, Aug-05, Volume: 928

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Creatinine; Drug Combinations; Heart Failure; Humans; Kidney; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials.
    Cardiovascular diabetology, 2022, 06-18, Volume: 21, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus; Enalapril; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemia; Insulins; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?
    Current protein & peptide science, 2022, Volume: 23, Issue:5

    Topics: Aldosterone; Aminobutyrates; Anti-Inflammatory Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Cathepsin G; COVID-19 Drug Treatment; Cytokines; Gastrin-Releasing Peptide; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Renin; Respiratory Distress Syndrome; Tetrazoles; Valsartan

2022
Sacubitril/Valsartan in Advanced Heart Failure: Shattering the Paradigm to Focus on Real LIFE.
    JACC. Heart failure, 2022, Volume: 10, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2022
Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2022, Volume: 76, Issue:2

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling

2022
Sacubitril-Valsartan Ameliorates Heart Failure by Inhibiting Cardiac Remodeling Potentially via MAPK/ERK Signaling.
    Annals of clinical and laboratory science, 2022, Volume: 52, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Heart Failure; Tetrazoles; Valsartan; Ventricular Remodeling

2022
Unraveling the interplay between dipeptidyl peptidase 4 and the renin-angiotensin system in heart failure.
    Life sciences, 2022, Sep-15, Volume: 305

    Topics: Animals; Dipeptidyl Peptidase 4; Heart Failure; Male; Rats; Rats, Wistar; Renin-Angiotensin System; Valsartan; Vildagliptin

2022
Recovery of complete left bundle branch block in a dilated cardiomyopathy patient after treatment with sacubitril/valsartan: A case report.
    Medicine, 2022, Jul-08, Volume: 101, Issue:27

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bundle-Branch Block; Cardiomyopathy, Dilated; Drug Combinations; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment?
    Kardiologia polska, 2022, Volume: 80, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Valsartan

2022
Cost-benefit analysis of sacubitril/valsartan in a Medicaid population.
    The American journal of managed care, 2022, Volume: 28, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Medicaid; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan

2022
[Chinese expert consensus on clinical application of angiotension-neprilysin inhibitor in patients with heart failure].
    Zhonghua xin xue guan bing za zhi, 2022, Jul-24, Volume: 50, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; China; Consensus; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2022
Sacubitril/valsartan adherence… because the best is sometimes difficult to replace the good.
    European journal of heart failure, 2022, Volume: 24, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial.
    European journal of heart failure, 2022, Volume: 24, Issue:10

    Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Kidney; Patient Discharge; Stroke Volume; Tetrazoles; Valsartan

2022
Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients.
    European journal of heart failure, 2022, Volume: 24, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Pyrimidines; Stroke Volume; Tetrazoles; Valsartan

2022
The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
    Journal of hypertension, 2022, 09-01, Volume: 40, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Drug Combinations; Fibrosis; Heart Failure; Hypertension; Myocardial Infarction; Rats; Rats, Inbred SHR; Tetrazoles; Valsartan

2022
Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995-2021.
    Medicine, 2022, Aug-05, Volume: 101, Issue:31

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Bibliometrics; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan

2022
Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy.
    ESC heart failure, 2022, Volume: 9, Issue:6

    Topics: Arrhythmias, Cardiac; Bundle-Branch Block; Cardiac Resynchronization Therapy; Electrocardiography; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2022
Sacubitril-valsartan: Hope or hype in the battle against cardiotoxicity due to cancer treatment? Authors' reply.
    Kardiologia polska, 2022, Volume: 80, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiotoxicity; Drug Combinations; Heart Failure; Humans; Neoplasms; Stroke Volume; Tetrazoles; Valsartan

2022
[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].
    Kardiologiia, 2022, Jul-31, Volume: 62, Issue:7

    Topics: Aminobutyrates; Amyloidosis; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Hypertrophy, Left Ventricular; Natriuretic Peptide, Brain; Phenotype; Spironolactone; Stroke Volume; Valsartan; Ventricular Function, Left

2022
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:14

    Topics: Aldosterone; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Guanylate Cyclase; Heart Failure; Hospitalization; Humans; Ivabradine; Natriuretic Peptides; Potassium; Renin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan

2022
Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice.
    BMC nephrology, 2022, 08-23, Volume: 23, Issue:1

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Renal Insufficiency, Chronic; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left

2022
Use and Out-of-Pocket Cost of Sacubitril-Valsartan in Patients With Heart Failure.
    Journal of the American Heart Association, 2022, 09-06, Volume: 11, Issue:17

    Topics: Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Health Expenditures; Heart Failure; Humans; Medicare; Retrospective Studies; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left

2022
Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways.
    Scientific reports, 2022, 08-27, Volume: 12, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Autophagy; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Epigenesis, Genetic; Fibrosis; Heart Failure; Hyperthyroidism; Male; MicroRNAs; Neprilysin; Rats; Rats, Wistar; Signal Transduction; Thyroxine; Valsartan

2022
Letter to the Editor regarding to 'Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control'.
    International journal of cardiology, 2022, 12-01, Volume: 368

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Glucagon-Like Peptide-1 Receptor; Glycemic Control; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Neuroendocrine hormone status and diuretic response to atrial natriuretic peptide in patients with acute heart failure.
    ESC heart failure, 2022, Volume: 9, Issue:6

    Topics: Atrial Natriuretic Factor; Diuretics; Heart Failure; Humans; Neurosecretory Systems; Valsartan; Vasopressins

2022
Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction.
    Current problems in cardiology, 2022, Volume: 47, Issue:12

    Topics: Cost-Benefit Analysis; Defibrillators, Implantable; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
Sacubitril/Valsartan Improves Sexual Function and Fibrosis of the Clitoral and Vaginal Tissues in Female Spontaneously Hypertensive Rats: Erratum.
    Journal of cardiovascular pharmacology, 2022, 09-01, Volume: 80, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Female; Fibrosis; Heart Failure; Rats; Rats, Inbred SHR; Stroke Volume; Tetrazoles; Valsartan

2022
Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan.
    JACC. Cardiovascular imaging, 2022, Volume: 15, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Neprilysin; Predictive Value of Tests; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2022
Sacubitril/valsartan combination enhanced cardiac glycophagy and prevented the progression of murine diabetic cardiomyopathy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153

    Topics: Aminobutyrates; Animals; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Drug Combinations; Glycogen; Heart Failure; Hyperglycemia; Mice; Rats; Stroke Volume; Tetrazoles; Valsartan

2022
[Do West African cardiologists adhere to the guidelines for the management of heart failure ?]
    Annales de cardiologie et d'angeiologie, 2022, Volume: 71, Issue:4

    Topics: Aminobutyrates; Biphenyl Compounds; Cardiologists; Cross-Sectional Studies; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Valsartan

2022
Implication of sacubitril/valsartan on N-terminal pro B-type natriuretic peptide levels in hypertensive patients.
    Annals of palliative medicine, 2022, Volume: 11, Issue:9

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Natriuretic Peptide, Brain; Retrospective Studies; Tetrazoles; Valsartan

2022
Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry.
    ESC heart failure, 2022, Volume: 9, Issue:6

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Outpatients; Prospective Studies; Registries; Stroke Volume; Tetrazoles; Valsartan

2022
Preoperative Preparation With Valsartan/Sacubitril in a Patient With Cardiac Paraganglioma and Catecholamine-Induced Cardiomyopathy.
    Journal of cardiothoracic and vascular anesthesia, 2022, Volume: 36, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathies; Catecholamines; Drug Combinations; Heart Failure; Humans; Paraganglioma; Stroke Volume; Tetrazoles; Valsartan

2022
Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes.
    International journal of cardiology, 2023, Jan-15, Volume: 371

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2023
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.
    Current molecular pharmacology, 2023, Volume: 16, Issue:6

    Topics: Antioxidants; Calcium; Collagen; Heart Failure; Hemodynamics; Humans; Isoproterenol; Myocardial Infarction; Ramipril; Simendan; Valsartan

2023
Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
    Journal of cardiac failure, 2022, Volume: 28, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Troponin T; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2022
[Management of chronic heart failure: state of the art according to the 2021 guideline].
    Innere Medizin (Heidelberg, Germany), 2022, Volume: 63, Issue:11

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2022
Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2022, Volume: 22, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Outpatients; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study.
    International journal of cardiology, 2023, Jan-15, Volume: 371

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Heart Failure; Humans; Hypertension; Hypotension; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2023
Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
    Circulation, 2022, 11-22, Volume: 146, Issue:21

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Mitral Valve Insufficiency; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis.
    Oxidative medicine and cellular longevity, 2022, Volume: 2022

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Heart Failure; Histone-Lysine N-Methyltransferase; Methyltransferases; Myocardial Infarction; Neprilysin; Osteopontin; Rats; Repressor Proteins; Stroke Volume; Tetrazoles; Valsartan

2022
Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF).
    JACC. Heart failure, 2023, Volume: 11, Issue:1

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan

2023
Effect of sacubitril/valsartan on cognitive impairment in colchicine-induced Alzheimer's model in rats.
    Fundamental & clinical pharmacology, 2023, Volume: 37, Issue:2

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cognitive Dysfunction; Colchicine; Drug Combinations; Heart Failure; Male; Neurodegenerative Diseases; Rats; Rats, Wistar; Tetrazoles; Valsartan

2023
Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.
    International journal of cardiology, 2023, Jan-01, Volume: 370

    Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
    Journal of the American College of Cardiology, 2022, 10-18, Volume: 80, Issue:16

    Topics: Aminobutyrates; Atrial Natriuretic Factor; Biomarkers; Biphenyl Compounds; Dose-Response Relationship, Drug; Guanosine Monophosphate; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Natriuretic Peptide, Brain; Stroke Volume; Troponin T; Valsartan; Ventricular Dysfunction, Left; Ventricular Remodeling

2022
Guideline-Directed Medical Therapy: Even a Little Is Better Than None.
    Journal of the American College of Cardiology, 2022, 10-18, Volume: 80, Issue:16

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2022
Sacubitril-Valsartan and Heart Function in End-stage Kidney Disease.
    JAMA, 2022, 10-25, Volume: 328, Issue:16

    Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Stroke Volume; Valsartan

2022
The HF-POL study - the first real-life multicenter study of Polish patients with heart failure and left ventricular ejection fraction >40%: Study rationale and design.
    Kardiologia polska, 2022, Volume: 80, Issue:11

    Topics: Heart Failure; Humans; Poland; Stroke Volume; Valsartan; Ventricular Function, Left

2022
Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction.
    ESC heart failure, 2023, Volume: 10, Issue:1

    Topics: Biomarkers; Fibroblasts; Glycogen Synthase Kinase 3; Heart Failure; Humans; Interleukin-6; Matrix Metalloproteinase 9; Proto-Oncogene Proteins c-akt; Sodium-Glucose Transporter 2; Spironolactone; Stroke Volume; Valsartan

2023
Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
    Circulation. Heart failure, 2023, Volume: 16, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
    European journal of heart failure, 2022, Volume: 24, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Male; Mineralocorticoid Receptor Antagonists; Stroke Volume; Tetrazoles; Valsartan

2022
Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice.
    European journal of histochemistry : EJH, 2022, Nov-11, Volume: 66, Issue:4

    Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Doxorubicin; Fibrosis; Heart Failure; Inflammation; Kidney; Kidney Diseases; Mice; Stroke Volume; Tolvaptan; Valsartan; Ventricular Function, Left

2022
Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye?
    European journal of heart failure, 2023, Volume: 25, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry.
    ESC heart failure, 2023, Volume: 10, Issue:2

    Topics: Aged; Atrial Fibrillation; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2023
Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure.
    Journal of the American Heart Association, 2022, 12-20, Volume: 11, Issue:24

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2022
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
    JACC. Heart failure, 2022, Volume: 10, Issue:12

    Topics: Aged; Biomarkers; Female; Health Status; Heart Atria; Heart Failure; Humans; Male; Stroke Volume; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2022
Safety and Efficacy of Sacubitril/Valsartan in Patients With a Failing Systemic Right Ventricle: A Prospective Single-Center Study.
    Circulation. Heart failure, 2023, Volume: 16, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Congenitally Corrected Transposition of the Great Arteries; Drug Combinations; Female; Heart Failure; Heart Ventricles; Humans; Male; Prospective Studies; Quality of Life; Stroke Volume; Tetrazoles; Transposition of Great Vessels; Valsartan

2023
Short term effect of sacubitril/valsartan on comprehensive geriatric assessment in chronic heart failure: a real life analysis.
    Internal and emergency medicine, 2023, Volume: 18, Issue:1

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Female; Geriatric Assessment; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Valsartan

2023
The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
    ESC heart failure, 2023, Volume: 10, Issue:2

    Topics: Aged; Atrial Fibrillation; Diabetes Mellitus; Heart Failure; Humans; Stroke Volume; Tachycardia, Ventricular; Tetrazoles; Troponin I; Valsartan; Ventricular Function, Left

2023
Renal Safety of de Novo Angiotensin-Neprilysin Inhibition in Older Adults: Insights From a Population-Based Analysis.
    Journal of cardiac failure, 2023, Volume: 29, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2023
Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
    Open heart, 2022, Volume: 9, Issue:2

    Topics: Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2022
Starting sacubitril-valsartan is safe in patients with transthyretin cardiac amyloidosis and impaired ejection fraction.
    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2023, Volume: 42, Issue:2

    Topics: Aminobutyrates; Amyloidosis; Biphenyl Compounds; Heart Failure; Humans; Prealbumin; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan.
    JACC. Heart failure, 2023, Volume: 11, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2023
Renal Safety of Sacubitril/Valsartan: A Meta-Analysis of Randomized Controlled Trials.
    Journal of cardiovascular pharmacology, 2023, 02-01, Volume: 81, Issue:2

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enzyme Inhibitors; Heart Failure; Humans; Hyperkalemia; Kidney; Potassium; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan

2023
Comparison of the population of Polish patients participating in the TRANSITION study with the international population: a post hoc analysis.
    Polish archives of internal medicine, 2023, 06-23, Volume: 133, Issue:6

    Topics: Aftercare; Angiotensin Receptor Antagonists; Heart Failure; Humans; Male; Patient Discharge; Poland; Stroke Volume; Tetrazoles; Valsartan

2023
Effect of sacubitril/valsartan on natriuretic peptide in patients with compensated heart failure.
    Heart and vessels, 2023, Volume: 38, Issue:6

    Topics: Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents; Ventricular Function, Left

2023
The Real-World Price of Switching to an ARNI: A Case for De Novo Sacubitril/Valsartan Initiation.
    Journal of the American College of Cardiology, 2023, 01-31, Volume: 81, Issue:4

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Valsartan

2023
Comprehensive analysis of the RNA transcriptome expression profiles and construction of the ceRNA network in heart failure patients with sacubitril/valsartan therapeutic heterogeneity after acute myocardial infarction.
    European journal of pharmacology, 2023, Apr-05, Volume: 944

    Topics: Heart Failure; Humans; MicroRNAs; Myocardial Infarction; RNA, Circular; RNA, Messenger; Transcriptome; Valsartan

2023
Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension.
    Journal of clinical hypertension (Greenwich, Conn.), 2023, Volume: 25, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan

2023
Characteristics of patients hospitalized for acute heart failure and discharged from an emergency medicine ward with sacubitril-valsartan: differences with patients in the PIONEER-HF and TRANSITION studies.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2023, 03-01, Volume: 24, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Emergency Medicine; Heart Failure; Humans; Patient Discharge; Stroke Volume; Tetrazoles; Valsartan

2023
Deconvolution of BNP and NT-proBNP Immunoreactivities by Mass Spectrometry in Heart Failure and Sacubitril/Valsartan Treatment.
    Clinical chemistry, 2023, 04-03, Volume: 69, Issue:4

    Topics: Aminobutyrates; Biomarkers; Dyspnea; Heart Failure; Humans; Mass Spectrometry; Natriuretic Peptide, Brain; Peptide Fragments; Serine; Valsartan

2023
Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, 07-31, Volume: 38, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Dialysis Solutions; Drug Combinations; Heart Failure; Humans; Hypertension; Peritoneal Dialysis; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2023
Safety and feasibility of angiotensin receptor neprilysin inhibitor in real-world patients with acute decompensated heart failure.
    Minerva cardiology and angiology, 2023, Volume: 71, Issue:3

    Topics: Aged; Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Feasibility Studies; Female; Heart Failure; Humans; Male; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Next-Level Natriuretic Peptide Measurement.
    Clinical chemistry, 2023, 04-03, Volume: 69, Issue:4

    Topics: Heart Failure; Humans; Mass Spectrometry; Natriuretic Peptide, Brain; Natriuretic Peptides; Peptide Fragments; Valsartan

2023
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
    Journal of the American College of Cardiology, 2023, 04-18, Volume: 81, Issue:15

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enzyme Inhibitors; Heart Failure; Humans; Kidney; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Diuretic and renal effects of angiotensin receptor-neprilysin inhibitor in patients hospitalized for acute heart failure.
    Heart and vessels, 2023, Volume: 38, Issue:8

    Topics: Antihypertensive Agents; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Kidney; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2023
Pharmacology Focus: Sacubitril/Valsartan - A Review.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2022, Volume: 75, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2022
Reply: Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment.
    JACC. Heart failure, 2023, Volume: 11, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2023
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment.
    JACC. Heart failure, 2023, Volume: 11, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2023
Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i.
    ESC heart failure, 2023, Volume: 10, Issue:3

    Topics: Female; Heart Failure; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan

2023
The dual inhibitor Sacubitril-valsartan ameliorate high-fat high-fructose-induced metabolic disorders in rats superiorly compared to valsartan only.
    The Journal of pharmacy and pharmacology, 2023, Jun-05, Volume: 75, Issue:6

    Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cattle; Drug Combinations; Heart Failure; Insulin; Metabolic Diseases; Rats; Tetrazoles; Valsartan

2023
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs.
    Journal of the American Heart Association, 2023, 04-04, Volume: 12, Issue:7

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiologists; Cost-Benefit Analysis; Drug Combinations; Health Expenditures; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2023
Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril/valsartan in Chinese patients with heart failure.
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; East Asian People; Heart Failure; Humans; Hypotension; Neprilysin; Polymorphism, Genetic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
    Clinical drug investigation, 2023, Volume: 43, Issue:4

    Topics: Aged; Biphenyl Compounds; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Delivery of Health Care; Drug Combinations; East Asian People; Heart Failure; Humans; Stroke Volume; Valsartan

2023
The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    European journal of internal medicine, 2023, Volume: 112

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Brain Ischemia; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Stroke; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study.
    ESC heart failure, 2023, Volume: 10, Issue:3

    Topics: Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2023
LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 162

    Topics: Animals; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Glycogen Synthase Kinase 3 beta; Heart Failure; Hypertension, Pulmonary; Male; Mice; Molecular Docking Simulation; Valsartan; Ventricular Remodeling

2023
Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study.
    Journal of cardiothoracic surgery, 2023, Apr-11, Volume: 18, Issue:1

    Topics: Heart Failure; Heart Valves; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2023
Geographic differences in patients with acute myocardial infarction in the PARADISE-MI trial.
    European journal of heart failure, 2023, Volume: 25, Issue:8

    Topics: Europe; Europe, Eastern; Heart Failure; Humans; Myocardial Infarction; Valsartan

2023
Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure.
    Journal of the American Heart Association, 2023, 04-18, Volume: 12, Issue:8

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan

2023
Angiotensin receptor-neprilysin inhibitors and cardiac remodeling.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2023, Volume: 56

    Topics: Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2023
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
    European journal of heart failure, 2023, Volume: 25, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atmosphere; Biphenyl Compounds; Comorbidity; Drug Combinations; Heart Failure; Humans; Hypertension; Multimorbidity; Stroke; Stroke Volume; Tetrazoles; Valsartan

2023
Marked Increase in Urinary C-peptide Levels after Treatment with Sacubitril/Valsartan in Patients with Type 2 Diabetes Mellitus and Hypertension.
    Internal medicine (Tokyo, Japan), 2023, Dec-01, Volume: 62, Issue:23

    Topics: Aged; Angiotensin Receptor Antagonists; Biphenyl Compounds; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Hypertension; Male; Stroke Volume; Tetrazoles; Valsartan

2023
Atrial natriuretic peptide stimulates autophagy/mitophagy and improves mitochondrial function in chronic heart failure.
    Cellular and molecular life sciences : CMLS, 2023, Apr-26, Volume: 80, Issue:5

    Topics: Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Heart Failure; Humans; Leukocytes, Mononuclear; Mitochondria; Mitophagy; Reactive Oxygen Species; Stroke Volume; Tetrazoles; Valsartan

2023
Budget Impact Analysis of Utilization of Sacubitril/Valsartan for the Treatment of Heart Failure With Reduced Ejection Fraction in the Philippines.
    Value in health regional issues, 2023, Volume: 36

    Topics: Aminobutyrates; Biphenyl Compounds; Enalapril; Heart Failure; Humans; Philippines; Stroke Volume; Tetrazoles; Valsartan

2023
Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan.
    JACC. Heart failure, 2023, Volume: 11, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptides; Phenotype; Stroke Volume; Tetrazoles; Valsartan

2023
Association of Heart Failure Patients With and Without Sacubitril-Valsartan Use With Incident Cancer Risk.
    Journal of cardiovascular pharmacology, 2023, 08-01, Volume: 82, Issue:2

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neoplasms; Risk; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Clinical efficacy of enhanced external counter pulsation plus sacubitril/valsartan in the treatment of patients with chronic heart failure and the effect on ankle-arm index and cardiac function.
    European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:8

    Topics: Angiotensin Receptor Antagonists; Ankle; Ankle Brachial Index; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society.
    Kardiologia polska, 2023, Volume: 81, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Expert Testimony; Heart Failure; Humans; Poland; Prospective Studies; Stroke Volume; United States; Valsartan; Ventricular Function, Left

2023
Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: You Win Some, You Lose Some.
    Journal of the American College of Cardiology, 2023, 07-04, Volume: 82, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2023
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States.
    JACC. Heart failure, 2023, Volume: 11, Issue:8 Pt 1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; United States; Valsartan

2023
Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.
    Circulation. Cardiovascular quality and outcomes, 2023, Volume: 16, Issue:6

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Combinations; Glucose; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left

2023
Sacubitril-valsartan shows benefit in heart failure with ejection fraction of >40.
    Nature reviews. Cardiology, 2023, Volume: 20, Issue:8

    Topics: Aminobutyrates; Heart Failure; Humans; Stroke Volume; Valsartan

2023
Early improvement of strain imaging parameters predicts long-term response to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: An observational prospective study.
    International journal of cardiology, 2023, 09-15, Volume: 387

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Risk stratification for worsening renal function and renal decline in heart failure patients with reduced ejection fraction after sacubitril/valsartan treatment.
    Journal of cardiology, 2023, Volume: 82, Issue:6

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Kidney; Risk Assessment; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF.
    JACC. Heart failure, 2023, Volume: 11, Issue:10

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Glucose; Heart Failure; Hospitalization; Humans; Longitudinal Studies; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Peripheral Arterial Disease; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Stroke Volume; United States; Valsartan

2023
Impact of the angiotensin receptor-neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls.
    Journal of diabetes investigation, 2023, Volume: 14, Issue:9

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; C-Peptide; Diabetes Mellitus; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2023
Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Exercise Tolerance; Heart Failure; Humans; Prognosis; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension.
    Heart and vessels, 2023, Volume: 38, Issue:11

    Topics: Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Valsartan

2023
Using Sacubitril/Valsartan to Decrease Health care Costs in Population Health Patients.
    The American journal of cardiology, 2023, 08-15, Volume: 201

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Health Care Costs; Heart Failure; Humans; Male; Medicare; Spironolactone; Stroke Volume; Tetrazoles; United States; Valsartan

2023
Angiotensin Receptor-neprilysin Inhibitor Versus Renin-angiotensin System Inhibitor for Dementia Risk in Patients With Heart Failure.
    Journal of cardiovascular pharmacology, 2023, 09-01, Volume: 82, Issue:3

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Dementia; Enzyme Inhibitors; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan

2023
Sex Differences in the Effectiveness of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril-Valsartan for the Treatment of Heart Failure.
    Journal of the American Heart Association, 2023, 07-18, Volume: 12, Issue:14

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Sex Characteristics; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Scientific reports, 2023, 07-16, Volume: 13, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Male; Mitral Valve Insufficiency; Rats; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Ventricular Remodeling

2023
Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
    Vascular pharmacology, 2023, Volume: 152

    Topics: Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tachycardia, Ventricular; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2023
Sacubitril-Valsartan in Heart Failure: The Hard Sell of Spending More to Save Later.
    The American journal of cardiology, 2023, 09-01, Volume: 202

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2023
The use of sacubitril / valsartan in Takotsubo syndrome with severe impairment of left ventricular systolic function.
    Polish archives of internal medicine, 2023, 09-29, Volume: 133, Issue:9

    Topics: Heart Failure; Humans; Takotsubo Cardiomyopathy; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Clinical and Hemodynamic Improvement in Pulmonary Hypertension After Switching to Sacubitril/Valsartan in Patients With Heart Failure With Preserved Ejection Fraction.
    Journal of cardiovascular pharmacology, 2023, Nov-01, Volume: 82, Issue:5

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan

2023
Penalized Model-Based Unsupervised Phenomapping Unravels Distinctive HFrEF Phenotypes With Improved Outcomes Discrimination From Sacubitril/Valsartan Treatment Independent of MAGGIC Score.
    Journal of the American Heart Association, 2023, 09-19, Volume: 12, Issue:18

    Topics: Antihypertensive Agents; Female; Heart Failure; Humans; Male; Stroke Volume; Valsartan; Ventricular Function, Left

2023
Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways.
    Drugs in R&D, 2023, Volume: 23, Issue:4

    Topics: Aged; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan

2023
Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions.
    JAMA cardiology, 2023, 11-01, Volume: 8, Issue:11

    Topics: Angiotensins; Cost-Benefit Analysis; Heart Failure; Humans; Neprilysin; Stroke Volume; Valsartan

2023
Sacubitril/Valsartan: A Breakthrough in Heart Failure Management - Addressing Quality of Life and Mortality.
    Arquivos brasileiros de cardiologia, 2023, Volume: 120, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2023
[Titration strategy of sacubitril/valsartan in patients with heart failure with reduced ejection fraction and hypotension].
    Zhonghua xin xue guan bing za zhi, 2023, Oct-24, Volume: 51, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: A retrospective cohort study.
    Medicine, 2023, Oct-27, Volume: 102, Issue:43

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Neprilysin; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensión Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC).
    Archivos de cardiologia de Mexico, 2023, Volume: 93, Issue:Supl

    Topics: Angiotensin Receptor Antagonists; Cardiology; Consensus; Heart Failure; Humans; Hypertension; Quality of Life; Stroke Volume; Tetrazoles; United States; Valsartan; Ventricular Dysfunction, Left

2023
Development and validation of a sensitive and simple LC-MS/MS method for simultaneous quantitation of valsartan, sacubitril and sacubitrilat in pediatric population.
    Journal of pharmaceutical and biomedical analysis, 2024, Jan-20, Volume: 238

    Topics: Adult; Antihypertensive Agents; Child; Chromatography, Liquid; Heart Failure; Humans; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles; Valsartan

2024
Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
    International heart journal, 2023, Nov-30, Volume: 64, Issue:6

    Topics: Heart Failure; Humans; Stroke Volume; Tetrazoles; Traction; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2023
Effect on the Quality of Life of Patients with Heart Failure and Reduced/Preserved Ejection Fraction Using Sacubitril/Valsartan.
    Arquivos brasileiros de cardiologia, 2023, Volume: 120, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Quality of Life; Stroke Volume; Tetrazoles; Valsartan

2023
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients.
    Medicine, 2023, Nov-17, Volume: 102, Issue:46

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cerebrovascular Disorders; Heart Failure; Humans; Irbesartan; Losartan; Myocardial Infarction; Retrospective Studies; Telmisartan; Tetrazoles; Valsartan

2023
Sacubitril/Valsartan Cannot Improve Cardiac Function Compared with Valsartan in Patients Suffering Nonvalvular Atrial Fibrillation without Systolic Heart Failure.
    International heart journal, 2023, Volume: 64, Issue:6

    Topics: Atrial Fibrillation; Biomarkers; Heart Failure; Heart Failure, Systolic; Humans; Stroke Volume; Tetrazoles; Valsartan

2023
Natriuretic Peptides as Markers of Left Ventricular Reverse Remodeling After Angiotensin Receptor-Neprilysin Inhibitor Therapy.
    International heart journal, 2023, Volume: 64, Issue:6

    Topics: Antihypertensive Agents; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Remodeling

2023
Evolution of economic burden of heart failure by ejection fraction in newly diagnosed patients in Spain.
    BMC health services research, 2023, Dec-01, Volume: 23, Issue:1

    Topics: Angiotensin Receptor Antagonists; Drug Combinations; Financial Stress; Heart Failure; Humans; Retrospective Studies; Spain; Stroke Volume; Tetrazoles; Valsartan

2023
The art of caring for adults with congenital heart disease in the face of imperfect data.
    International journal of cardiology, 2020, 02-01, Volume: 300

    Topics: Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2020
Sacubitril/valsartan and B-type natriuretic peptide value: recalculating route.
    European journal of heart failure, 2020, Volume: 22, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Tetrazoles; Valsartan

2020
Medical journals and editorial quality control.
    ESC heart failure, 2019, Volume: 6, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Multimorbidity; Periodicals as Topic; Quality Control; Tetrazoles; Valsartan

2019
Response to: Medical journals and editorial quality control by Erviti et al.
    ESC heart failure, 2019, Volume: 6, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Multimorbidity; Periodicals as Topic; Quality Control; Tetrazoles; Valsartan

2019
In heart failure with reduced ejection fraction patients' left ventricular global longitudinal strain is enhanced after 1-year therapy with sacubitril/valsartan compared with conventional therapy with angiotensin-converting enzyme-inhibitors or AT1 blocke
    Journal of cardiovascular medicine (Hagerstown, Md.), 2019, Volume: 20, Issue:12

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2019
PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
    Cardiovascular research, 2019, Nov-01, Volume: 115, Issue:13

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2019
Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Pharmacotherapy, 2019, Volume: 39, Issue:11

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Retrospective Studies; Tetrazoles; United States; United States Department of Veterans Affairs; Valsartan

2019
Angiotensin- neprilysin inhibitors: should we initiate them in hospital for patients with acute decompensated heart failure?
    BMJ evidence-based medicine, 2020, Volume: 25, Issue:4

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Treatment Outcome; Valsartan

2020
Choices in Heart Failure Treatment Goals: The Role of Patient-Reported Health Status.
    JACC. Heart failure, 2019, Volume: 7, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Health Status; Heart Failure; Humans; Patient Reported Outcome Measures; Stroke Volume; Tetrazoles; Valsartan

2019
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction.
    JACC. Heart failure, 2019, Volume: 7, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
The effect of sacubitril / valsartan on the occurrence of ventricular arrhythmia and the risk of sudden cardiac death in patients with chronic heart failure with reduced left ventricular ejection fraction. Expert opinion of the Heart Rhythm and Heart Fail
    Kardiologia polska, 2019, 10-25, Volume: 77, Issue:10

    Topics: Aminobutyrates; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiology; Death, Sudden, Cardiac; Drug Combinations; Female; Heart Failure; Humans; Male; Poland; Societies, Medical; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2019
ARNIs: balancing "the good and the bad" of neuroendocrine response to HF.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2020, Volume: 109, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Neurosecretory Systems; Tetrazoles; Valsartan

2020
Mechanisms of sacubitril-valsartan benefit in HFrEF.
    Nature reviews. Cardiology, 2019, Volume: 16, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan

2019
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019, Volume: 22, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Germany; Heart Failure; Humans; Tetrazoles; Treatment Outcome; Valsartan

2019
Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management.
    Journal of cardiology, 2020, Volume: 75, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Recovery of Function; Tetrazoles; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2020
The potential antiarrhythmic properties of sacubitril/valsartan: a case report.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2019, Volume: 20, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Rate; Humans; Male; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2019
Risk Factors for Intolerance of Inpatient Sacubitril/Valsartan Initiation.
    Journal of pharmacy practice, 2021, Volume: 34, Issue:3

    Topics: Adolescent; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Inpatients; Neprilysin; Prospective Studies; Retrospective Studies; Risk Factors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients.
    The international journal of cardiovascular imaging, 2020, Volume: 36, Issue:2

    Topics: Adult; Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Case-Control Studies; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Predictive Value of Tests; Prospective Studies; Protease Inhibitors; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Vascular Stiffness; Vasodilation

2020
Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
    Minerva cardioangiologica, 2019, Volume: 67, Issue:6

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Retrospective Studies; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2019
Sacubitril/valsartan in heart failure and end-stage renal insufficiency.
    ESC heart failure, 2019, Volume: 6, Issue:6

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Tetrazoles; Valsartan

2019
The Risk for Sudden Cardiac Death and Effect of Treatment With Sacubitril/Valsartan in Heart Failure.
    JACC. Heart failure, 2019, Volume: 7, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2019
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
    The American journal of cardiology, 2019, 12-15, Volume: 124, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Black or African American; Cohort Studies; Drug Combinations; Drug Utilization; Female; Heart Failure; Humans; Hydralazine; Male; Middle Aged; Neprilysin; Prognosis; Registries; Retrospective Studies; Risk Assessment; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan

2019
Determinants of maximal dose titration of sacubitril/valsartan in clinical practice.
    Acta cardiologica, 2021, Volume: 76, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Valsartan

2021
Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.
    ESC heart failure, 2019, Volume: 6, Issue:6

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan

2019
Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug Substitution; Female; Heart Failure; Humans; Male; Malnutrition; Middle Aged; Neprilysin; Nutrition Assessment; Nutritional Status; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Circulation. Heart failure, 2019, Volume: 12, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Drug Combinations; Drug Substitution; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Valsartan; Ventricular Function, Left; Veterans Health Services

2019
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    Circulation, 2020, 02-04, Volume: 141, Issue:5

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Sex Factors; Stroke Volume; Tetrazoles; Valsartan

2020
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Circulation, 2020, 02-04, Volume: 141, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.
    JAMA cardiology, 2020, 03-01, Volume: 5, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Drug Utilization; Heart Failure; Humans; Ivabradine; Medicaid; Medicare Part D; Tetrazoles; United States; Valsartan

2020
Use of sacubitril/valsartan in Marfan syndrome-related cardiomyopathy: The first case report.
    Medicine, 2019, Volume: 98, Issue:47

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Marfan Syndrome; Tetrazoles; Treatment Outcome; Valsartan; Young Adult

2019
Efficacy of sacubitril valsartan sodium tablet for the treatment of chronic heart failure: A systematic review protocol of randomized controlled trials.
    Medicine, 2019, Volume: 98, Issue:47

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic; Tablets; Tetrazoles; Treatment Outcome; Valsartan

2019
Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Drug Substitution; Female; Heart Failure; Humans; Male; Maximum Tolerated Dose; Middle Aged; Patient Safety; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2019
LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Aminobutyrates; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; ERG1 Potassium Channel; Female; Heart Failure; Heart Rate; Heart Ventricles; Male; Myocardial Infarction; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channels, Voltage-Gated; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2019
The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Drug Combinations; Eligibility Determination; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Patient Selection; Protease Inhibitors; Recovery of Function; Registries; Risk Assessment; Risk Factors; Stroke Volume; Sweden; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Dissecting the benefits of sacubitril-valsartan for heart failure.
    Nature reviews. Cardiology, 2020, Volume: 17, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
    Journal of cardiovascular pharmacology, 2020, Volume: 75, Issue:2

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Comorbidity; Drug Combinations; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan

2020
PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction.
    Journal of cardiac failure, 2019, Volume: 25, Issue:12

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2019
Early Implementation of Sacubitril/Valsartan for Patients With Heart Failure.
    JAMA cardiology, 2020, 02-01, Volume: 5, Issue:2

    Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2020
From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies.
    JACC. Heart failure, 2020, Volume: 8, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    JACC. Heart failure, 2020, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Young Adult

2020
Angiotensin-neprilysin inhibition in de novo heart failure - starting off strong.
    European journal of heart failure, 2020, Volume: 22, Issue:2

    Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Neprilysin; Tetrazoles; Valsartan

2020
Is the glass half full or half empty after PARAGON-HF?
    Cardiovascular research, 2020, 01-01, Volume: 116, Issue:1

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Patient Readmission; Protease Inhibitors; Recovery of Function; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan

2020
Switching to sacubitril/valsartan or adding aldosterone antagonist: which first?
    ESC heart failure, 2019, Volume: 6, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan

2019
Response to "Grey Areas and Open Questions in Neprilysin Inhibition".
    Journal of cardiology, 2020, Volume: 75, Issue:4

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan

2020
Grey areas and open questions in neprilysin inhibition.
    Journal of cardiology, 2020, Volume: 75, Issue:4

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Neprilysin; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan

2020
Tolerability and efficacy of sacubitril/valsartan in clinical practice.
    Internal medicine journal, 2021, Volume: 51, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Quality of Life; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan.
    Cardiology, 2020, Volume: 145, Issue:5

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Logistic Models; Male; Middle Aged; Outpatients; Prospective Studies; Recovery of Function; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Heart Failure With Preserved Ejection Fraction: Separating the Wheat From the Chaff.
    Journal of the American College of Cardiology, 2020, 01-28, Volume: 75, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Myocardial work improvement after sacubitril-valsartan therapy: a new echocardiographic parameter for a new treatment.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction; Neprilysin; Predictive Value of Tests; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2020
Substance and Substrate: LVEF and Sex Subgroup Analyses of PARAGON-HF and PARADIGM-HF Trials.
    Circulation, 2020, 02-04, Volume: 141, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Tetrazoles; Valsartan

2020
Effectiveness of sacubitril-valsartan in cancer patients with heart failure.
    ESC heart failure, 2020, Volume: 7, Issue:2

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left

2020
Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
    ESC heart failure, 2020, Volume: 7, Issue:3

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Middle Aged; Retrospective Studies; Stroke Volume; Valsartan

2020
[The PARAGON-HF trial: missed opportunity or first personalized therapy?]
    Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Precision Medicine; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan

2020
In-silico simulated prototype-patients using TPMS technology to study a potential adverse effect of sacubitril and valsartan.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Computer Simulation; Drug Combinations; Heart; Heart Failure; Humans; Neprilysin; Software; Stroke Volume; Systems Biology; Tetrazoles; Valsartan; Ventricular Function, Left

2020
Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.
    Circulation. Heart failure, 2020, Volume: 13, Issue:2

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hypertension, Pulmonary; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Waiting Lists

2020
Health-related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan.
    Nursing open, 2020, Volume: 7, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Heart Failure; Humans; Quality of Life; Valsartan

2020
Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease.
    ESC heart failure, 2020, Volume: 7, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Prospective Studies; Retrospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left

2020
Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure.
    ESC heart failure, 2020, Volume: 7, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left

2020
Adoption of sacubitril-valsartan in the Medicare population.
    American heart journal, 2020, Volume: 223

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Medicare; Tetrazoles; United States; Valsartan

2020
Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    Future cardiology, 2020, Volume: 16, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Valsartan; Ventricular Function, Left

2020
Heart Failure With Preserved Ejection Fraction: The Quest for a Blood Pressure Goal.
    Journal of the American College of Cardiology, 2020, 04-14, Volume: 75, Issue:14

    Topics: Aminobutyrates; Biphenyl Compounds; Blood Pressure; Drug Combinations; Goals; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Early Initiation of Sacubitril/Valsartan in Patients with Chronic Heart Failure After Acute Decompensation: A Case Series Analysis.
    Clinical drug investigation, 2020, Volume: 40, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Prognosis; Tetrazoles; Valsartan

2020
Sacubitril/Valsartan Therapy Ameliorates Ventricular Tachyarrhythmia Inducibility in a Rabbit Myocardial Infarction Model.
    Journal of cardiac failure, 2020, Volume: 26, Issue:6

    Topics: Aminobutyrates; Animals; Biphenyl Compounds; Drug Combinations; Heart Failure; Myocardial Infarction; Rabbits; Stroke Volume; Tachycardia, Ventricular; Valsartan; Ventricular Function, Left

2020
A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
    European heart journal, 2020, 07-01, Volume: 41, Issue:25

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2020
Short-term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan.
    ESC heart failure, 2020, Volume: 7, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left

2020
The Challenges of NT-proBNP Testing in HFpEF: Shooting Arrows in the Wind.
    JACC. Heart failure, 2020, Volume: 8, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Valsartan; Wind

2020
Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
    Circulation. Heart failure, 2020, Volume: 13, Issue:4

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Clinical Decision-Making; Drug Combinations; Eligibility Determination; Evidence-Based Medicine; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Admission; Patient Selection; Peptide Fragments; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Registries; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Sacubitril-Valsartan, a New Opportunity for Heart Failure with Recovered Ejection Fraction?
    Cardiology, 2020, Volume: 145, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2020
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Heart, lung & circulation, 2020, Volume: 29, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Australia; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Female; Follow-Up Studies; Forecasting; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan

2020
Prognostic Usefulness of Myocardial Work in Patients With Heart Failure and Reduced Ejection Fraction Treated by Sacubitril/Valsartan.
    The American journal of cardiology, 2020, 06-15, Volume: 125, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan

2020
Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction.
    Scientific reports, 2020, 04-20, Volume: 10, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arterial Pressure; Biphenyl Compounds; Cardiotonic Agents; Case-Control Studies; Diuretics; Drug Combinations; Echocardiography; Female; Furosemide; Heart; Heart Failure; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Patient Readmission; Regression Analysis; Retrospective Studies; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2020
Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril/Valsartan: An Early Australian Real-World Experience.
    Heart, lung & circulation, 2020, Volume: 29, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Australia; Biphenyl Compounds; Drug Combinations; Drug Tolerance; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Morbidity; Neprilysin; Prognosis; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Time Factors; Valsartan

2020
Ejection fraction in heart failure revisited- where does the evidence start?
    European heart journal, 2020, 07-01, Volume: 41, Issue:25

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS).
    ESC heart failure, 2020, Volume: 7, Issue:4

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Primary Health Care; Prospective Studies; Retrospective Studies; Stroke Volume; Switzerland; Valsartan

2020
Combination treatment of perifosine and valsartan showed more efficiency in protecting against pressure overload induced mouse heart failure.
    Journal of pharmacological sciences, 2020, Volume: 143, Issue:3

    Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Glycogen Synthase Kinase 3 beta; Heart Failure; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Organ Size; Phosphorylcholine; Pressure; Proto-Oncogene Proteins c-akt; Signal Transduction; Valsartan

2020
Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
    Journal of cardiac failure, 2020, Volume: 26, Issue:9

    Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cyclic GMP-Dependent Protein Kinase Type I; Drug Combinations; Guanosine Monophosphate; Heart Failure; Male; Mice; Mice, Inbred C57BL; Random Allocation; Valsartan; Ventricular Function, Left

2020
Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ireland; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
    Circulation. Heart failure, 2020, Volume: 13, Issue:6

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Disease Progression; Drug Combinations; Heart Failure; Hospitalization; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2020
Improving physical activity and exercise capacity in heart failure. Taking the first step is always the hardest.
    European journal of heart failure, 2020, Volume: 22, Issue:9

    Topics: Accelerometry; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Exercise; Exercise Tolerance; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Looking at the heart failure through the prism of liver dysfunction.
    European journal of heart failure, 2020, Volume: 22, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Liver Diseases; Prognosis; Stroke Volume; Tetrazoles; Valsartan

2020
In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization.
    Annals of internal medicine, 2020, 06-16, Volume: 172, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
    Journal of cardiovascular translational research, 2021, Volume: 14, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Croatia; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Sacubitril/valsartan in patients post-left ventricular assist device implant: a single-centre case series.
    European journal of heart failure, 2020, Volume: 22, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart-Assist Devices; Humans; Stroke Volume; Valsartan

2020
Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 129

    Topics: Administration, Oral; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomegaly; Chronic Disease; Disease Models, Animal; Dogs; Drug Combinations; Heart Failure; Myocardial Ischemia; Neprilysin; Protease Inhibitors; Rats, Sprague-Dawley; Recovery of Function; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2020
Sacubitril/valsartan in the treatment of cancer therapy-related cardiac dysfunction.
    International journal of cardiology, 2020, 11-01, Volume: 318

    Topics: Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Neoplasms; Tetrazoles; Valsartan

2020
NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth.
    JACC. Heart failure, 2020, Volume: 8, Issue:7

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan

2020
Reply: NT-proBNP in Heart Failure With Preserved Ejection Fraction: Quest for a Marker Reflecting the Truth.
    JACC. Heart failure, 2020, Volume: 8, Issue:7

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan

2020
Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
    Circulation, 2020, 07-07, Volume: 142, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Tetrazoles; Valsartan

2020
Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
    Circulation, 2020, 07-07, Volume: 142, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Tetrazoles; Valsartan

2020
The Protective Effects of Compound 21 and Valsartan in Isoproterenol-Induced Myocardial Injury in Rats.
    Cardiovascular toxicology, 2021, Volume: 21, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Drug Therapy, Combination; Heart Failure; Heart Rate; Isoproterenol; Male; Myocardium; Rats, Wistar; Receptor, Angiotensin, Type 2; Stroke Volume; Sulfonamides; Thiophenes; Valsartan; Ventricular Function, Left

2021
Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
    Cardiovascular drugs and therapy, 2020, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiomyopathies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Systole; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure.
    Cardiology journal, 2020, Volume: 27, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Feasibility Studies; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left

2020
Expanding the indications for sacubitril/valsartan to unchartered territories.
    International journal of cardiology, 2020, 12-15, Volume: 321

    Topics: Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Defects, Congenital; Heart Failure; Humans; Tetrazoles; Valsartan

2020
Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.
    ESC heart failure, 2020, Volume: 7, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Receptors, Angiotensin; Stroke Volume; Taiwan; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Use of sacubitril/valsartan as 'bridge to transplant' in patients with end-stage hypertrophic cardiomyopathy.
    Future cardiology, 2021, Volume: 17, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Hypertrophic; Drug Combinations; Heart Failure; Humans; Stroke Volume; Valsartan; Ventricular Function, Left

2021
Sacubitril/Valsartan as Antifibrotic Drug: Rejuvenating the Fibrosed HFpEF Heart.
    Journal of the American College of Cardiology, 2020, 08-04, Volume: 76, Issue:5

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction.
    JACC. Heart failure, 2020, Volume: 8, Issue:8

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan

2020
Reply: The PARAGON-HF Trial: Toward Extension to Patients With HF Middle Range Ejection Fraction.
    JACC. Heart failure, 2020, Volume: 8, Issue:8

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Tetrazoles; Valsartan

2020
Three cases of psychosis after use of sacubitril/valsartan.
    Revista espanola de cardiologia (English ed.), 2021, Volume: 74, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Psychotic Disorders; Tetrazoles; Valsartan

2021
Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Disease Progression; Drug Combinations; Female; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Neprilysin; Protease Inhibitors; Pulmonary Circulation; Recovery of Function; Retrospective Studies; Stroke Volume; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling

2020
The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value?
    JAMA cardiology, 2020, 11-01, Volume: 5, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
    JAMA cardiology, 2020, 11-01, Volume: 5, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost of Illness; Cost-Benefit Analysis; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2020
Quadruple Therapy Is the New Standard of Care for HFrEF.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Standard of Care; Stroke Volume; Tetrazoles; Valsartan

2020
NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aftercare; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Patient Discharge; Peptide Fragments; Stroke Volume; Valsartan

2020
Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan.
    Circulation. Cardiovascular quality and outcomes, 2020, Volume: 13, Issue:9

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Attitude of Health Personnel; Biphenyl Compounds; Clinical Decision-Making; Cost-Benefit Analysis; Decision Making, Shared; Decision Support Techniques; Drug Combinations; Drug Costs; Health Expenditures; Heart Failure; Humans; Neprilysin; Patient Participation; Protease Inhibitors; Stakeholder Participation; Valsartan

2020
Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
    The international journal of cardiovascular imaging, 2021, Volume: 37, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Echocardiography, Doppler, Pulsed; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Pulmonary Artery; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Vascular Stiffness; Ventricular Function, Left

2021
A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study.
    European journal of clinical pharmacology, 2021, Volume: 77, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Substitution; Female; Heart Failure; Humans; Male; Medication Therapy Management; Models, Theoretical; Valsartan

2021
Utilization of Sacubitril/Valsartan in Real-World Settings.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020, Volume: 20, Issue:6

    Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Severity of Illness Index; Socioeconomic Factors; Valsartan; Young Adult

2020
Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
    European journal of heart failure, 2020, Volume: 22, Issue:11

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Prospective Studies; Randomized Controlled Trials as Topic; Stroke Volume; Treatment Outcome; Uric Acid; Valsartan

2020
Consider Everything When Prescribing Sacubitril/Valsartan: Perfection Is the Enemy of Good.
    Journal of the American College of Cardiology, 2020, 09-01, Volume: 76, Issue:9

    Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valsartan

2020
Effects of sacubitril/valsartan in patients with left ventricular assist devices: Case series.
    Artificial organs, 2021, Volume: 45, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Proof of Concept Study; Valsartan

2021
Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2020
Similar Yet Different: Examining the Effects of Sacubitril/Valsartan by Race in the PIONEER-HF Trial.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Black or African American; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis.
    JACC. Heart failure, 2020, Volume: 8, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; North America; Prospective Studies; Stroke Volume; Tetrazoles; Valsartan

2020
Cause and duration of heart failure may impact on the response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 03-01, Volume: 22, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Use of sacubitril-valsartan in blood pressure control with left ventricular assist devices.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020, Volume: 39, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Alternative payment models and innovation: a case study of US health system adoption of a sacubitril/valsartan to treat acute decompensated heart failure.
    Journal of medical economics, 2020, Volume: 23, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Medicare; United States; Valsartan

2020
Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
    European journal of heart failure, 2020, Volume: 22, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Valsartan; Ventricular Remodeling

2020
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions].
    Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Biphenyl Compounds; Chronic Disease; Continuity of Patient Care; Coronavirus Infections; COVID-19; Delivery of Health Care; Disease Progression; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Pandemics; Pneumonia, Viral; Quarantine; Recurrence; SARS-CoV-2; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Telephone; Tetrazoles; Valsartan; Withholding Treatment

2020
PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure.
    American heart journal, 2020, Volume: 230

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Case-Control Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Preliminary Data; Propensity Score; Prospective Studies; Quality of Life; Tetrazoles; Valsartan

2020
Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Open heart, 2020, Volume: 7, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug Substitution; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Quality of Life; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population.
    Journal of cardiovascular pharmacology, 2020, Volume: 76, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Asian People; Biphenyl Compounds; China; Drug Combinations; Exercise Tolerance; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Safety and Tolerability of Sacubitril/Valsartan Initiation in Inpatient Versus Outpatient Setting: A Retrospective Real World Study.
    Heart, lung & circulation, 2021, Volume: 30, Issue:5

    Topics: Aftercare; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Inpatients; Outpatients; Patient Discharge; Retrospective Studies; Stroke Volume; Valsartan

2021
Management of patients with chronic heart failure and type 2 diabetes mellitus: the SCODIAC-II study.
    Internal and emergency medicine, 2021, Volume: 16, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Italy; Male; Valsartan

2021
Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy.
    Arquivos brasileiros de cardiologia, 2020, Volume: 115, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Middle Aged; Oxygen; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2020
Ins and Outs: Perspectives of Inpatient Prescribing for Sacubitril/Valsartan.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Inpatients; Stroke Volume; Tetrazoles; Valsartan

2021
Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment.
    European heart journal. Cardiovascular pharmacotherapy, 2022, 02-16, Volume: 8, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2022
Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan in primary care and cardiologist settings in Germany.
    ESC heart failure, 2020, Volume: 7, Issue:5

    Topics: Adolescent; Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiologists; Drug Combinations; Germany; Heart Failure; Humans; Prescriptions; Primary Health Care; Referral and Consultation; Retrospective Studies; Valsartan

2020
Should the LIFE Trial Assess Improvement in Ejection Fraction as a Primary Endpoint?
    JACC. Heart failure, 2020, Volume: 8, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Heart failure features and sacubitril/valsartan effects.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 03-01, Volume: 22, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2021
Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry.
    ESC heart failure, 2021, Volume: 8, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Health Status; Heart Failure; Humans; Prospective Studies; Quality of Life; Registries; Stroke Volume; Valsartan

2021
Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions.
    Circulation. Heart failure, 2020, Volume: 13, Issue:11

    Topics: Adult; Aged; Aminobutyrates; Attitude of Health Personnel; Biphenyl Compounds; Cardiovascular Agents; Choice Behavior; Decision Making, Shared; Drug Combinations; Drug Costs; Female; Health Expenditures; Health Knowledge, Attitudes, Practice; Heart Failure; Humans; Interviews as Topic; Male; Middle Aged; Patient Participation; Patient Preference; Patient-Centered Care; Physician-Patient Relations; Tetrazoles; Valsartan

2020
Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF.
    Journal of the American College of Cardiology, 2020, 11-17, Volume: 76, Issue:20

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Reply: Circulating Biomarkers Specific to Myocardial Extracellular Matrix Are Required to Embrace the Heterogeneity of HFpEF.
    Journal of the American College of Cardiology, 2020, 11-17, Volume: 76, Issue:20

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2020
Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction.
    JACC. Heart failure, 2021, Volume: 9, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Drug Combinations; Female; Health Status; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2021
Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
    JACC. Heart failure, 2021, Volume: 9, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Middle Aged; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Renin profiling predicts neurohormonal response to sacubitril/valsartan.
    ESC heart failure, 2021, Volume: 8, Issue:1

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cohort Studies; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Renin; Stroke Volume; Valsartan

2021
When and for Whom Should We Use SGLT2 Inhibitors in HFrEF?
    JACC. Heart failure, 2020, Volume: 8, Issue:12

    Topics: Aminobutyrates; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan

2020
Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels.
    Clinical cardiology, 2021, Volume: 44, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Drug Tolerance; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Retrospective Studies; Valsartan

2021
Angiotensin Receptor-Neprilysin Inhibition Therapy and Improved Exercise Parameters in Heart Failure with Reduced Ejection Fraction.
    Arquivos brasileiros de cardiologia, 2020, Volume: 115, Issue:5

    Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Oxygen; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan

2020
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients.
    Journal of cardiovascular pharmacology, 2021, 03-01, Volume: 77, Issue:3

    Topics: Aged; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hypotension; Inappropriate Prescribing; Male; Middle Aged; Neprilysin; Outpatients; Practice Guidelines as Topic; Protease Inhibitors; Recovery of Function; Retrospective Studies; Time Factors; Treatment Outcome; Valsartan

2021
Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence.
    International journal of cardiology, 2021, 03-15, Volume: 327

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost.
    Circulation. Cardiovascular quality and outcomes, 2020, Volume: 13, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Colorado; Cost-Benefit Analysis; Decision Making, Shared; Decision Support Techniques; Drug Combinations; Drug Costs; Female; Georgia; Health Expenditures; Heart Failure; Humans; Interviews as Topic; Male; Middle Aged; Neprilysin; Patient Participation; Patient Satisfaction; Protease Inhibitors; Treatment Outcome; Valsartan

2020
Beneficial effects of one-month sacubitril/valsartan treatment in a patient affected by end-stage dystrophinopathic cardiomyopathy.
    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 2020, Volume: 39, Issue:3

    Topics: Activities of Daily Living; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Drug Monitoring; Dystrophin; Echocardiography; Exercise Tolerance; Heart Failure; Humans; Male; Middle Aged; Muscular Dystrophy, Duchenne; Stroke Volume; Symptom Assessment; Treatment Outcome; Valsartan

2020
Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes.
    JACC. Heart failure, 2021, Volume: 9, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2021
Chronic asymptomatic hyponatraemia following angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy: a case report.
    Postgraduate medical journal, 2022, Volume: 98, Issue:1157

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Drug Combinations; Heart Failure; Humans; Hyponatremia; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2022
How to appropriately update practicing clinicians on innovations in heart failure therapy waiting for the new version of the guidelines?
    International journal of cardiology, 2021, 04-15, Volume: 329

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2021
Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy.
    Journal of cardiac failure, 2021, Volume: 27, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamics; Humans; Prospective Studies; Retrospective Studies; Tetrazoles; Valsartan; Vasodilator Agents

2021
Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 133

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Fibrosis; Heart Failure; Hemodynamics; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocardial Contraction; Myocardial Infarction; Myocardium; Neprilysin; Protease Inhibitors; Renin; Tetrazoles; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left

2021
Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.
    The Annals of pharmacotherapy, 2021, Volume: 55, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Effect of sacubitril valsartan on cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction.
    Clinical hemorheology and microcirculation, 2021, Volume: 77, Issue:4

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
    ESC heart failure, 2021, Volume: 8, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Ivabradine; Stroke Volume; Valsartan; Ventricular Function, Left

2021
Sacubitril/valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide? Author's reply.
    Kardiologia polska, 2021, 01-25, Volume: 79, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Sacubitril / valsartan for patients with heart failure with preserved ejection fraction: what will the FDA decide?
    Kardiologia polska, 2021, 01-25, Volume: 79, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Sacubitril/valsartan in the treatment of systemic right ventricular failure.
    Heart (British Cardiac Society), 2021, Volume: 107, Issue:21

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Retrospective Studies; Treatment Outcome; Valsartan; Ventricular Function, Right

2021
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
    Medical hypotheses, 2021, Volume: 147

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Biphenyl Compounds; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Drug Combinations; Heart Failure; Homeostasis; Humans; Inflammation; Models, Theoretical; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Receptor, Angiotensin, Type 2; Tetrazoles; Valsartan; World Health Organization

2021
Effects of Sacubitril/Valsartan in Patients with High Arrhythmic Risk and an ICD: A Longitudinal Study.
    Clinical drug investigation, 2021, Volume: 41, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Peptide Fragments; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Positive Recommendation for Angiotensin Receptor-Neprilysin Inhibitor: First Medication Approval for Heart Failure Without Reduced Ejection Fraction.
    The Canadian journal of cardiology, 2021, Volume: 37, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; United States; United States Food and Drug Administration; Valsartan

2021
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    ESC heart failure, 2021, Volume: 8, Issue:2

    Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Heart Failure; Rats; Rats, Sprague-Dawley; Stroke Volume; Valsartan

2021
Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF.
    JACC. Heart failure, 2021, Volume: 9, Issue:2

    Topics: Advisory Committees; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Presumed Sudden Cardiac Deaths in the PARADIGM-HF Trial.
    JACC. Heart failure, 2021, Volume: 9, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Valsartan

2021
Reply: Presumed Sudden Cardiac Deaths in the PARADIGM-HF Trial.
    JACC. Heart failure, 2021, Volume: 9, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Valsartan

2021
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.
    ESC heart failure, 2021, Volume: 8, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Retrospective Studies; Stroke Volume; Valsartan

2021
Sacubitril/valsartan for heart failure with reduced ejection fraction: A first real-life observational study in Poland.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2021, Volume: 30, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Poland; Stroke Volume; Tetrazoles; Valsartan

2021
Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction.
    European heart journal. Cardiovascular pharmacotherapy, 2021, 05-23, Volume: 7, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Heart Failure; Humans; Stroke Volume; Valsartan

2021
Sacubitril-valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction.
    International journal of cardiology, 2021, 05-01, Volume: 330

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sleep Apnea, Central; Stroke Volume; Tetrazoles; Valsartan

2021
Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2021, Volume: 28, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diastole; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis.
    European journal of preventive cardiology, 2021, 12-29, Volume: 28, Issue:15

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Glucosides; Heart Failure; Humans; Stroke Volume; Treatment Outcome; Valsartan

2021
Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter?
    European journal of preventive cardiology, 2021, 12-29, Volume: 28, Issue:15

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sodium-Glucose Transporter 2 Inhibitors; Valsartan

2021
Improvement in quality of life with sacubitril/ /valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry.
    Cardiology journal, 2021, Volume: 28, Issue:3

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Cardiac Resynchronization Therapy; Drug Combinations; Female; Heart Failure; Humans; Male; Neprilysin; Quality of Life; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Synchronized determination of the novel heart failure combination therapy containing sacubitril calcium and valsartan by a validated spectrofluorimetric method.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2021, May-15, Volume: 253

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium; Drug Combinations; Heart Failure; Humans; Spectrometry, Fluorescence; Tetrazoles; Valsartan

2021
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction.
    ESC heart failure, 2021, Volume: 8, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Prognosis; Retrospective Studies; Stroke Volume; Valsartan

2021
The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
    Anatolian journal of cardiology, 2021, Volume: 25, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2021
Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
    European heart journal. Quality of care & clinical outcomes, 2022, 06-06, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left

2022
Comparison of the prognosis and outcome of heart failure with reduced ejection fraction patients treated with sacubitril/valsartan according to age.
    Future cardiology, 2021, Volume: 17, Issue:6

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Prognosis; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Current medical research and opinion, 2021, Volume: 37, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Coronary Disease; Drug Combinations; Echocardiography; Heart Failure; Humans; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2021
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
    International journal of molecular sciences, 2021, Mar-30, Volume: 22, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Connectin; Cyclic GMP; Diastole; Disease Models, Animal; Drug Combinations; Electrocardiography; Female; Fibrosis; Glycated Hemoglobin; Heart Failure; Muscle, Skeletal; Muscular Atrophy; Natriuretic Peptide, Brain; Peptide Fragments; Phosphorylation; Rats, Mutant Strains; Valsartan; Ventricular Function, Left

2021
Trend of perceived quality of life and functional capacity in outpatients with chronic heart failure and in treatment with sacubitril/valsartan: a real-life experience.
    Minerva cardiology and angiology, 2022, Volume: 70, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Outpatients; Quality of Life; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022
Clinical Application of Sacubitril/Valsartan in Heart Failure.
    American journal of therapeutics, 2021, Apr-08, Volume: 28, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Making the Case for an Expanded Indication for Sacubitril/Valsartan in Heart Failure.
    Journal of cardiac failure, 2021, Volume: 27, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop.
    Journal of pharmacy practice, 2022, Volume: 35, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Diuretics; Drug Combinations; Furosemide; Heart Failure; Humans; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2022
The evolution of guideline-directed medical therapy among decompensated HFrEF patients in sacubitril/valsartan era: Medical expenses and clinical effectiveness.
    Journal of the Chinese Medical Association : JCMA, 2021, 06-01, Volume: 84, Issue:6

    Topics: Aged; Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Female; Health Expenditures; Heart Failure; Humans; Male; Middle Aged; Practice Guidelines as Topic; Propensity Score; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan

2021
Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
    American heart journal, 2021, Volume: 236

    Topics: Aminobutyrates; Attention; Biphenyl Compounds; Drug Combinations; Glucose; Heart Failure; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Symporters; Tetrazoles; Valsartan

2021
Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2021, Volume: 28, Issue:4

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2021
Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients.
    Yonsei medical journal, 2021, Volume: 62, Issue:5

    Topics: Aminobutyrates; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2021
Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction.
    ESC heart failure, 2021, Volume: 8, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Health Status; Heart Failure; Humans; Quality of Life; Stroke Volume; Valsartan

2021
In brief: Sacubitril/valsartan (Entresto) expanded indication.
    The Medical letter on drugs and therapeutics, 2021, 05-03, Volume: 63, Issue:1623

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Stroke Volume; Valsartan

2021
Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
    PloS one, 2021, Volume: 16, Issue:5

    Topics: Aged; Aminobutyrates; Biomarkers; Biphenyl Compounds; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Prognosis; Proportional Hazards Models; Stroke Volume; Valsartan

2021
Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
    Annals of palliative medicine, 2021, Volume: 10, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Bisoprolol; Cardiac Rehabilitation; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Sodium; Stroke Volume; Tablets; Valsartan; Ventricular Function, Left

2021
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2022, Volume: 166, Issue:3

    Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Antihypertensive Agents; Czech Republic; Heart Failure; Humans; Losartan; Neprilysin; Perindopril; Ramipril; Retrospective Studies; Telmisartan; Valsartan

2022
Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
    Circulation, 2021, 06-08, Volume: 143, Issue:23

    Topics: Aminobutyrates; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Drug Combinations; Heart Failure; Hospitalization; Humans; Probability; Stroke Volume; Valsartan

2021
Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization.
    Journal of cardiac failure, 2021, Volume: 27, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Stroke Volume; Valsartan

2021
Association of Body Mass Index With Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan.
    Journal of cardiovascular pharmacology and therapeutics, 2021, Volume: 26, Issue:6

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Body Mass Index; Cause of Death; Cohort Studies; Drug Combinations; Heart Failure; Humans; Male; Middle Aged; Overweight; Retrospective Studies; Risk Factors; Stroke Volume; Valsartan; West Virginia

2021
Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study.
    Pharmacotherapy, 2021, Volume: 41, Issue:9

    Topics: Adolescent; Adult; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Mineralocorticoid Receptor Antagonists; Retrospective Studies; Stroke Volume; Treatment Outcome; Valsartan

2021
Characteristics of Heart Failure Patients With or Without Hypotension When Transitioning From Nitroprusside to Sacubitril-Valsartan.
    Journal of cardiovascular pharmacology, 2021, 09-01, Volume: 78, Issue:3

    Topics: Adult; Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Coronary Care Units; Diuretics; Drug Combinations; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Neprilysin; Nitroprusside; Protease Inhibitors; Retrospective Studies; Risk Factors; Treatment Outcome; Valsartan; Vasodilator Agents

2021
Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study.
    Autonomic neuroscience : basic & clinical, 2021, Volume: 235

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Pilot Projects; Prospective Studies; Stroke Volume; Treatment Outcome; Valsartan

2021
Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis.
    BMC cardiovascular disorders, 2021, 07-02, Volume: 21, Issue:1

    Topics: Adult; Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Drug Utilization; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Neprilysin; Pilot Projects; Practice Patterns, Physicians'; Protease Inhibitors; Recovery of Function; Retrospective Studies; Thailand; Time Factors; Treatment Outcome; Valsartan

2021
Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?
    Journal of cardiovascular pharmacology, 2021, 09-01, Volume: 78, Issue:3

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Clinical Decision-Making; Disease Models, Animal; Drug Combinations; Evidence-Based Medicine; Heart Disease Risk Factors; Heart Failure; Humans; Myocardial Infarction; Neprilysin; Protease Inhibitors; Protective Factors; Risk Assessment; Treatment Outcome; Valsartan

2021
Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease - A case series.
    British journal of clinical pharmacology, 2022, Volume: 88, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2022
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial.
    JACC. Heart failure, 2021, Volume: 9, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Troponin T; Valsartan; Ventricular Function, Left

2021
Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan.
    Circulation. Heart failure, 2021, Volume: 14, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Pulmonary Artery; Stroke Volume; Valsartan

2021
Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction.
    Revista espanola de cardiologia (English ed.), 2021, Volume: 74, Issue:12

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
    Circulation, 2021, 07-13, Volume: 144, Issue:2

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Defibrillators, Implantable; Female; Heart Failure; Humans; Male; Valsartan

2021
Monitoring the dynamics of clinical and laboratory markers of chronic heart failure during 12 months of sacubitril/valsartan treatment.
    Vnitrni lekarstvi, 2021,Summer, Volume: 67, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Quality of Life; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2021
Impact of Sacubitril/Valsartan on Right Heart Failure.
    International heart journal, 2021, Jul-30, Volume: 62, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Valsartan

2021
Effect of SAcubitril/Valsartan on left vEntricular ejection fraction and on the potential indication for Implantable Cardioverter Defibrillator in primary prevention: the SAVE-ICD study.
    European journal of clinical pharmacology, 2021, Volume: 77, Issue:12

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Comorbidity; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Valsartan; Ventricular Function, Left

2021
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR).
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2021, Volume: 49, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Female; Furosemide; Glycated Hemoglobin; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Retrospective Studies; Stroke Volume; Turkey; Valsartan; Ventricular Dysfunction, Left

2021
The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 130

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Chronic Disease; Clinical Studies as Topic; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Patient Readmission; Prognosis; Severity of Illness Index; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2020
Effect of sacubitril-valsartan on cardiac function in hemodialysis patients.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2022, Volume: 26, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Pilot Projects; Renal Dialysis; Treatment Outcome; Valsartan; Ventricular Function, Left

2022
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
    Acta cardiologica, 2022, Volume: 77, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2022
Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure.
    Journal of cardiac failure, 2021, Volume: 27, Issue:8

    Topics: Aftercare; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Medicare; Patient Discharge; Stroke Volume; Tetrazoles; United States; Valsartan

2021
National Trends in the Use of Sacubitril/Valsartan.
    Journal of cardiac failure, 2021, Volume: 27, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2021
Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis.
    Scientific reports, 2021, 08-11, Volume: 11, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Stroke Volume; Valsartan; Ventricular Function, Left

2021
Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
    European heart journal, 2021, 09-21, Volume: 42, Issue:36

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypertension; Stroke Volume; Tetrazoles; Valsartan

2021
Angiotensin Receptor Blocker and Neprilysin Inhibitor Suppresses Cardiac Dysfunction by Accelerating Myocardial Angiogenesis in Apolipoprotein E-Knockout Mice Fed a High-Fat Diet.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2021, Volume: 2021

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apolipoproteins; Biphenyl Compounds; Diet, High-Fat; Drug Combinations; Heart Failure; Male; Mice; Mice, Knockout; Neprilysin; Stroke Volume; Tetrazoles; Valsartan; Vascular Endothelial Growth Factor A

2021
Clinical characteristics, prescription patterns, and persistence associated with sacubitril/valsartan adoption: A STROBE-compliant study.
    Medicine, 2021, Jul-30, Volume: 100, Issue:30

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Valsartan

2021
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    European journal of preventive cardiology, 2021, 08-09, Volume: 28, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan

2021
Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis.
    European journal of preventive cardiology, 2021, 08-09, Volume: 28, Issue:9

    Topics: Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Enalapril; Heart Failure; Humans; Valsartan

2021
Angiotensin receptor-neprilysin inhibitor improves New York Heart Association class and N-terminal-pro B-type natriuretic peptide levels: initial experience in a Singapore single-centre cohort.
    Singapore medical journal, 2021, Volume: 62, Issue:7

    Topics: Angiotensin Receptor Antagonists; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; New York; Receptors, Angiotensin; Singapore; Stroke Volume; Valsartan

2021
Reverse remodeling in a heart failure patient with cardiomegaly treated with sacubitril/valsartan: a case report.
    Die Pharmazie, 2021, 08-01, Volume: 76, Issue:8

    Topics: Aminobutyrates; Biphenyl Compounds; Cardiomegaly; Drug Combinations; Heart Failure; Humans; Percutaneous Coronary Intervention; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2021
Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
    International journal of molecular sciences, 2021, Aug-10, Volume: 22, Issue:16

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cells, Cultured; Drug Combinations; Endothelial Cells; Heart Failure; Humans; Male; Mitral Valve; Mitral Valve Insufficiency; Myocardial Infarction; Myocardial Reperfusion Injury; Neprilysin; Rats; Rats, Sprague-Dawley; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2021
Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society.
    Kardiologia polska, 2017, Volume: 75, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiology; Drug Combinations; Heart Failure; Humans; Patient Care Management; Poland; Recovery of Function; Societies, Medical; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2017
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
    JACC. Heart failure, 2017, Volume: 5, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Neprilysin; Practice Patterns, Physicians'; Registries; Severity of Illness Index; Stroke Volume; Tetrazoles; Valsartan

2017
Diabetes: Sacubitril/valsartan improves glycaemic control.
    Nature reviews. Cardiology, 2017, Volume: 14, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Diabetes Mellitus; Drug Combinations; Enalapril; Heart Failure; Humans; Tetrazoles; Valsartan

2017
The renal and cardiovascular effects of natriuretic peptides.
    Advances in physiology education, 2017, Jun-01, Volume: 41, Issue:2

    Topics: Aminobutyrates; Atrial Natriuretic Factor; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Kidney; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Natriuretic Peptides; Tetrazoles; Valsartan

2017
[The relationship between natriuretic peptides and neprilysin pathways: the clinical simplification against the complexity of biological systems].
    Giornale italiano di cardiologia (2006), 2017, Volume: 18, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biological Phenomena; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Tetrazoles; Valsartan

2017
Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction.
    Annals of internal medicine, 2017, 04-18, Volume: 166, Issue:8

    Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2017
Cost-Effectiveness of Sacubitril-Valsartan in Patients Who Have Heart Failure With Reduced Ejection Fraction.
    Annals of internal medicine, 2017, 04-18, Volume: 166, Issue:8

    Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2017
Sacubitril-Valsartan in Heart Failure.
    Annals of internal medicine, 2017, 05-02, Volume: 166, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Sacubitril-Valsartan in Heart Failure.
    Annals of internal medicine, 2017, 05-02, Volume: 166, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Sacubitril-Valsartan in Heart Failure.
    Annals of internal medicine, 2017, 05-02, Volume: 166, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Sacubitril-Valsartan in Heart Failure.
    Annals of internal medicine, 2017, 05-02, Volume: 166, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Margaret McCartney: Only data can say if new is better.
    BMJ (Clinical research ed.), 2017, 05-08, Volume: 357

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Approval; Enalapril; Equivalence Trials as Topic; Heart Failure; Humans; United Kingdom; Valsartan

2017
[Sacubitril/valsartan, a new and effective treatment for heart failure with reduced ejection fraction].
    Giornale italiano di cardiologia (2006), 2017, Volume: 18, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2017
Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).
    Circulation, 2017, 05-23, Volume: 135, Issue:21

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Practice Guidelines as Topic; Registries; Tetrazoles; Valsartan

2017
Response by Dr Packer to the Letter of Dr Blankfield.
    Journal of cardiovascular pharmacology and therapeutics, 2018, Volume: 23, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2018
Sacubitril/valsartan in PARADIGM-HF.
    The lancet. Diabetes & endocrinology, 2017, Volume: 5, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Sacubitril/valsartan in PARADIGM-HF.
    The lancet. Diabetes & endocrinology, 2017, Volume: 5, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Sacubitril/valsartan in PARADIGM-HF.
    The lancet. Diabetes & endocrinology, 2017, Volume: 5, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Sacubitril/valsartan in PARADIGM-HF - Authors' reply.
    The lancet. Diabetes & endocrinology, 2017, Volume: 5, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
[Update on the clinical application of valsartan/sacubitril in patients with heart failure].
    Zhonghua xin xue guan bing za zhi, 2017, Jun-24, Volume: 45, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Evolving Pharmacologic Therapies for Heart Failure.
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2017, Volume: 70, Issue:4

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2017
Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context.
    European journal of heart failure, 2017, Volume: 19, Issue:11

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Middle Aged; Morbidity; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan

2017
Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.
    JACC. Heart failure, 2017, Volume: 5, Issue:9

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Sacubitril-valsartan: novel therapy for heart failure.
    Canadian family physician Medecin de famille canadien, 2017, Volume: 63, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Tetrazoles; Valsartan

2017
Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
    Journal of medical economics, 2018, Volume: 21, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Markov Chains; Multivariate Analysis; Quality-Adjusted Life Years; Severity of Illness Index; Singapore; Stroke Volume; Survival Analysis; Tetrazoles; Valsartan

2018
Use of sacubitril/valsartan in acute decompensated heart failure: a case report.
    ESC heart failure, 2018, Volume: 5, Issue:1

    Topics: Acute Disease; Aminobutyrates; Angiotensin Receptor Antagonists; Anti-Retroviral Agents; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Middle Aged; Recovery of Function; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Pressure

2018
Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney.
    Journal of the American College of Cardiology, 2017, Oct-24, Volume: 70, Issue:17

    Topics: Aminobutyrates; Angiotensin II; Animals; Biphenyl Compounds; Bisoprolol; Blood Pressure; Drug Combinations; Echocardiography; Heart Failure; Kidney; Myocardium; Neprilysin; Nitrites; Norepinephrine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Artery; Renin; Reperfusion Injury; Sympathectomy; Tetrazoles; Valsartan; Ventricular Function, Left

2017
Valsartan regulates TGF-β/Smads and TGF-β/p38 pathways through lncRNA CHRF to improve doxorubicin-induced heart failure.
    Archives of pharmacal research, 2018, Volume: 41, Issue:1

    Topics: Animals; Antihypertensive Agents; Apoptosis; Cells, Cultured; Disease Models, Animal; Doxorubicin; Heart Failure; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; p38 Mitogen-Activated Protein Kinases; RNA, Long Noncoding; Smad Proteins; Transforming Growth Factor beta1; Valsartan

2018
Sacubitril/Valsartan: Practice Changing Guideline in the Management of Congestive Heart Failure.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2017, Volume: 27, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Tetrazoles; Treatment Outcome; Valsartan

2017
Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
    Circulation. Heart failure, 2017, Volume: 10, Issue:11

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Decision-Making; Conservative Treatment; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Stroke Volume; Tetrazoles; Time Factors; Time-to-Treatment; Valsartan; Ventricular Remodeling

2017
Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kardiologia polska, 2018, Volume: 76, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Patient Safety; Peptide Fragments; Poland; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2018
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeco
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2017, Volume: 20, Issue:10

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Economics, Pharmaceutical; Enalapril; Female; Guidelines as Topic; Heart Failure; Humans; Male; Middle Aged; Models, Economic; Neprilysin; Netherlands; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan

2017
Sacubitril/Valsartan in an Elderly Patient with Heart Failure: A Case Report.
    Cardiology, 2017, Volume: 138 Suppl 1

    Topics: Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Echocardiography; Heart Failure; Heart Ventricles; Humans; Male; Stroke Volume; Tetrazoles; Valsartan

2017
Sacubitril/Valsartan in Clinical Practice: The Italian Experience.
    Cardiology, 2017, Volume: 138 Suppl 1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2017
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    Heart (British Cardiac Society), 2018, Volume: 104, Issue:12

    Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Colombia; Cost-Benefit Analysis; Denmark; Drug Combinations; Drug Costs; Heart Failure; Humans; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; United Kingdom; Valsartan; Ventricular Function, Left

2018
LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
    Journal of cardiac failure, 2018, Volume: 24, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Disease Models, Animal; Drug Combinations; Fibrosis; Heart Failure; Male; Neprilysin; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke Volume; Tetrazoles; Valsartan

2018
Uric acid is important, but there is something that matters even more: to deliver sacubitril/valsartan to eligible heart failure patients.
    European journal of heart failure, 2018, Volume: 20, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Uric Acid; Valsartan

2018
The clinical relevance of drug-drug interaction between co-trimoxazole and sacubitril/valsartan treatment in a heart failure patient: a case report and overview of mechanisms and management in clinical practice.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2018, Volume: 107, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Anti-Bacterial Agents; Biphenyl Compounds; Drug Combinations; Drug Interactions; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Trimethoprim, Sulfamethoxazole Drug Combination; Valsartan

2018
Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study.
    ESC heart failure, 2018, Volume: 5, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Eligibility Determination; Female; Follow-Up Studies; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Morbidity; Population Surveillance; Retrospective Studies; Stroke Volume; Survival Rate; Sweden; Tetrazoles; Treatment Outcome; Valsartan

2018
Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction : A retrospective cohort study.
    Herz, 2019, Volume: 44, Issue:5

    Topics: Aminobutyrates; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
    European heart journal, 2018, 06-21, Volume: 39, Issue:24

    Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stroke; Valsartan

2018
Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study.
    Revista espanola de cardiologia (English ed.), 2019, Volume: 72, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Exercise Tolerance; Female; Heart Failure; Humans; Male; Neprilysin; Pilot Projects; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany.
    Postgraduate medicine, 2018, Volume: 130, Issue:3

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Body Mass Index; Comorbidity; Drug Combinations; Electronic Health Records; Female; Germany; Glycated Hemoglobin; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Sex Factors; Tetrazoles; Valsartan

2018
Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study.
    Herz, 2019, Volume: 44, Issue:6

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cognition; Drug Combinations; Heart Failure; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan

2019
Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Circulation. Heart failure, 2018, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Young Adult

2018
From Molecules to Markets: Broadening the Focus of Cardiovascular Innovation.
    Circulation. Heart failure, 2018, Volume: 11, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2018
Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018, Volume: 18, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Drug Combinations; Female; Heart Failure; Humans; Male; Outpatients; Pharmacists; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan

2018
Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
    Journal of the American Heart Association, 2018, 03-03, Volume: 7, Issue:5

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Heart Failure; Hypertension; Male; Myocardium; Natriuretic Peptides; Neprilysin; Nitric Oxide; Protease Inhibitors; Rats, Inbred SHR; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2018
In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization : A retrospective cohort study.
    Herz, 2019, Volume: 44, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2019
Chronic Heart Failure.
    Deutsches Arzteblatt international, 2018, Feb-23, Volume: 115, Issue:8

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy; Diuretics; Drug Combinations; Germany; Guidelines as Topic; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan

2018
Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.
    Pharmacotherapy, 2018, Volume: 38, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Heart Failure; Hospitalization; Humans; Markov Chains; Quality-Adjusted Life Years; Stroke Volume; Tetrazoles; Valsartan

2018
Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database.
    Journal of cardiac failure, 2018, Volume: 24, Issue:8

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cognition; Cognition Disorders; Dementia; Drug Combinations; Female; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan

2018
Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart
    Circulation. Heart failure, 2018, Volume: 11, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2018
Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means.
    American heart journal, 2018, Volume: 199

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2018
The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Cardiovascular therapeutics, 2018, Volume: 36, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Belgium; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography, Doppler; Female; Heart Failure; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2018
An Early View of Real-World Patient Response to Sacubitril/Valsartan: A Retrospective Study of Patients with Heart Failure with Reduced Ejection Fraction.
    Advances in therapy, 2018, Volume: 35, Issue:6

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; United States; Valsartan; Ventricular Dysfunction, Left

2018
Is the PARADIGM-HF cohort representative of the real-world heart failure patient population?
    Revista portuguesa de cardiologia, 2018, Volume: 37, Issue:6

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Reproducibility of Results; Tetrazoles; Valsartan

2018
Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial.
    Journal of cardiovascular pharmacology, 2018, Volume: 72, Issue:2

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Health Status; Heart Failure; Humans; Kidney; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Registries; Risk Factors; Spain; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2018
Sacubitril/valsartan: Can haemodynamic monitoring help with up-take?
    International journal of cardiology, 2018, 11-15, Volume: 271

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hemodynamic Monitoring; Tetrazoles; Valsartan

2018
Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
    Journal of the American Heart Association, 2018, 06-12, Volume: 7, Issue:12

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Observational Studies as Topic; Patient Selection; Protease Inhibitors; Randomized Controlled Trials as Topic; Recovery of Function; Registries; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2018
Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptions.
    Acta cardiologica, 2019, Volume: 74, Issue:2

    Topics: Aged; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Belgium; Biphenyl Compounds; Drug Combinations; Drug Prescriptions; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Incidence; Male; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan

2019
Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018, Volume: 18, Issue:5

    Topics: Aged; Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Needs Assessment; Outcome and Process Assessment, Health Care; Quality-Adjusted Life Years; Stroke Volume; Survival Analysis; Tetrazoles; Thailand; Valsartan; Ventricular Dysfunction, Left

2018
Renal effects of sacubitril/valsartan in patients with diabetes.
    The lancet. Diabetes & endocrinology, 2018, Volume: 6, Issue:7

    Topics: Aminobutyrates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Combinations; Heart Failure; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan

2018
Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.
    JAAPA : official journal of the American Academy of Physician Assistants, 2018, Volume: 31, Issue:7

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valsartan

2018
A Case of Palpitations Due to T-Wave Oversensing Caused by Sacubitril/Valsartan.
    The Canadian journal of cardiology, 2018, Volume: 34, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Biphenyl Compounds; Drug Combinations; Electrocardiography; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2018
Angiotensin receptor neprilysin inhibitors in older patients with heart failure.
    BMJ evidence-based medicine, 2019, Volume: 24, Issue:1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2019
RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
    Journal of medical economics, 2018, Volume: 21, Issue:12

    Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2018
Sacubitril-valsartan in heart failure and multimorbidity patients.
    ESC heart failure, 2018, Volume: 5, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Drug Combinations; Female; Heart Failure; Humans; Male; Neprilysin; Retrospective Studies; Tetrazoles; Treatment Outcome; Valsartan

2018
Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany.
    PharmacoEconomics, 2018, Volume: 36, Issue:10

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Budgets; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Monte Carlo Method; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2018
Characteristics of early sacubitril/valsartan patients and considerations for studies in electronic health record data.
    Journal of comparative effectiveness research, 2018, Volume: 7, Issue:11

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Electronic Health Records; Heart Failure; Humans; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2018
Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2018, Volume: 19, Issue:10

    Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Cost-Benefit Analysis; Defibrillators, Implantable; Drug Combinations; Drug Costs; Electric Countershock; Female; Health Care Costs; Heart Failure; Hospital Costs; Hospitalization; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2018
A Drug Utilization Study of Sacubitril/Valsartan in Catalonia.
    Revista espanola de cardiologia (English ed.), 2019, Volume: 72, Issue:7

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Utilization; Female; Heart Failure; Humans; Male; Middle Aged; Prevalence; Spain; Tetrazoles; Valsartan

2019
Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?
    Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Practice Patterns, Physicians'; Protease Inhibitors; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Tetrazoles; Treatment Outcome; United States; United States Food and Drug Administration; Valsartan

2018
Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction.
    Journal of medical economics, 2018, Volume: 21, Issue:12

    Topics: Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2018
[ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Contraindications, Drug; Drug Combinations; Early Termination of Clinical Trials; Heart Failure; Humans; Hypotension; Monitoring, Physiologic; Multicenter Studies as Topic; Neprilysin; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Reproducibility of Results; Stroke Volume; Tetrazoles; Valsartan

2018
Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
    ESC heart failure, 2018, Volume: 5, Issue:6

    Topics: Aminobutyrates; Biphenyl Compounds; Chagas Cardiomyopathy; Drug Combinations; Heart Failure; Humans; Ivabradine; Tetrazoles; Valsartan

2018
Growth differentiation factor-15 reveals the dark side of heart failure.
    European journal of heart failure, 2018, Volume: 20, Issue:12

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Growth Differentiation Factor 15; Heart Failure; Humans; Tetrazoles; Valsartan

2018
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
    Circulation. Heart failure, 2018, Volume: 11, Issue:9

    Topics: Aged; Aged, 80 and over; Ambulatory Care; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Decision-Making; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Patient Selection; Patients; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protease Inhibitors; Registries; Specialization; Tetrazoles; Time Factors; Treatment Outcome; United States; Valsartan

2018
IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure.
    Circulation. Heart failure, 2018, Volume: 11, Issue:10

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Biomarkers; Female; Heart Failure; Humans; Insulin-Like Growth Factor Binding Proteins; Male; Middle Aged; Neprilysin; Stroke Volume; Valsartan

2018
Is Sacubitril/Valsartan (Also) an Antiarrhythmic Drug?
    Circulation, 2018, 08-07, Volume: 138, Issue:6

    Topics: Aminobutyrates; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Heart Failure; Heart Rate; Humans; Risk Factors; Tetrazoles; Treatment Outcome; Valsartan

2018
Safety and efficacy of sacubitril─valsartan in acute heart failure.
    Nature reviews. Cardiology, 2019, Volume: 16, Issue:1

    Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2019
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2019, Feb-01, Volume: 128

    Topics: Aldosterone; Aminobutyrates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptides; Renin-Angiotensin System; Sodium, Dietary; Tetrazoles; Valsartan

2019
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
    European journal of heart failure, 2019, Volume: 21, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; CD146 Antigen; Chronic Disease; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Fructosamine; Glucagon-Like Peptide 1; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Substance P; Tetrazoles; Treatment Outcome; Troponin I; Valsartan

2019
Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.
    Journal of cardiovascular pharmacology, 2019, Volume: 73, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Retrospective Studies; Tertiary Care Centers; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2019
Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
    Journal of cardiovascular pharmacology, 2019, Volume: 73, Issue:2

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Protease Inhibitors; Recovery of Function; Registries; Spain; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left

2019
Discussing Out-of-Pocket Costs With Patients: Shared Decision Making for Sacubitril-Valsartan in Heart Failure.
    Journal of the American Heart Association, 2019, 01-08, Volume: 8, Issue:1

    Topics: Adult; Aged; Aminobutyrates; Biphenyl Compounds; Cost-Benefit Analysis; Cross-Sectional Studies; Decision Making, Shared; Drug Combinations; Drug Costs; Female; Health Expenditures; Heart Failure; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Tetrazoles; United States; Valsartan

2019
Beta-Endorphin Elevation: Another Mechanism of Action of Sacubitril/Valsartan in Heart Failure?
    Journal of cardiac failure, 2019, Volume: 25, Issue:2

    Topics: Aminobutyrates; Animals; beta-Endorphin; Biphenyl Compounds; Drug Combinations; Exercise Tolerance; Heart Failure; Rats; Tetrazoles; Valsartan

2019
Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure - A Single Centre Case Series and Call for an International Registry.
    Heart, lung & circulation, 2020, Volume: 29, Issue:1

    Topics: Adult; Aminobutyrates; Biphenyl Compounds; Chronic Disease; Drug Combinations; Female; Heart Defects, Congenital; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Registries; Tetrazoles; Valsartan

2020
Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.
    Journal of the American Heart Association, 2019, 02-05, Volume: 8, Issue:3

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Hospitalization; Humans; Male; Medication Adherence; Middle Aged; Neprilysin; Registries; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; United States; Valsartan

2019
Sacubitril + valsartan (Entresto°) in chronic heart failure.
    Prescrire international, 2017, Volume: 26, Issue:179

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Patient Selection; Tetrazoles; Treatment Outcome; Valsartan

2017
PIONEERing the In-Hospital Initiation of Sacubitril-Valsartan.
    The New England journal of medicine, 2019, 02-07, Volume: 380, Issue:6

    Topics: Aminobutyrates; Angiotensins; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2019
Unravelling the effect of sacubitril/valsartan on loop diuretic dosing.
    European journal of heart failure, 2019, Volume: 21, Issue:3

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Sodium Potassium Chloride Symporter Inhibitors; Tetrazoles; Valsartan

2019
Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
    Journal of pharmacy practice, 2020, Volume: 33, Issue:5

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Hyponatremia; Neprilysin; Tetrazoles; Valsartan

2020
Is Sacubitril/Valsartan Antifibrotic?
    Journal of the American College of Cardiology, 2019, 02-26, Volume: 73, Issue:7

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2019
Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2019, Volume: 108, Issue:10

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Arrhythmias, Cardiac; Belgium; Biphenyl Compounds; Death, Sudden, Cardiac; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Male; Neprilysin; Retrospective Studies; Stroke Volume; Survival Rate; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2019
Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities.
    Irish journal of medical science, 2019, Volume: 188, Issue:4

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Hospitalization; Humans; Patient Discharge; Retrospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas à cause du BNP?
    European journal of heart failure, 2019, Volume: 21, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Tetrazoles; Valsartan

2019
Effect of low-dose sacubitril/valsartan on body composition, bioelectrical impedance analysis, heart rate variability and T-peak to T-end index in elderly patients with severe chronic heart failure: a pilot experience.
    Current medical research and opinion, 2019, Volume: 35, Issue:sup1

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Body Composition; Chronic Disease; Drug Combinations; Electric Impedance; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Pilot Projects; Stroke Volume; Tetrazoles; Valsartan

2019
Sacubitril/valsartan: preliminary experience in post-acute stabilized patients with reduced ejection fraction heart failure.
    Current medical research and opinion, 2019, Volume: 35, Issue:sup1

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2019
Management of a patient with heart failure by sacubitril/valsartan: improvement of functional capacity.
    Current medical research and opinion, 2019, Volume: 35, Issue:sup1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Stroke Volume; Tetrazoles; Valsartan

2019
Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
    Current medical research and opinion, 2019, Volume: 35, Issue:sup1

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan

2019
How does neprilysin inhibition in heart failure work?
    European journal of heart failure, 2019, Volume: 21, Issue:5

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Tetrazoles; Valsartan

2019
Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series.
    Current medical research and opinion, 2019, Volume: 35, Issue:sup3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
Sacubitril/valsartan effect on left ventricular remodeling: the case of a super-responder.
    Current medical research and opinion, 2019, Volume: 35, Issue:sup3

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2019
Effects of sacubitril/valsartan on B-type natriuretic peptide circulating levels and loop diuretic dose in a case series of stabilized heart failure patients with left ventricular ejection fraction ≤35.
    Current medical research and opinion, 2019, Volume: 35, Issue:sup3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan.
    Current medical research and opinion, 2019, Volume: 35, Issue:sup3

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Heart Failure; Hospitalization; Humans; Male; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays.
    Journal of the American College of Cardiology, 2019, 03-26, Volume: 73, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Drug Monitoring; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Pharmacological Phenomena; Stroke Volume; Tetrazoles; Valsartan

2019
What Explains the Benefits of ARNI Therapy in Heart Failure?
    Journal of the American College of Cardiology, 2019, 03-26, Volume: 73, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Tetrazoles; Valsartan

2019
"Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
    Cardiovascular drugs and therapy, 2019, Volume: 33, Issue:3

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Clinical Decision-Making; Drug Combinations; Eligibility Determination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Patient Selection; Peptide Fragments; Protease Inhibitors; Recovery of Function; Registries; Stroke Volume; Sweden; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2019
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Scientific reports, 2019, 04-08, Volume: 9, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Drug Combinations; Heart; Heart Failure; Male; Myocardial Reperfusion Injury; Myocardium; Neovascularization, Physiologic; Neprilysin; Organotechnetium Compounds; Peptides, Cyclic; Rats; Rats, Inbred Lew; Single Photon Emission Computed Tomography Computed Tomography; Tetrazoles; Valsartan; Vascular Endothelial Growth Factor A; Ventricular Remodeling

2019
Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany.
    European journal of heart failure, 2019, Volume: 21, Issue:5

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiologists; Cohort Studies; Databases, Factual; Diuretics; Drug Combinations; Female; General Practitioners; Germany; Heart Failure; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Neprilysin; Practice Patterns, Physicians'; Retrospective Studies; Tetrazoles; Valsartan

2019
Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation.
    Journal of cardiology, 2019, Volume: 74, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Middle Aged; Renal Insufficiency, Chronic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
Psychiatric Manifestations With Sacubitril/Valsartan: A Case Report.
    Journal of pharmacy practice, 2020, Volume: 33, Issue:4

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Mental Disorders; Stroke Volume; Tetrazoles; Valsartan

2020
Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
    Circulation. Heart failure, 2019, Volume: 12, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cyclic GMP-Dependent Protein Kinases; Drug Combinations; Fibroblasts; Fibrosis; Heart; Heart Failure; Heart Ventricles; Male; Mice, Inbred C57BL; Neprilysin; Tetrazoles; Valsartan

2019
Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Journal of the American Heart Association, 2019, 05-07, Volume: 8, Issue:9

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Female; Health Care Costs; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Stroke Volume; Tetrazoles; United States; Valsartan

2019
Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.
    BMC pharmacology & toxicology, 2019, 05-03, Volume: 20, Issue:1

    Topics: Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Creatine Kinase, MB Form; Drug Combinations; Female; Fumarates; Heart Failure; Heart Rate; Kidney; Matrix Metalloproteinase 9; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Ramipril; Rats, Wistar; Renin; Tetrazoles; Troponin I; Valsartan

2019
Early Experience With Sacubitril/Valsartan in Adult Patients With Congenital Heart Disease.
    World journal for pediatric & congenital heart surgery, 2019, Volume: 10, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2019
A per-protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region.
    ESC heart failure, 2019, Volume: 6, Issue:4

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Protocols; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Tetrazoles; Treatment Outcome; United Arab Emirates; Valsartan

2019
Effect of sacubitril/valsartan on cardiac filling pressures in patients with heart failure: Suggestions for statistical analysis.
    International journal of cardiology, 2019, 08-01, Volume: 288

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Combinations; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey.
    European heart journal, 2019, 10-21, Volume: 40, Issue:40

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valsartan

2019
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
    European journal of heart failure, 2019, Volume: 21, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Registries; Stroke Volume; Tetrazoles; United States; United States Food and Drug Administration; Valsartan

2019
Confirmatory Trials for Drugs Approved on a Single Trial.
    Circulation. Cardiovascular quality and outcomes, 2019, Volume: 12, Issue:6

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Drug Approval; Drug Combinations; Eicosapentaenoic Acid; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Research Design; Tetrazoles; Treatment Outcome; Valsartan

2019
Sacubitril/valsartan improves medium-term reverse left ventricular remodeling: why wait?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2019, Volume: 20, Issue:10

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Time-to-Treatment; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2019
The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Blood pressure, 2019, Volume: 28, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hypertension; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2019
No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril.
    Journal of the American College of Cardiology, 2019, 06-18, Volume: 73, Issue:23

    Topics: Aldosterone; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2019
Sacubitril/Valsartan, Cardiac Fibrosis, and Remodeling in Heart Failure.
    Journal of the American College of Cardiology, 2019, 06-18, Volume: 73, Issue:23

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Fibrosis; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2019
In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time.
    European journal of heart failure, 2019, Volume: 21, Issue:8

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Discharge; Tetrazoles; Valsartan

2019
Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation.
    Heart and vessels, 2020, Volume: 35, Issue:1

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Neprilysin; Protease Inhibitors; Risk Assessment; Risk Factors; Spain; Tachycardia, Ventricular; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2020
Sacubitril/valsartan for heart failure in adults with complex congenital heart disease.
    International journal of cardiology, 2020, 02-01, Volume: 300

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies; Tetrazoles; Valsartan

2020
Alteration of medical therapy in patients with heart failure relative to change in symptom severity.
    ESC heart failure, 2019, Volume: 6, Issue:5

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Registries; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left

2019
Searching for Optimal Prognostic Marker of Heart Failure Progression in the Era of ARNI.
    Journal of the American College of Cardiology, 2019, 07-09, Volume: 74, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Prognosis; Tetrazoles; Valsartan

2019
In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?
    Journal of cardiovascular pharmacology, 2019, Volume: 74, Issue:1

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Evidence-Based Medicine; Heart Failure; Hospitalization; Humans; Neprilysin; Protease Inhibitors; Recovery of Function; Tetrazoles; Treatment Outcome; Valsartan

2019
Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.
    JAMA cardiology, 2019, 08-01, Volume: 4, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Health Expenditures; Heart Failure; Humans; Insurance Coverage; Medicare Part D; Tetrazoles; United States; Valsartan

2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
    JACC. Heart failure, 2019, Volume: 7, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Comorbidity; Diuretics; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Randomized Controlled Trials as Topic; Self Efficacy; Severity of Illness Index; Sex Factors; Stroke Volume; Tetrazoles; Valsartan

2019
Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure.
    Clinical chemistry, 2019, Volume: 65, Issue:10

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Animals; Biphenyl Compounds; Cross Reactions; Drug Combinations; Epitopes; Heart Failure; Humans; Immunoassay; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Rats, Wistar; Tetrazoles; Valsartan

2019
The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting.
    Internal and emergency medicine, 2019, Volume: 14, Issue:8

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Follow-Up Studies; Heart Failure; Humans; Life; Tetrazoles; Valsartan

2019
The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant.
    Arquivos brasileiros de cardiologia, 2019, 07-15, Volume: 112, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diuretics; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2019
Role of BNP vs NT-proBNP Testing in the Age of New Drug Therapies: Sacubitril-Valsartan.
    Clinical chemistry, 2019, Volume: 65, Issue:9

    Topics: Aminobutyrates; Biomarkers; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Tetrazoles; Valsartan

2019
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?
    European journal of heart failure, 2019, Volume: 21, Issue:11

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2019
[Proportion of patients with heart failure in a specialized clinic eligible for novel therapies].
    Revista medica de Chile, 2019, Volume: 147, Issue:3

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Selection; Tetrazoles; Valsartan

2019
First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Clinical pharmacology and therapeutics, 2013, Volume: 94, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Models, Biological; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2013
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
    European journal of heart failure, 2014, Volume: 16, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diuretics; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Selection; Platelet Aggregation Inhibitors; Quality of Life; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2014
Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies.
    Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:12

    Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Denmark; Female; Heart Failure; Humans; Insurance, Health, Reimbursement; Losartan; Male; Tetrazoles; Valine; Valsartan

2014
Neprilysin inhibition--a novel therapy for heart failure.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Neprilysin; Tetrazoles; Valsartan

2014
PARADIGM-HF--the experts' discussion.
    The New England journal of medicine, 2014, Sep-11, Volume: 371, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2014
Clinical trial results may lead to changes in cardiovascular care.
    JAMA, 2014, Nov-19, Volume: 312, Issue:19

    Topics: Aminobutyrates; Angioplasty; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Myocardial Infarction; Practice Guidelines as Topic; Tetrazoles; Valsartan

2014
Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount?
    Circulation, 2015, Jan-06, Volume: 131, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Disease Progression; Drug Combinations; Enalapril; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2015
Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).
    Current vascular pharmacology, 2014, Volume: 12, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2014
Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction.
    Internal and emergency medicine, 2015, Volume: 10, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Enalapril; Heart Failure; Hospitalization; Humans; Neprilysin; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan

2015
[New therapy concepts for heart failure with preserved ejection fraction].
    Herz, 2015, Volume: 40, Issue:2

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Evidence-Based Medicine; Heart Failure; Heart-Assist Devices; Humans; MicroRNAs; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2015
[Internal medicine in the hospital setting].
    Revue medicale suisse, 2015, Jan-21, Volume: 11, Issue:458

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases; Atrial Fibrillation; Biphenyl Compounds; Carotid Stenosis; Colchicine; Diuretics; Drug Combinations; Heart Failure; Hospitals; Humans; Internal Medicine; Liver Cirrhosis; Narcotics; Neprilysin; Pericarditis; Peritonitis; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Spironolactone; Stroke; Tetrazoles; Valsartan

2015
Breakthroughs in internal and respiratory medicine.
    The Lancet. Respiratory medicine, 2015, Volume: 3, Issue:8

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Crohn Disease; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Oligonucleotides; Pulmonary Medicine; Respiratory Tract Diseases; Tetrazoles; Translational Research, Biomedical; Valsartan

2015
Combination product approved for chronic heart failure.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Aug-15, Volume: 72, Issue:16

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Approval; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Tetrazoles; Valsartan

2015
[Still trivialized too often].
    MMW Fortschritte der Medizin, 2015, Sep-10, Volume: 157, Issue:15

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Enalapril; Germany; Heart Failure; Humans; Tetrazoles; Valsartan

2015
New Drug Entresto for Heart Failure Drums Up a Lot of Enthusiasm.
    Managed care (Langhorne, Pa.), 2015, Volume: 24, Issue:8

    Topics: Angiotensin Receptor Antagonists; Drug Approval; Drug Combinations; Drug Costs; Heart Failure; Humans; Managed Care Programs; Neprilysin; Tetrazoles; Valine; Valsartan

2015
The Role of Neprilysin Inhibitors in Cardiovascular Disease.
    Current heart failure reports, 2015, Volume: 12, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2015
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
    The New England journal of medicine, 2015, Dec-03, Volume: 373, Issue:23

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cause of Death; Drug Combinations; Heart Failure; Humans; Kaplan-Meier Estimate; Life Expectancy; Middle Aged; Tetrazoles; Valsartan

2015
Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations.
    JAMA, 2016, Jan-05, Volume: 315, Issue:1

    Topics: Alzheimer Disease; Aminobutyrates; Amyloid beta-Peptides; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Brain; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Haplorhini; Heart Failure; Humans; Mice; Neprilysin; Retinal Degeneration; Tetrazoles; Valsartan

2016
Sacubitril/Valsartan (Entresto): The Next Blockbuster Medication?
    South Dakota medicine : the journal of the South Dakota State Medical Association, 2015, Volume: 68, Issue:11

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2015
Heart failure in 2015: Better results from prevention than from additional treatment.
    Nature reviews. Cardiology, 2016, Volume: 13, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2016
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
    European journal of heart failure, 2016, Volume: 18, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Diabetes Mellitus, Experimental; Drug Combinations; Fibrosis; Heart; Heart Failure; Heart Ventricles; Male; Mice; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Myocardium; Neprilysin; RNA, Messenger; Stroke Volume; Tetrazoles; Transforming Growth Factor beta; Valsartan

2016
Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
    European heart journal. Acute cardiovascular care, 2017, Volume: 6, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Peptide Fragments; Predictive Value of Tests; Stroke Volume; Tetrazoles; Valsartan

2017
Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
    Arquivos brasileiros de cardiologia, 2016, Volume: 106, Issue:1

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2016
Different Susceptibility of B-Type Natriuretic Peptide (BNP) and BNP Precursor (proBNP) to Cleavage by Neprilysin: The N-Terminal Part Does Matter.
    Clinical chemistry, 2016, Volume: 62, Issue:4

    Topics: Aminobutyrates; Antibodies, Monoclonal; Biphenyl Compounds; Drug Combinations; Epitopes; Escherichia coli; Glycosylation; Heart Failure; Humans; Immunoassay; Limit of Detection; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Protein Precursors; Proteolysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetrazoles; Valsartan

2016
Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:2

    Topics: Animals; Cardio-Renal Syndrome; Cardiomegaly; Disease Models, Animal; Down-Regulation; Echocardiography; Galectin 3; Glomerular Filtration Rate; Heart; Heart Failure; Kidney; Male; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Signal Transduction; Valsartan

2016
Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure.
    European heart journal, 2016, Mar-01, Volume: 37, Issue:9

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiologists; Drug Approval; Drug Combinations; Drug Discovery; Drug Industry; Heart Failure; Humans; Interprofessional Relations; Neprilysin; Tetrazoles; Valsartan

2016
[Sacubitril/valsartan receives European approval].
    MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; Early Termination of Clinical Trials; Europe; Heart Failure; Humans; Survival Rate; Tetrazoles; Valsartan

2015
The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure.
    International journal of cardiology, 2016, Jun-01, Volume: 212

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Neprilysin; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan

2016
Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    JACC. Heart failure, 2016, Volume: 4, Issue:5

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Markov Chains; Middle Aged; Neprilysin; Quality-Adjusted Life Years; Stroke Volume; Tetrazoles; Valsartan

2016
["It is important to reach the target dose"].
    MMW Fortschritte der Medizin, 2016, Apr-21, Volume: 158 Spec No 1

    Topics: Aminobutyrates; Biphenyl Compounds; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Germany; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan

2016
NICE approves innovative treatment for moderate to severe heart failure.
    BMJ (Clinical research ed.), 2016, Apr-26, Volume: 353

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Approval; Drug Combinations; England; Heart Failure; Humans; Tetrazoles; Valsartan

2016
[A new medication - when should one switch?].
    MMW Fortschritte der Medizin, 2016, May-12, Volume: 158, Issue:9

    Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Substitution; Heart Failure; Humans; Tetrazoles; Valsartan

2016
▼ Sacubitril valsartan for heart failure.
    Drug and therapeutics bulletin, 2016, Volume: 54, Issue:6

    Topics: Adult; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan

2016
Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions.
    Journal of the American College of Cardiology, 2016, 07-19, Volume: 68, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Patient Readmission; Tetrazoles; Valsartan

2016
[Sacubitril-valsartan is a new cornerstone in heart failure therapy].
    Lakartidningen, 2016, 07-13, Volume: 113

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Sweden; Tetrazoles; Valsartan

2016
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    JAMA cardiology, 2016, 09-01, Volume: 1, Issue:6

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Stroke Volume; Tetrazoles; Valsartan

2016
Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies.
    International journal of cardiology, 2016, Oct-15, Volume: 221

    Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiomyopathy, Dilated; Drug Combinations; Female; Genetic Markers; Genetic Predisposition to Disease; Heart Failure; Humans; Male; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Stroke Volume; Syndecan-4; Tetrazoles; Transforming Growth Factor beta1; Valsartan

2016
Chronic congestive heart failure - a new therapeutic choice.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2016, Nov-01, Volume: 188, Issue:16

    Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Canada; Chronic Disease; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan

2016
New Recommendations for Heart Failure Treatment.
    The American journal of nursing, 2016, Volume: 116, Issue:9

    Topics: Antihypertensive Agents; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Valsartan

2016
Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
    Annals of internal medicine, 2016, Nov-15, Volume: 165, Issue:10

    Topics: Aminobutyrates; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Hospitalization; Humans; Lisinopril; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2016
Sacubitril-Valsartan in Heart Failure: Why Are More Physicians Not Prescribing It?
    Annals of internal medicine, 2016, 11-15, Volume: 165, Issue:10

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Tetrazoles; Valsartan

2016
Practical considerations on the introduction of sacubitril/valsartan in clinical practice: Current evidence and early experience.
    International journal of cardiology, 2016, Nov-15, Volume: 223

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan

2016
Hyperkalemia, Sacubitril/Valsartan, and Mineralocorticoid Antagonists in Patients With Heart Failure.
    JAMA cardiology, 2017, 01-01, Volume: 2, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan

2017
Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.
    Future cardiology, 2017, Volume: 13, Issue:2

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valsartan

2017
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
    Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:12

    Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Early Medical Intervention; Echocardiography; Europe; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptides; Practice Guidelines as Topic; Spain; Stroke Volume; Tetrazoles; Valsartan

2016
Heart failure: Neprilysin inhibition attenuates risk of hyperkalaemia in HFrEF.
    Nature reviews. Cardiology, 2017, Volume: 14, Issue:1

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Neprilysin; Tetrazoles; Valsartan

2017
Sacubitril/Valsartan (Entresto) for Heart Failure.
    American family physician, 2016, Oct-15, Volume: 94, Issue:8

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Neprilysin; Renal Insufficiency; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan

2016
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
    Cardiovascular therapeutics, 2017, Volume: 35, Issue:2

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Diuretics; Fibroblasts; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hydrochlorothiazide; Male; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Smad2 Protein; Stroke Volume; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2017
Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
    European heart journal, 2017, 04-14, Volume: 38, Issue:15

    Topics: Aminobutyrates; Biphenyl Compounds; Drug Combinations; Heart Failure; Humans; Hypotension; Stroke Volume; Tetrazoles; Valsartan

2017
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2017, Volume: 20, Issue:3

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cost-Benefit Analysis; Drug Combinations; Financing, Personal; Health Care Costs; Heart Failure; Hospital Costs; Hospitalization; Humans; Kaplan-Meier Estimate; Netherlands; Quality-Adjusted Life Years; Tetrazoles; Treatment Outcome; Valsartan

2017
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
    European journal of pharmacology, 2009, Jan-14, Volume: 602, Issue:2-3

    Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; Cardiomegaly; Cyclic AMP Response Element Modulator; Cyclic AMP Response Element-Binding Protein; Cyclic Nucleotide Phosphodiesterases, Type 3; Gene Expression Regulation; Heart; Heart Failure; Myocardial Infarction; Myocardium; Rats; Tetrazoles; Valine; Valsartan; Ventricular Remodeling

2009
[Effects of valsartan on sarcoplasmic reticulum calcium adenosine triphosphatase, protein kinase A and protein phosphatase 1 alpha in a rabbit model of heart failure].
    Zhonghua xin xue guan bing za zhi, 2008, Volume: 36, Issue:9

    Topics: Animals; Cyclic AMP-Dependent Protein Kinases; Female; Heart Failure; Male; Protein Phosphatase 1; Rabbits; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Valine; Valsartan

2008
[Valsartan improves symptoms and quality of life in patients with chronic heart failure].
    MMW Fortschritte der Medizin, 2008, Dec-04, Volume: 150, Issue:49-50

    Topics: Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Multicenter Studies as Topic; Prospective Studies; Quality of Life; Tetrazoles; Valine; Valsartan

2008
Combination of ARB and ACE inhibitors in heart failure patients.
    American family physician, 2009, Mar-15, Volume: 79, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Tetrazoles; Valine; Valsartan

2009
[Effects of valsartan on myocardial calcium/calmodulin-dependent protein kinase-II expression and activity in a rabbit model of heart failure].
    Zhonghua xin xue guan bing za zhi, 2009, Volume: 37, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Female; Heart Failure; Male; Myocardium; Rabbits; Tetrazoles; Valine; Valsartan

2009
The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9, Issue:6

    Topics: Age Factors; Aged; Antihypertensive Agents; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Female; Heart Failure; Hospital Costs; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Statistical; Quality of Life; Quality-Adjusted Life Years; Sex Factors; Tetrazoles; Valine; Valsartan

2009
Continuous positive airway pressure treatment in addition to optimal medical therapy for ventricular ectopy in a patient with heart failure and sleep-related breathing disorder.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2013, Volume: 14, Issue:9

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Continuous Positive Airway Pressure; Coronary Artery Disease; Heart Failure; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Propanolamines; Radiography; Sleep Apnea, Obstructive; Tachycardia, Ventricular; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Premature Complexes

2013
HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials.
    European journal of heart failure, 2010, Volume: 12, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Evidence-Based Medicine; Heart Failure; Humans; Losartan; Tetrazoles; Time Factors; Valine; Valsartan

2010
Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
    Circulation, 2010, Mar-09, Volume: 121, Issue:9

    Topics: Aged; Analog-Digital Conversion; Angiotensin II Type 1 Receptor Blockers; Death; Disease Progression; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Motion; Myocardial Contraction; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stress, Mechanical; Tetrazoles; Ultrasonography; Valine; Valsartan; Ventricular Dysfunction, Left; Video Recording

2010
Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.
    British journal of pharmacology, 2010, Volume: 160, Issue:1

    Topics: Acetamides; Animals; Biomarkers; Cardiac Volume; Cellular Senescence; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Inflammation; Mitochondria, Heart; Myocardial Infarction; Myocytes, Cardiac; Pyridazines; Random Allocation; Rats; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilator Agents; Ventricular Pressure

2010
Determinants of masked hypertension in hypertensive patients treated in a primary care setting.
    Internal medicine journal, 2012, Volume: 42, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Masked Hypertension; Middle Aged; Obesity; Prevalence; Primary Health Care; Quebec; Risk; Tetrazoles; Valine; Valsartan; White Coat Hypertension

2012
Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition.
    Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:2

    Topics: Adipocytes; Adrenergic beta-Agonists; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Cells, Cultured; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Isoproterenol; Lipolysis; Male; Middle Aged; Neprilysin; Receptors, Angiotensin; Tetrazoles; Valsartan; Ventricular Dysfunction, Left

2011
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
    Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:3

    Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confounding Factors, Epidemiologic; Electronic Health Records; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Losartan; Male; Models, Structural; Proportional Hazards Models; Retrospective Studies; Risk; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan

2012
Cardiovascular effects of the combination of levosimendan and valsartan in hypertensive Dahl/Rapp rats.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2011, Volume: 62, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Diet, Sodium-Restricted; Echocardiography; Heart; Heart Failure; Heart Rate; Hydrazones; Hypertension; Kidney; Male; Myocytes, Cardiac; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Simendan; Sodium Chloride, Dietary; Sodium, Dietary; Tetrazoles; Valine; Valsartan; Vasodilator Agents; Ventricular Remodeling

2011
Subtle issues in model specification and estimation of marginal structural models.
    Pharmacoepidemiology and drug safety, 2012, Volume: 21, Issue:3

    Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; Humans; Irbesartan; Losartan; Male; Tetrazoles; Valine; Valsartan

2012
Heart failure--does it matter whether LVEF is reduced?
    Lancet (London, England), 2012, Oct-20, Volume: 380, Issue:9851

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Drug Combinations; Female; Heart Failure; Humans; Male; Neprilysin; Tetrazoles; Valsartan

2012
Trial watch: dual-acting combination meets heart failure end point.
    Nature reviews. Drug discovery, 2012, Volume: 11, Issue:10

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials, Phase II as Topic; Drug Combinations; Endpoint Determination; Heart Failure; Humans; Tetrazoles; Valsartan

2012
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2

    Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
    Journal of cardiovascular pharmacology, 2013, Volume: 61, Issue:4

    Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan

2013
Ask the doctor. I have had heart failure since my heart attack a year ago. My physician initially prescribed lisinopril, an angiotensin-converting enzyme (ACE) inhibitor. Unfortunately, I was one of the unlucky people who got a cough with this drug that w
    Harvard heart letter : from Harvard Medical School, 2002, Volume: 12, Issue:11

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cough; Heart Failure; Humans; Lisinopril; Myocardial Infarction; Tetrazoles; Valine; Valsartan

2002
[Therapy of heart failure. 2 neurohormone blockers are enough].
    MMW Fortschritte der Medizin, 2002, Sep-05, Volume: 144, Issue:35-36

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Journal of the American College of Cardiology, 2002, Oct-16, Volume: 40, Issue:8

    Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2002
Angiotensin receptor blockers in heart failure: a work in progress.
    Journal of the American College of Cardiology, 2002, Oct-16, Volume: 40, Issue:8

    Topics: Angiotensin II; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan

2002
Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta.
    Journal of molecular and cellular cardiology, 2002, Volume: 34, Issue:10

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Progression; Echocardiography; Enzyme Activation; Heart Failure; Hypertension; Male; Myocardium; Organ Size; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-epsilon; Protein Transport; Rats; Rats, Inbred Dahl; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

2002
Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
    The American journal of cardiology, 2002, Nov-01, Volume: 90, Issue:9

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
BP drug approved for heart failure.
    Health news (Waltham, Mass.), 2002, Volume: 8, Issue:10

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Approval; Heart Failure; Humans; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan

2002
[Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor].
    MMW Fortschritte der Medizin, 2002, Oct-03, Volume: 144, Issue:40

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Heart Failure; Humans; Randomized Controlled Trials as Topic; Survival Rate; Tetrazoles; Treatment Outcome; United States; United States Food and Drug Administration; Valine; Valsartan

2002
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Current hypertension reports, 2002, Volume: 4, Issue:6

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Evaluation Studies as Topic; Heart Failure; Humans; Incidence; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Heart failure monitor, 2002, Volume: 2, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
Cardiology patient page. Angiotensin receptor blockers.
    Circulation, 2003, Jun-24, Volume: 107, Issue:24

    Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan

2003
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context.
    European journal of heart failure, 2003, Volume: 5, Issue:4

    Topics: Aged; Angiotensin Receptor Antagonists; Captopril; Double-Blind Method; Female; Glyceraldehyde-3-Phosphate Dehydrogenases; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptide Fragments; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2003
Effect of valsartan on hospitalization in Val-HeFT.
    Journal of cardiac failure, 2003, Volume: 9, Issue:5

    Topics: Heart Failure; Humans; Length of Stay; Patient Readmission; Prognosis; Tetrazoles; Valine; Valsartan

2003
[ACE inhibitors and/or sartans in heart failure: is there a difference?].
    Revue medicale de Bruxelles, 2003, Volume: 24, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Losartan; Tetrazoles; Valine; Valsartan

2003
Angiotensin-receptor blockade in acute myocardial infarction--a matter of dose.
    The New England journal of medicine, 2003, Nov-13, Volume: 349, Issue:20

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2003
[Value in heart failure proven again. AT II blocker soon also for post-infarct patients?].
    MMW Fortschritte der Medizin, 2003, Oct-23, Volume: 145, Issue:43

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Survival Rate; Tetrazoles; Valine; Valsartan

2003
Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
    Circulation, 2004, Feb-24, Volume: 109, Issue:7

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dobutamine; Dogs; Drug Evaluation, Preclinical; Heart Failure; Myocardial Contraction; Norepinephrine; Phosphorylation; Protein Processing, Post-Translational; Receptors, Adrenergic, beta; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Tachycardia, Ventricular; Tacrolimus Binding Proteins; Tetrazoles; Valine; Valsartan; Ventricular Remodeling

2004
[When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
    MMW Fortschritte der Medizin, 2003, Dec-04, Volume: 145, Issue:49

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left

2003
[New options against undertreatment].
    MMW Fortschritte der Medizin, 2003, Dec-04, Volume: 145, Issue:49

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Hospitalization; Humans; Losartan; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan

2003
Implications of recent clinical trials for heart failure performance measures.
    Journal of cardiac failure, 2004, Volume: 10, Issue:1

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Practice Guidelines as Topic; Quality of Health Care; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

2004
Valsartan, captopril, or both in myocardial infarction.
    The New England journal of medicine, 2004, Feb-26, Volume: 350, Issue:9

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Ethics, Clinical; Heart Failure; Humans; Myocardial Infarction; Placebos; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2004
Normalization of renal aquaporin-2 water channel expression by fosinopril, valsartan, and combination therapy in congestive heart failure: a new mechanism of action.
    Journal of molecular and cellular cardiology, 2004, Volume: 36, Issue:3

    Topics: Administration, Oral; Animals; Antihypertensive Agents; Aquaporin 2; Aquaporins; Drug Therapy, Combination; Fosinopril; Gene Expression; Heart Failure; Kidney Cortex; Kidney Medulla; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan

2004
VALIANT and EUROPA.
    Preventive cardiology, 2004,Winter, Volume: 7, Issue:1

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2004
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
    European heart journal, 2004, Volume: 25, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2004
Aldosterone levels after angiotensin receptor blocker treatment.
    Circulation, 2004, Apr-13, Volume: 109, Issue:14

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Tetrazoles; Valine; Valsartan

2004
[Hyperkalemia. Main symptoms: muscle weakness, cardiac arrhythmias].
    Praxis, 2004, Jul-14, Volume: 93, Issue:29-30

    Topics: Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Heart Failure; Humans; Hyperkalemia; Hypertension; Male; Middle Aged; Muscle Weakness; Spironolactone; Tetrazoles; Valine; Valsartan

2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Circulation, 2004, Sep-21, Volume: 110, Issue:12

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left

2004
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    American heart journal, 2005, Volume: 149, Issue:3

    Topics: Aged; Atrial Fibrillation; Comorbidity; Electrocardiography; Female; Heart Failure; Humans; Incidence; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan

2005
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
    European journal of heart failure, 2005, Volume: 7, Issue:5

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzopyrans; Biphenyl Compounds; Bisoprolol; Captopril; Carbazoles; Carvedilol; Drug Therapy, Combination; Enalapril; Ethanolamines; Evidence-Based Medicine; Guideline Adherence; Heart Failure; Humans; Indoles; Lisinopril; Metoprolol; Mineralocorticoid Receptor Antagonists; Nebivolol; Practice Guidelines as Topic; Propanolamines; Ramipril; Spironolactone; Stroke Volume; Tetrazoles; Valine; Valsartan

2005
Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Clinical therapeutics, 2005, Volume: 27, Issue:6

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Budgets; Cost-Benefit Analysis; Heart Failure; Hospitalization; Humans; Models, Economic; Tetrazoles; Time Factors; Valine; Valsartan

2005
How FDA currently makes decisions on clinical studies.
    Clinical trials (London, England), 2005, Volume: 2, Issue:4

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Child; Clinical Trials as Topic; Diabetic Nephropathies; Evidence-Based Medicine; Heart Failure; Humans; Propanolamines; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan

2005
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
    The American journal of medicine, 2006, Volume: 119, Issue:1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Disease Progression; Echocardiography; Heart Failure; Heart Ventricles; Humans; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stroke Volume; Survival Rate; Tetrazoles; Valine; Valsartan

2006
[Successful mega studies with heart patients. Valsartan possesses cardioprotective action].
    MMW Fortschritte der Medizin, 2006, Feb-02, Volume: 148, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Long-Term Care; Myocardial Infarction; Secondary Prevention; Tetrazoles; Treatment Outcome; Valine; Valsartan

2006
[Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
    MMW Fortschritte der Medizin, 2006, May-04, Volume: 148, Issue:18

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Evidence-Based Medicine; Family Practice; Germany; Heart Failure; Humans; Hypertension; Myocardial Infarction; Product Surveillance, Postmarketing; Tetrazoles; Treatment Outcome; Valine; Valsartan

2006
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
    International journal of cardiology, 2007, Jun-25, Volume: 119, Issue:1

    Topics: Aged; Antihypertensive Agents; C-Reactive Protein; Cholesterol; Chronic Disease; Creatinine; Databases, Factual; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; Prognosis; Retrospective Studies; Tetrazoles; Valine; Valsartan

2007
Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study.
    Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 2006, Volume: 19, Issue:12

    Topics: Aged; Antihypertensive Agents; Comorbidity; Echocardiography; Female; Heart Failure; Humans; Internationality; Male; Middle Aged; Myocardial Infarction; Prevalence; Prognosis; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Stroke Volume; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2006
Left bundle branch block is not good for your heart.
    Heart rhythm, 2007, Volume: 4, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Heart Failure; Humans; Myocardial Infarction; Risk Factors; Stroke Volume; Tetrazoles; Time Factors; Valine; Valsartan; Ventricular Dysfunction, Left

2007
Angiotensin II receptor blockers for the treatment of heart failure: a class effect?
    Pharmacotherapy, 2007, Volume: 27, Issue:4

    Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; British Columbia; Drug Prescriptions; Female; Heart Failure; Hospital Information Systems; Humans; Irbesartan; Losartan; Male; Ontario; Proportional Hazards Models; Quebec; Retrospective Studies; Survival Analysis; Survival Rate; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2007
Molecular signaling mediated by angiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart failure.
    Journal of cardiac failure, 2007, Volume: 13, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Urea Nitrogen; Blotting, Western; Creatinine; Disease Models, Animal; DNA; Heart Failure; Immunohistochemistry; Kidney Failure, Chronic; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Nephrectomy; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1; Treatment Outcome; Up-Regulation; Valine; Valsartan; Ventricular Function, Left

2007
[Convincing results from the JIKEI Study].
    MMW Fortschritte der Medizin, 2006, Dec-14, Volume: 148, Issue:51-52

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Controlled Clinical Trials as Topic; Coronary Disease; Heart Failure; Humans; Hypertension; Tetrazoles; Treatment Outcome; Valine; Valsartan

2006
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:1

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2008
[New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschritte der Medizin, 2007, Nov-15, Volume: 149, Issue:46

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diabetic Nephropathies; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Prognosis; Tetrazoles; Treatment Outcome; Valine; Valsartan

2007
Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
    Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Blood Pressure; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Failure; In Vitro Techniques; Male; Myocardial Infarction; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; Rats, Sprague-Dawley; Tetrazoles; Time Factors; Valine; Valsartan; Vasodilation; Ventricular Function, Left; Ventricular Remodeling

2007
From black and white to shades of gray: race and renin-angiotensin system blockade.
    Journal of the American College of Cardiology, 2008, May-13, Volume: 51, Issue:19

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Captopril; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People

2008
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
    Journal of the American College of Cardiology, 2008, May-13, Volume: 51, Issue:19

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Black or African American; Captopril; Female; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Systole; Tetrazoles; United States; Valine; Valsartan; Ventricular Dysfunction, Left; White People

2008
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Circulation, 1997, Oct-07, Volume: 96, Issue:7

    Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Diastole; Disease Models, Animal; Endothelins; Epinephrine; Heart Failure; Heart Rate; Hemodynamics; Norepinephrine; Pulmonary Artery; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

1997
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes.
    Circulation, 1997, Oct-07, Volume: 96, Issue:7

    Topics: Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Calcium Channels; Calcium Channels, L-Type; Calcium-Binding Proteins; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cell Membrane; Cells, Cultured; Dihydropyridines; Heart Failure; Myocardial Contraction; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin-Angiotensin System; Sarcoplasmic Reticulum; Sodium-Potassium-Exchanging ATPase; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

1997
Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns.
    Cardiovascular research, 1998, Volume: 38, Issue:3

    Topics: Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiac Pacing, Artificial; Endothelins; Epinephrine; Heart Failure; Hemodynamics; Male; Norepinephrine; Physical Exertion; Regional Blood Flow; Renin; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

1998
AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
    Journal of cardiac failure, 1998, Volume: 4, Issue:4

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; Exercise Test; Heart Failure; Hemodynamics; Male; Regional Blood Flow; Swine; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left

1998
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
    Journal of cardiac failure, 1999, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Reference Values; Research Design; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan

1999
Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
    Cardiology, 1999, Volume: 91 Suppl 1

    Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Quality of Life; Tetrazoles; Valine; Valsartan

1999
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
    Cardiovascular research, 1999, Volume: 42, Issue:3

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Diuresis; Heart Failure; Male; Myocardium; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Statistics, Nonparametric; Tetrazoles; Valine; Valsartan

1999
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers.
    European heart journal, 2000, Volume: 21, Issue:1

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Losartan; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2000
AT1-receptor blockers.
    European heart journal, 2000, Volume: 21, Issue:4

    Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Meta-Analysis as Topic; Tetrazoles; Valine; Valsartan

2000
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Circulation, 2000, Feb-29, Volume: 101, Issue:8

    Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Fosinopril; Heart Failure; Humans; Lisinopril; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Treatment Failure; Valine; Valsartan

2000
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
    Circulation, 2000, Sep-19, Volume: 102, Issue:12

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2000
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
    Circulation, 2001, Jan-02, Volume: 103, Issue:1

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Catecholamines; Collagen; Diastole; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin-1; Gene Expression; Heart Failure; Heart Function Tests; Hydroxyproline; Myocardium; Myosin Heavy Chains; Organ Size; Rats; Rats, Inbred Dahl; Receptors, Angiotensin; RNA, Messenger; Sodium Chloride, Dietary; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Remodeling

2001
[AT1-blocker in heart failure. Patients are readmitted more infrequently to the clinic].
    MMW Fortschritte der Medizin, 2000, Nov-30, Volume: 142, Issue:48

    Topics: Angiotensin Receptor Antagonists; Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan

2000
[Info-congress. COPERNICUS and Val-HEFT studies].
    Revue medicale de Liege, 2000, Volume: 55, Issue:11

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Coronary Disease; Heart Failure; Humans; Propanolamines; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Valine; Valsartan

2000
[Heart failure. With the AT1-blocker less frequent rehospitalization].
    MMW Fortschritte der Medizin, 2001, May-17, Volume: 143, Issue:20

    Topics: Angiotensin Receptor Antagonists; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan

2001
Alterations of load-induced p38 MAP kinase activation in failing rat hearts.
    Biochemical and biophysical research communications, 2001, Jul-13, Volume: 285, Issue:2

    Topics: Animals; Antihypertensive Agents; Body Weight; Diastole; Enzyme Activation; Heart; Heart Failure; Hemodynamics; In Vitro Techniques; Mitogen-Activated Protein Kinases; Myocardial Contraction; Myocardium; Organ Size; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Inbred Dahl; Reference Values; Systole; Tetrazoles; Valine; Valsartan; Ventricular Function, Left; Weight-Bearing

2001
Combined angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on survival and cardiac remodeling in chronic heart failure in rats.
    Journal of cardiac failure, 2001, Volume: 7, Issue:3

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Enalapril; Heart Failure; Male; Rats; Rats, Wistar; Tetrazoles; Valine; Valsartan

2001
Angiotensin II type 1 receptor blockers and congestive heart failure.
    Circulation, 2001, Oct-09, Volume: 104, Issue:15

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Receptor, Angiotensin, Type 1; Sample Size; Selection Bias; Tetrazoles; Treatment Outcome; Valine; Valsartan

2001
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
    Circulation, 2001, Oct-30, Volume: 104, Issue:18

    Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan

2001
Are angiotensin II receptor blockers indicated in chronic heart failure?
    Heart (British Cardiac Society), 2002, Volume: 87, Issue:1

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan

2002
[Heart failure. Who benefits from an AT1 blocker?].
    MMW Fortschritte der Medizin, 2001, Nov-22, Volume: 143, Issue:47

    Topics: Angiotensin Receptor Antagonists; Clinical Trials as Topic; Heart Failure; Humans; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan

2001
[ESC guidelines for therapy of heart failure. AT1 blockers are now also included].
    MMW Fortschritte der Medizin, 2002, Jan-24, Volume: 144, Issue:3-4

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Heart Failure; Humans; Practice Guidelines as Topic; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
[Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
    Revue medicale de Liege, 2002, Volume: 57, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Spironolactone; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left

2002
Myocardial bradykinin following acute angiotensin-converting enzyme inhibition, AT1 receptor blockade, or combined inhibition in congestive heart failure.
    Journal of cardiovascular pharmacology and therapeutics, 2001, Volume: 6, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Bradykinin; Heart Failure; Male; Myocardium; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Swine; Tetrazoles; Valine; Valsartan

2001
Valsartan in chronic heart failure.
    The New England journal of medicine, 2002, Apr-11, Volume: 346, Issue:15

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Hypotension; Tetrazoles; Valine; Valsartan

2002
Valsartan in chronic heart failure.
    The New England journal of medicine, 2002, Apr-11, Volume: 346, Issue:15

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Tetrazoles; Valine; Valsartan

2002
Valsartan in chronic heart failure.
    The New England journal of medicine, 2002, Apr-11, Volume: 346, Issue:15

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Risk; Tetrazoles; Valine; Valsartan

2002
Valsartan in chronic heart failure.
    The New England journal of medicine, 2002, Apr-11, Volume: 346, Issue:15

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2002